Arthritis Research & Therapy Volume 7 Supplement 1, February 2005
Meeting abstracts
25th European Workshop for Rheumatology Research
Glasgow, UK
24–27 February 2005
Received: 11 January 2005 Published: 17 February 2005
© 2005 BioMed Central Ltd

Speaker abstracts

S1
Stem cells now and in the future in medicine
A Smith
MRC Centre Development in Stem Cell Biology, Institute for Stem Cell Research, University of Edinburgh, UK
Abstract not submitted.

S2
Chaperonins and the regulation of immunity
GS Panayi, VC Corrigall
Academic Department of Rheumatology, King’s College London, Guy’s Hospital, London, UK
Chaperonins have classically been thought of as intracellular molecules involved in the correct folding of proteins. Their expression is upregulated during times of stress such as heat (hence their common nomenclature as heat shock proteins [HSPs]) or in response to reactive oxygen species [1]. These are conditions found in infected tissues or in tissues with chronic inflammation such as the rheumatoid synovium. In their intracellular location they protect the cell from apoptotic death due to stress. Increasingly chaperonins have been recognised to subserve extracellular functions for which they have received the name ‘chaperokines’ since they bind to specific receptors on the cell surface and activate cells of the innate immune system to secrete inflammatory cytokines, chemokines and small molecular weight mediators such as prostaglandins [2]. Indeed, an early event in inflammation is cell stress/necrosis leading to the release of HSP60 and HSP70 that binds via a CD14-mediated mechanism to Toll-like receptors 2 and 4 [2] as part of the ‘danger’ signal [3]. The secretion of tumour necrosis factor alpha, IL-1, IL-12 and other chemokines prepares the environment for a TH1 adaptive immune response. It is now recognised that some chaperonins, such as BiP and HSP27, may activate the innate immune system to secrete anti-inflammatory cytokines, such as IL-10 [4,5] that may skew the adaptive immune response to TH2. Recent work by our group has shown that BiP can not only prevent but also treat ongoing collagen-induced arthritis in DBA/1 mice [6], suggesting that chaperonins may downmodulate ongoing TH1 responses. Thus, it may be possible to suppress rheumatoid inflammation by administration of appropriate chaperonins such as BiP. Finally, chaperonins may be important system regulators determining the outcome between TH1 and TH2 immune responses.

References

Acknowledgements GSP and VCC are shareholders in Immune Regulation Ltd that is investigating the potential of BiP as an immunotherapeutic agent for the treatment of rheumatoid arthritis.

S3
Autoimmune diabetes: mechanisms
A Cooke
University of Cambridge, UK
Type 1 diabetes is an autoimmune disease that is increasing dramatically in incidence in the developed world. Explanations for this increase in incidence include viral precipitation of disease and the so-called ‘hygiene hypothesis’.
In Type 1 diabetes the insulin-producing beta cells of the pancreas are selectively destroyed by the immune system. Type 1 diabetes is generally recognised as a T-cell-mediated autoimmune disease with the autoantibody response to islet antigens serving as markers of ongoing beta cell destruction.
Studies of spontaneous animal models of this human condition suggest that it is a Th1-mediated autoimmune disease with an involvement of both CD8+ T cells and macrophages in pathology. There are multiple ways in which the beta cell could be destroyed including a Class I restricted killing by CD8+ T cells, pronflammatory cytokine-mediated cell death and death induced by Fas/FasL interactions.
At the time of clinical diagnosis it is possible that the patient will have destroyed 70% of their beta cell mass and exogenous insulin is required to maintain glucose homeostasis. There is currently much interest in the development of tolerogenic strategies to inhibit and halt beta destruction. This coupled with strategies to facilitate the replacement of the destroyed beta cells would constitute a cure for this disease.

S4
Autoimmunity or immune deficiency? On the role and function of regulatory T cells in chronic arthritis
BJ Prakken, I de Kleer
Department of Paediatric Immunology, University Medical Centre Utrecht, The Netherlands
Human autoimmune diseases are characterized by chronic, non-remitting inflammation. In the early phase of chronic arthritis auto-reactive T cells initiate a cascade of events that leads to chronic inflammation. Following the initial phase of the disease, other cells such as macrophages and monocytes mainly mediate the ongoing non-specific inflammation. At this later stage, auto reactive T cells presumably do not play an important role in sustaining the chronic inflammation. Mechanisms underlying the perpetuation of this cascade of non-specific inflammation are still poorly understood. As a consequence, treatment of the disease until now has been mainly focused on non-specific suppression of inflammation. In patients with chronic arthritis, such juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA) blockade of the tumour necrosis factor alpha pathway has proven to be a very potent treatment option. On the other hand, such treatment is costly and fails to induce a long-lasting remission of the disease. As a consequence long-term treatment with immune suppressive agents is necessary, which increases not only the costs of the treatment but also harbours considerable risk for long-term side effects. Thus, the need for additive and/or alternative strategies is growing. Ideally such alternative treatment should be safe, not expensive and specifically modulate cells that are responsible for the inflammation and/or counter-regulation. Lately, a lot of attention has focused on the role of regulatory T cells for the control of autoimmunity. There are currently two well-characterized types of regulatory T cells, Tr1 cells and CD4+CD25+ T regulatory cells. The CD4+CD25+ T regulatory cells are a heterogeneous group of cells identified by the expression of CD25 and the transcription factor foxP3. We recently showed that these so-called naturally occurring T regulatory cells and regulatory T cells with specificity towards heat shock proteins may play a role in determining disease outcome in JIA [1,2]. Following autologous stem cell transplantation for arthritis T regulatory cell function is restored coinciding with a remission of the arthritis (de Kleer et al., submitted). Moreover, oral treatment with a peptide (dnap11), derived from heat shock protein dnap, restored T regulatory cells in peripheral blood mononuclear cells from patients with RA [3]. Thus, due to insufficient numbers of regulatory T cells, feedback mechanisms fail, resulting in an un restrained pronflammatory immune response and severe tissue damage in RA and JIA. A lack of a counter-regulatory mechanism based by regu-

Arthritis Research & Therapy Vol 7 Suppl 1 Abstracts of the 25th European Workshop for Rheumatology Research

S2


S5

Tracking immune responses in vivo

MK Jenkins

Center for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota, USA


We have developed new tools that allow detection of peptide–MHC II presentation to naïve CD4+ T cells in vivo. These tools were used to track early events in the immune response to a subcutaneously injected antigen. Following such an injection, antigen is quickly carried via lymphatic vessels into the draining lymph nodes, and down through afferent lymph-node-based conduits that run through the T-cell-dependent Langerhans cells and dermal dendritic cells near the conduits acquired antigen, produced peptide–MHC II complexes, and were the first cells to stimulate naïve antigen-specific CD4+ T cells. About 18 hours after antigen injection, dermal dendritic cells migrated from the injection site and arrived in the lymph nodes displaying a large number of peptide–MHC II complexes. Elimination of these cells truncated CD25 expression by antigen-specific CD4+ T cells and ablated the development of cell-mediated immunity. Injection of antigen with the adjuvant lipopolysaccharide allowed spreading of antigen through the lymph node conduits, and allowed antigens to be acquired and presented peptide–MHC II complexes. The small calcium binding protein S100A9 (MRP14) was identified as a discriminating marker protein in SF by global proteomic analysis [5,6]. These results were confirmed by ELISA and it was found that plasma levels of the S100A9/A9 heteroreceptor are correlating well with levels in SF; hence determination of plasma levels is applicable for distinguishing RA patients from patients with other inflammatory joint diseases as well as from OA patients and from controls. Initial studies on RA samples indicate that plasma levels of the S100A9/A9 heteroreceptor may become a useful marker in monitoring anti-tumor necrosis factor alpha therapy responses.

References


S8

Chemokine decoy receptors in inflammation

G Graham

Division of Immunology, Infection and Inflammation, University of Glasgow, UK


S9

Follow up study of B-lymphocyte depletion in the treatment of patients with systemic lupus erythematosus

MJ Leandro, J CW Edwards, MR Ehrenstein, G Cambridge, DA Isenberg

Centre for Rheumatology, University College London, London, UK


See page S59
Mechanisms of cartilage matrix turnover: synergistic interactions of proinflammatory cytokines with oncostatin M in upregulating matrix metalloproteinases and ADAMTS metalloproteinases

TE Cavston, H Bigg, J Milner, J Catterall, T Morgan, E Barksby, W Hui, A Rowan
Rheumatology, School of Clinical Medical Sciences, The Medical School, University of Newcastle, UK


Cartilage is a highly organised tissue where the arrangement of collagen and proteoglycan and minor components is carefully controlled. The chondrocytes maintain a precise balance between anabolic and catabolic processes that maintains this extracellular matrix. Proteoglycan removal is rapid and reversible while collagen removal is slower but, once removed, is difficult to replace. Our main research focus is to discover the mechanism of collagen turnover and we study the members of the matrix metalloproteinase (MMP) family that specifically cleave type II collagen to give characteristic one-quarter and three-quarter fragments; MMP-1, MMP-8, MMP-13 and also MMP-2 and MMP-14 cleave in this way.

Oncostatin M (OSM) is a member of the IL-6 family that synergises with IL-1 to induce cartilage proteoglycan and collagen degradation in a cartilage explant culture system [1]. A significant finding is the synergistic induction of the collagenase, MMP-1, which occurs via interplay between the JAK/STAT, AP-1 and MAPK pathways. Other collagenases such as MMP-8 and MMP-13 are also upregulated along with MMP-14 and MMP-3. This latter enzyme can activate the collagenases, and an important feature of OSM may be its ability to promote the activation of enzymes that initiate activation cascades that lead to the production of active collagenases. OSM can also exacerbate the effects of other important proinflammatory mediators such as tumour necrosis factor alpha (TNF-α) and IL-17. Molecular and cellular studies aim to discover the mechanism of action of OSM that leads to synergy. Affymetrix microarrays show that a specific cohort of genes are upregulated by these cytokine mixtures including MMPs, ADAMs (A disintegrin and metalloproteinases), activators, cell surface proteins and cytokines. Two-dimensional gel electrophoresis and proteomic analysis confirm that many of the corresponding proteins are made by chondrocytes after stimulation. Purification of specific proteins from conditioned culture medium has been undertaken to try and determine the enzymes responsible for collagen turnover.

In order to assess the effects of these cytokine combinations in vivo, we have injected OSM in combination with either IL-1 or TNF-α intra-articularly into murine knee joints using recombinant adenoaviruses. Engineered adenoaviruses were administered for only 7 days, after which time joints were fixed, decalcified and sectioned. Histological analyses indicated marked synovial hyperplasia and inflammatory cell infiltration for IL-1, TNF-α and OSM treated joints but not in controls (joints treated with an ‘empty’ adenoavirus). The inflammation was more pronounced for both OSM + IL-1 and OSM + TNF-α combinations with evidence of extensive cartilage and bone destruction. Significant loss of both proteoglycan and collagen was also seen for these combinations, and an increased expression of MMPs with decreased tissue inhibitors of metalloproteinases was found in both articular cartilage and synovium. The effects of these combinations were significantly greater than those seen with any of the cytokines alone. Cytokine combinations also upregulated RANK/RANKL, and increased the number of TRAP-positive cells showing an increase in osteoclast formation and bone damage. Taken together, these data confirm that, in vivo, OSM can significantly exacerbate the effects of both IL-1 and TNF-α resulting in inflammation and tissue destruction characteristic of that seen in rheumatoid arthritis.

Reference

Collagenases and aggrecanases: understanding the role of non-catalytic domains in cartilage matrix breakdown

H Nagase, R Visse, M Kashwagi, C Grendon, Y Isho
Kennedy Institute of Rheumatology Division, Imperial College London, UK

Degradation of cartilage matrix, which mainly consists of collagen fibrils and aggrecan, seriously impairs the function of joints. The primary cause of this process is elevated proteolytic enzymes. Collagen fibrils are degraded by a group of matrix metalloproteinases (MMPs) including collagenases (MMP-1, MMP-8 and MMP-13), gelatinase A (MMP-2) and MT1-MMP (MMP-14). Aggrecan is degraded by MMPs and ‘aggrecanases’ belonging to the ADAMTS family. Inhibitors of these metalloproteinases are considered as potential therapeutic agents to protect cartilage degradation, and many active site-directed inhibitors with a zinc-chelating moiety have been developed. Unfortunately, those compounds have serious side effects possibly due to lack of selectivity [1]. In the hope of developing new types of inhibitors we have been investigating the mechanisms of action of collagenases and aggrecanases. Collagenases are unique as they can degrade triple helical collagen into one-quarter and three-quarter fragments, a crucial step for collagenolysis in the tissue. Typical collagenases consist of a catalytic domain and a hemoprotein domain that are connected by a linker peptide. Both domains are essential for collagenolysis. The three-dimensional structure of the active MMP-1, however, indicated that the active site of the enzyme is too narrow to accommodate triple-helical collagen. We have recently shown that collagenase locally unwinds triple helical collagen before it hydrolyses the peptide bonds [2]. Based on a series of mutagenesis mutagenesis we predict that the collagen binding site is created by a catalytic and the hemoprotein domains. The protein binding groove is partially blocked by the prodomain in the zymogen of MMP-1 (proMMP-1), explaining its inability to bind to collagen unless it is activated. Overall proMMP-1 has a ‘closed’ configuration in contrast to the ‘open’ configuration of the active MMP-1. The exact mechanism of how collagenase unwinds collagen is under investigation.

Another key collagenase is MT1-MMP. It is highly expressed in rheumatoid synovium lining cells invading into the cartilage. Overexpression of recombiant MT1-MMP in COS7 cells in vitro degradate reconstituted type I collagen films. This reaction requires dimerisation of the enzyme on the cell surface through the hemoprotein domain. When dimerisation of MT1-MMP is prevented by overexpression of the membrane-anchored MT1-MMP hemoprotein domain, the collagenolytic activity was blocked, but not its general photolytic activity.

Among 19 ADAMTSs in humans, six have been shown to have aggrecanase activity. These are disintegrin, one hemoprotein domain and one cysteine-rich and one spacer domain, one cysteine-rich and one spacer domain. Full-length ADAMTS-4 (aggrecanase 1) is active on aggrecan only, but when the C-terminal spacer domain is deleted it expresses broader proteolytic activity and digests fibronectin, fibromodulin, decorin and biglycan, as well as maintaining aggrecanase activity [3]. Further deletion of the cysteine-rich and hemoprotein domains greatly reduces both activities [3]. These studies suggest that activities of collagenases and aggrecanases will be attenuated by inhibitors or antibodies that interact directly with their non-catalytic ancillary domains (exosite/allosteric inhibitors). Such molecules will be attractive for therapy as they will be highly selective because they are based on the unique mechanism of each proteinase.

References

Acknowledgements This work was supported by grants from the Wellcome Trust, Cancer Research UK, the Arthritis Research Campaign and the National Institutes of Health (USA).

The effects of inflammatory arthritis on bone remodeling

SR Goldring
Beth Israel Deaconess Medical Center, Division of Rheumatology, and New England Baptist Bone & Joint Institute, Harvard Institutes of Medicine, Boston, Massachusetts, USA

Rheumatoid arthritis (RA) represents an excellent model for gaining insights into the adverse effects of inflammatory arthritis on skeletal remodeling. Bone erosions at the margins of diarthrodial joints represent the radiographic hallmark of RA. Histopathologic examination of the bone–pannus interface in patients with RA reveals the presence of a heterogeneous population of cells lining the bone surface, including multinucleated cells expressing the phenotypic repertoire of osteoclasts, the cells that mediate bone resorption in physiologic remodeling. Further evidence implicating osteoclasts in the pathogenesis of marginal joint erosions is derived from animal models of inflammatory arthritis in which animals lacking the capacity to form osteoclasts fail to develop joint erosions. Studies have shown that the RA synovial tissue contains abundant osteoclast precursors and that the RA synovium is a rich source of factors that potentiate osteoclast differentiation and activation activity. Particular attention has focused on receptor activator of NF-κB ligand (RANKL), a member of the tumor necrosis factor ligand family, because of the requirement of this factor for osteoclastogenesis. RANKL is expressed by synovial fibroblasts and activated T cells in RA synovial tissues and in culture of a prototypic collagenase, collagenase 1 (MMP-1), however, indicated that the active site of the enzyme is too narrow to accommodate triple-helical collagen. We have recently shown that collagenase locally unwinds triple helical collagen before it hydrolyses the peptide bonds [2]. Based on a series of mutagenesis mutagenesis we predict that the collagen binding site is created by a catalytic and the hemoprotein domains. The protein binding groove is partially blocked by the prodomain in the zymogen of MMP-1 (proMMP-1), explaining its inability to bind to collagen unless it is activated. Overall proMMP-1 has a ‘closed’ configuration in contrast to the ‘open’ configuration of the active MMP-1. The exact mechanism of how collagenase unwinds collagen is under investigation.

Available online http://arthritis-research.com/supplements/7/S1
resorption is not matched by a compensatory increase in bone formation. In addition to the disordered focal bone remodeling associated with the synovial lesion, patients with RA also exhibit evidence of generalized axial and appendicular bone loss at sites that are distant from inflamed joints. Assessment of biochemical markers of bone turnover indicates that there is a generalized increase in bone resorption, and that there is a correlation between disease activity and the rate of systemic bone resorption. It is likely that this generalized skeletal bone loss is mediated by synovial cytokines with osteoclastogenic activity that enter the circulation and act as ‘endocrine’ factors to adversely affect systemic bone remodeling. Recent studies indicate that agents, such as the bisphosphonates, that target osteoclast-mediated bone resorption have the capacity to reduce not only generalized bone osteoporosis but also may have efficacy in retarding the progression of focal joint erosions.

S13 Genetics and bone disease

SH Bolton

Rheumatic Diseases Unit, University of Edinburgh, UK


Bone diseases are a common cause of morbidity and mortality in developed countries, and genetic factors play an important role in the pathogenesis of these diseases. The most common form of bone disease is osteoporosis, which is characterized by reduced bone mineral density (BMD) and an increased risk of fracture. Environmental factors such as diet and exercise influence BMD, but genetic factors play a predominant role, accounting for up to 85% of the variation in peak BMD. Several candidate genes have been identified that regulate BMD and susceptibility to fracture, including bone morphogenic protein 2, collagen type I alpha 1, the vitamin D receptor, the estrogen receptor and lipoprotein receptor related protein 5 (LRP5). Paget’s disease of the bone (PDB) is characterised by focal abnormalities of increased bone turnover. Mutations in several genes have been identified as causes of PDB and related syndromes including receptor activator of NF-κB (RANK), osteoprotegerin, sequestosome 1 and valosin containing protein. All of these genes play a role in the RANK signaling pathway, which is essential for osteoclast activation. Rare bone diseases such as osteopetrosis and hereditary osteoclasts are also caused by mutations in genes that affect bone cell function. Osteopetrosis is characterised by increased BMD, and failure of osteoclastic bone resorption due to mutations in genes that encode proteins that are essential for osteoclast activity like the chloride pump and proton pump, or mutations in genes like cathepsin K, which breakdown bone matrix. Although the bones are dense, fractures are common in osteopetrosis because of reduced bone quality. Osteosclerosis occurs because of mutations in genes that increase osteoblast activity, including SOST, transforming growth factor beta and LRP5. Osteosclerotic patients also have increased BMD but fractures are rare, because bone quality is normal. From a clinical standpoint, advances in knowledge about the genetic basis of bone disease offers the prospect of developing new markers for assessing fracture risk and the identification of new molecular targets that will form the basis for the design of new treatments.

S14 Defining a role for fibroblasts in the persistence of chronic inflammatory joint disease

C Buckley, A Filer, O Heworth, G Parsonage, K Raza, M Salmon

Rheumatology Research Group, Division of Immunology and Infection, MRC Centre for Immune Regulation, The University of Birmingham, UK


One of the most important but as yet unanswered questions in inflammation research is not why chronic inflammation occurs but why it does not resolve. Current models of inflammation stress the role of antigen-specific lymphocyte responses and attempt to address the caustive agent. However, recent studies have begun to challenge the primacy of the lymphocyte and have begun to focus on an extended immune system in which stromal cells, such as macrophages and fibroblasts, play a role in the persistence of the inflammatory lesion.

In this lecture I will illustrate how fibroblasts play an important role in regulating the switch from acute to chronic persistent inflammation associated with the pathology of diseases such as rheumatoid arthritis [1]. In chronic inflammation the normal physiological process of the death and emigration of unwanted inflammatory effector cells becomes disordered leading to accumulation of leucocytes [2–4] with a persistent, self-sustaining role in changes of tissue homeostasis and have been found in a variety of malignancies as well as in the inflamed and hyperplastic synovium in rheumatoid arthritis. Accumulating evidence suggests that the activation of rheumatoid arthritis synovial fibroblasts (RASF) is associated with alterations in apoptosis, especially at sites of invasion into cartilage and bone. Specifically, it has been demonstrated that RASF are less susceptible to Fas-induced cell death than osteoarthritic synovial fibroblasts but show higher expression levels of Fas.

In this context, we have investigated the role of the small ubiquitin-like modifier SUMO-1 in the regulation of apoptosis. We found that increased levels of SUMO-1 in RASF but not in osteoarthritic synovial fibroblasts were associated with a reduced susceptibility of RASF to Fas-induced apoptosis. Using small interfering (si)RNA to knock-down the expression of SUMO-1 as well as retrolval gene transfer of SUMO-1, we could establish a functional relationship between the expression of SUMO-1 and the resistance of RASF against apoptosis. Moreover, it was demonstrated by gene transfer of the nuclear SUMO-protease SENP1 that, rather than by interacting directly with the Fas-associated death domain, SUMO-1 inhibits apoptosis through recruiting pro-apoptotic molecules such as DAXX into nuclear PML bodies, where they cannot exert their pro-apoptotic effects.

Taken together, there is growing evidence that in activated fibroblasts, such as in RASF, there is a close association between anti-apoptotic and destructive pathways. In addition to cytokine-dependent inflammatory mechanisms, the intrinsic upregulation of anti-apoptotic molecules contributes to the resistance of RASF against apoptosis. Post-translational modification of nuclear proteins through SUMO-1 appears to constitute an important mechanism of apoptosis regulation. Therefore, the inhibition of molecules that confer the resistance of RASF to apoptosis constitutes a most interesting therapeutic target.

References


S15 Regulating apoptosis in fibroblasts

T Pap, A Cinskla, A Drynda, A Wilie, A Baier, S Gay, I Meinlcek

1Division of Molecular Medicine of Musculoskeletal Tissue, University Hospital, Münster, Germany; 2Division of Experimental Rheumatology, University Hospital Magdeburg, Germany; 3Center of Experimental Rheumatology, Department of Rheumatology, University Hospital, Zürich, Switzerland; 4Department of Traumatology, Hand and Reconstructive Surgery, University Hospital, Münster, Germany


Apoptosis constitutes a highly selective way of eliminating unwanted inflammatory effector cells and is a key mechanism for the balanced growth and regeneration of tissues. In addition to genotoxic stress and the withdrawal of growth factors, apoptosis can be induced by death receptors. Such receptors trigger apoptosis through an approximately 90 amino acid death domain. Prominent and best-characterized members of the death domain receptor family are Fas (CD95/Apo-1) and the p55 TNF receptor (TNFR). Alterations in receptor-mediated apoptosis may result in changes of tissue homeostasis and have been found in a variety of malignancies as well as in the inflamed and hyperplastic synovium in rheumatoid arthritis. Accumulating evidence suggests that the activation of rheumatoid arthritis synovial fibroblasts (RASF) is associated with alterations in apoptosis, especially at sites of invasion into cartilage and bone. Specifically, it has been demonstrated that RASF are less susceptible to Fas-induced cell death than osteoarthritic synovial fibroblasts but show higher expression levels of Fas.

Recent studies have shown that both cytokine-dependent and cytokine-independen mechanisms contribute to the resistance of RASF against Fas-induced apoptosis. Thus, tumor necrosis factor alpha (TNF-α) – a major inflammatory cytokine in the rheumatoid synovium – fails to induce apoptosis in RASF, but reduces the susceptibility of these cells to Fas-mediated cell death through the induction of the transcription factor NF-κB. Providing a link between altered apoptosis and cartilage destruction, we have shown that overexpression of TIMP-3 through gene transfer not only reduces the invasiveness of RASF but also modulates the apoptosis-inhibiting effects of TNF-α. RASF overexpressing TIMP-3 are sensitized strongly to Fas-induced cell death by TNF-α, and gene transfer of TIMP-3 inhibits the TNF-α-induced activation of NF-κB. While these effects of TNF-α on apoptosis can be found in different fibroblasts, several anti-apoptotic molecules have been demonstrated to be upregulated specifically in RASF.

In this context, we have investigated the role of the small ubiquitin-like modifier SUMO-1 in the regulation of apoptosis. We found that increased levels of SUMO-1 in RASF but not in osteoarthritic synovial fibroblasts were associated with a reduced susceptibility of RASF to Fas-induced apoptosis. Using small interfering (si)RNA to knock-down the expression of SUMO-1 as well as retrolval gene transfer of SUMO-1, we could establish a functional relationship between the expression of SUMO-1 and the resistance of RASF against apoptosis. Moreover, it was demonstrated by gene transfer of the nuclear SUMO-protease SENP1 that, rather than by interacting directly with the Fas-associated death domain, SUMO-1 inhibits apoptosis through recruiting pro-apoptotic molecules such as DAXX into nuclear PML bodies, where they cannot exert their pro-apoptotic effects.

Taken together, there is growing evidence that in activated fibroblasts, such as in RASF, there is a close association between anti-apoptotic and destructive pathways. In addition to cytokine-dependent inflammatory mechanisms, the intrinsic upregulation of anti-apoptotic molecules contributes to the resistance of RASF against apoptosis. Post-translational modification of nuclear proteins through SUMO-1 appears to constitute an important mechanism of apoptosis regulation. Therefore, the inhibition of molecules that confer the resistance of RASF to apoptosis constitutes a most interesting therapeutic target.
S16 Innate immunity and the anti-viral state of rheumatoid synovium
GS Firestein
UCSD School of Medicine, La Jolla, California, USA
Rheumatoid arthritis (RA) is an immune-mediated disease with synovial inflammation and invasion of the extracellular matrix. While adaptive immunity plays a key role in the pathogenesis of RA, the contribution of innate immune responses has been increasingly appreciated in recent years. Toll-like receptors (TLRs) and cytokines in the rheumatoid synovium can activate signal transduction pathways that induce proinflammatory genes and perpetuate synovitis. Understanding these signaling mechanisms helps us understand the pathogenesis of disease and identify novel therapeutic targets.

Among the signaling pathways that are potentially involved in inflammation, the IKK-related kinase, inducible IKK (IKKβ or IKKγ), appears to play a key role in innate immune responses in the joint and modulates synovial inflammatory responses. This kinase, along with a second IKK-related kinase TANK binding kinase 1 (TBK1), was originally identified as a NF-κB activating enzyme that phosphorylates IκB. It is now clear, however, that this represents only one of several substrates for this family. For instance, IKKγ also phosphorylates interferon regulatory factor (IRF) and coordinates the activation of IRF and NF-κB after TLR ligation. IKKγ may also link the NF-κB and CCAAT enhancer binding protein (C/EBP) pathways in lipopolysaccharide-stimulated cells. The novel roles for IKKi suggest that it contributes to the signaling pathways involved in synovial inflammation. Moreover, IKKi appears to play a key role in the establishment of an ‘anti-viral state’ through the activation of NF3 and c-Jun with subsequent production of interferon beta (IFN-β) and other genes involved in host defense.

We previously demonstrated that IKKβ is constitutively expressed in RA synovial tissue and fibroblast-like synoviocytes (FLS), and that the gene can be induced by cytokine stimulation. More recent studies now show that functional activity of IKK in cultured synoviocytes is rapidly increased by exposure to proinflammatory cytokines and TLR agonists. We have also shown that IFNβ is activated in RA synovium, which represents an early step in the IKK-mediated expression of anti-viral genes like IFN-β. Additional preliminary data with human FLS suggest that the IKKi pathway can activate other signaling cascades, such as c-Jun, which play a role in assembly of the interferon enhancerosome to increase IFN-β expression. Using FLS from Ikki knockout mice, we have shown that IKKI can act as a key link between TLR/ckitcine receptor ligation and expression of cytokines and matrix metalloproteinases. IKKI might serve in an alternative signaling pathway for activation of innate immunity in RA and establishing an anti-viral state in the synovium, especially through the activation of IRF3-driven and c-Jun-driven genes.

S17 Signal transduction in T lymphocytes
D Cantrell
Division of Cell Biology & Immunology, School of Life Sciences, University of Dundee, Dundee, UK

S18 Title to be confirmed
J Kalden
University Erlangen-Nuremberg, Erlangen, Germany

Poster abstracts
P1 Differential effects of T-cell specific PKC-theta inhibition or selective intra-articular NF-κB inhibition on synovial inflammation in rat adjuvant arthritis
SW Tas1, MJ Vervoordeldonk1, N Haji1, M May2, S Ghosh3, PP Tal4
1Division of Clinical Immunology & Rheumatology, AMC/University of Amsterdam, The Netherlands; 2School of Veterinary Medicine, Department of Animal Biology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 3Immunobiology Section, Yale University School of Medicine, New Haven, Connecticut, USA
Objective NF-κB is a key regulator of synovial inflammation. In the initiation phase of rheumatoid arthritis (RA) dendritic cells and T cells are likely to be important, whereas in established arthritis other cells play a key role as well. We investigated the relative effect of upstream NF-κB inhibition specifically in T cells versus non-cell type specific NF-κB inhibition in different stages of rat adjuvant arthritis (AA), using either the T-cell specific PKC-theta inhibitory factor (PIF) peptides or non-cell type specific IKK-beta blocking NEMO binding domain (NBD) peptides. The effects of the NBD peptide on human RA synovial tissue in culture were also evaluated.

Methods AA was induced in Lewis rats by intradermal injection of heat-killed mycobacteria. Rats develop clinical signs of arthritis 10–12 days after immunization. PIF or NBD peptides (150 μg) were administered either intraperitoneally or intra-articularly into the ankle joint at different time-points. The course and severity of arthritis was monitored using water-displacement plethysmometry. On day 21 rats were sacrificed and tissue specimens were collected for routine histology and X-rays of the ankle joints. Human RA synovial tissue was collected by arthroscopy and cultured ex vivo. NBD (100 μM). Tumor necrosis factor alpha specific IL-1β production was measured in the supernatant after 7 days by ELISA.

Results Intra-articular injection of the T-cell specific PKC-theta inhibitor PIF on days 10 and 12 did not result in amelioration of arthritis nor reduced bone erosion. However, intraperitoneal injection of PIF on days –1, 1 and 3 resulted in reduced T-cell proliferation on day 6 in response to TCR triggering (50%; P<0.03) or cognate antigen (PPD) (30%; P=0.05). Furthermore, this resulted in a slightly reduced severity of arthritis (area under the curve 18.47 versus 22.86; P=not significant) and radiological damage (erosion score 4 versus 6; P=not significant). Non-cell type specific NF-κB blockade by the NBD peptide resulted, however, in significantly reduced severity of arthritis (P<0.0001) and radiological damage (P=0.04) when injected intra-articularly on days 10 and 12. In addition, proinflammatory cytokine expression was significantly lower in synovial tissue of NBD-treated rats. Incubation of human RA synovial tissue with NBD peptides resulted in 33% inhibition of tumor necrosis factor alpha induced IL-1β production in the supernatant (P<0.01).

Conclusions Specific NF-κB blockade using a small molecule inhibitor of IKK beta has anti-inflammatory effects in AA and human RA synovial tissue. Inhibition of PKC-theta has clear effects on T-cell proliferation when administered around the induction of arthritis, but very limited effects on the clinical course of arthritis, suggesting that NF-κB activity in other cell types contributes significantly to the inflammatory response. These results indicate that IKK-beta-targeted NF-κB blockade is superior to T-cell specific PKC-theta inhibition in established arthritis.

Acknowledgement This study was supported by a EULAR Young Investigator Award to SWT.

P2 Positive cytoplasmic indirect immunofluorescence on HEp2 cells of unknown pattern: what to report to rheumatologists
Z Rotar, B Boziè, B Rozman, T Kweder
University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia
The aim of our study was to evaluate antibodies against ‘specific liver’ antigens in selected sera from patients with positive ‘AMA like’ and unidentified (UD) Hep2 cytoplasmic immunofluorescence (ctp IIF).

Sera of 75 inpatients and outpatients from the Department of Rheumatology, Ljubljana met the inclusion criteria: 36 with AMA-like and 39 with UD pattern. All sera were also negative for anti-M2 and/or antibodies against pyruvat dehydrogenase complex as well as negative to other defined ctp IIF patterns according to European Consensus Finding Study: lysosomal-like, Golgi-like, vimentin-like and actin-like. The majority of patients fulfilled the criteria for connective tissue diseases and rheumatoid arthritis.

Antibodies against intracellular antigens were screened by IIF on Hep2 cells (Immunocentrics, Sacramento, CA, USA). Antibodies against LKM1, SLA, LC1 and Sp100 were performed by line immunoassay (Imtec, Berlin, Germany).

There was no difference in AMA-like and UD ctp IIF concerning antibodies against ‘specific liver’ antigens. A surprisingly high prevalence of positive anti-LKM1 was found in sera regardless of the IIF pattern (Table 1).

Table 1 Antibodies against ‘liver specific’ antigens in sera with AMA-like and UD ctp IIF

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Sp100</th>
<th>LKM1</th>
<th>SLA</th>
<th>LC1</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMA-like</td>
<td>42</td>
<td>4</td>
<td>19 (45%)</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Unidentified</td>
<td>33</td>
<td>4</td>
<td>14 (42%)</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>All</td>
<td>75</td>
<td>8 (11%)</td>
<td>33 (44%)</td>
<td>2 (3%)</td>
<td>1 (1%)</td>
</tr>
</tbody>
</table>

Anti-LKM1 has been considered as one of the markers for autoimmune hepatitis type II characterised by fulminant onset and high inflammatory activity according to Imtec data. None of our patients with positive anti-LKM1 had any serious
hepatic involvement, therefore they had not been histopathologically evaluated. Only few of them exhibited minor deviations in liver enzymes (less than 1 x upper normal limit). There was slightly lower prevalence of connective tissue disease patients found among UD ctp IIF (Table 2).

### Table 2

| Antibodies against 'liver specific' antigens in sera with AMA-like and UD ctp IIF |
|-------------------------------|-------------------|------------------|-------------------|---------|
| Patients                      | n (%)             | Sp100            | LKM1             | SLA LCL   |
| AMA (n = 42)                  |                   |                  |                  |         |
| Connective tissue diseases   | 25/42 (60%)       | 3                | 8                | 0 1     |
| Rheumatoid arthritis         | 6/42 (14%)        | 0                | 5                | 0 0     |
| Other                         | 11/42 (26%)       | 1                | 6                | 0 0     |
| Unidentified (n = 33)         |                   |                  |                  |         |
| Connective tissue diseases   | 15/33 (46%)       | 3                | 6                | 2 0     |
| Rheumatoid arthritis         | 6/33 (18%)        | 0                | 2                | 0 0     |
| Other                         | 12/33 (36%)       | 1                | 6                | 0 0     |

An UD ctp IIF pattern is a frequent laboratory finding by it seems not to be of much help to rheumatologists. A search for antibodies against 'specific liver' antigens seems not to be justified for delineation of hepatic involvement in patients with rheumatic diseases. According to the literature in patients with autoimmune hepatitis the meaning of these antibodies is different.

### P3

**Synovial hypoxia inducible factor-1α expression is inversely related to tissue oxygen levels in vivo in inflammatory arthritis**

**P Donovan1, V Sandhu2, D Peston2, A Sandison2, PC Taylor1, 2**

1Kennedy Institute of Rheumatology Division, Imperial College, London, UK; 2Charing Cross Hospital, London, UK


**Background** Tissue hypoxia in inflammation induces the upregulation of a gene program associated with angiogenesis, glycolysis and adaptation to pH via the hypoxia-inducible transcription factors (HIFs). In this study we investigate the relationship between synovial tissue oxygen levels in inflammatory arthritis and tissue expression of HIF-1α and vascular endothelial growth factor (VEGF).

**Methods** Novel silver microelectrode technology was used to measure synovial tissue oxygen levels under direct vision during arthroscopy in six patients with inflammatory arthritis of the knee. A sterile silver needle electrode comprising a teflon-insulated silver wire was embedded in a 19 G hypodermic needle of 10 cm length and introduced to the intra-articular space via a medial suprapatellar approach such that the electrode tip could be directly visualised by the arthrooscope introduced from a standard lateral infrapatellar approach. The voltage applied was adjusted to give a diffusion-limited current for the reduction of oxygen. Synovial biopsies were taken under direct vision from exactly the point at which tissue oxygen levels were measured and snap-frozen immediately. HIF-1α, HIF-2α and VEGF were detected by immunohistochemistry in fixed synovial biopsy sections and the imunopositive area fraction was determined by quantitative digital image analysis.

**Results** The mean and standard deviation for oxygen tension in the synovial tissue of the joints sampled was 15.4 ± 9.6 mmHg, range 24.4 ± 4.4 mmHg. The mean and standard deviation for immunopositive area fraction for HIF-1α was 0.64 ± 0.39% and for HIF-2α was 4.9 ± 6.7%. HIF-1α and HIF-2α staining were detected predominantly in the synovial lining layer. There was a significant, inverse relationship between synovial tissue oxygen measurement in vivo and tissue expression of HIF-1 (Pearson r = −0.86, P = 0.03) and similarly between synovial tissue oxygen and tissue expression of VEGF (Pearson r = −0.89, P = 0.02). There was a positive, highly significant correlation between synovial expression of HIF-1α and VEGF (Pearson r = 0.97, P = 0.0005).

**Conclusions** In this study we directly demonstrate that intra-articular pO2 is markedly reduced in inflammatory arthritis. Furthermore, in the same patients, synovial tissue oxygen tensions are inversely proportional to HIF-1α and VEGF expression, suggesting that this environment contributes to the perpetuation of inflammation and associated tissue destruction.

### P4

**Prophylactic administration of abatacept (CTLA4-Ig; BMS-188667) prevents disease induction and bone destruction in a rat model of collagen-induced arthritis**

**C Kliwinska, DKukral, JPostelnik, BKrishnan, LKillar, SNadler, RTownsend**

Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, USA


**Background and objectives** Rheumatoid arthritis is an autoreactive disease in which activated T cells play an important role orchestrating the autoimmune response giving rise to the inflammatory cascade required for joint inflammation and bone destruction. The CD28/B7 costimulatory pathway is critical for full T-cell activation, and modulating this pathway has been shown to inhibit T-cell activation leading to inhibition of these immune responses. Abatacept modulates T-cell activation by interfering with the engagement of CD80/86 with CD28.

Abatacept has been shown to provide significant improvement in the signs and symptoms of rheumatoid arthritis in a phase II trial. Here, we examine the effect abatacept administration has on disease induction, anti-collagen antibody production and bone destruction in a rat model of collagen-induced arthritis.

**Methods** Female DA rats were immunized subcutaneously on day 0 with 300 μg bovine type II collagen in incomplete Freund’s adjuvant at the base of the tail. Immunized rats were administered either 1 mg/kg abatacept or a control human IgG IP on days –1, 0, 2, 4, 6, 8 and 10. Disease progression was monitored by measuring the paw volume in milliliters with a plethysmometer. Both hind paws were measured and the change in volume from baseline measurements (day 0) were recorded. At the conclusion of the study (day 27), synovium and bone were collected from each animal for measurement of collagen-specific antibodies by ELISA as well as serum cytokine measurements. Legs from the rats were removed and placed in formalin and prepared for histological analysis as well as analysis of bone morphology by micro-CT.

**Results** By day 16 of the study, significant paw swelling was observed in the IgG-treated control animals and continued to increase throughout the study until reaching a plateau (~3–5 ml) on day 21. Administration of abatacept abrogated paw swelling throughout the course of the study. The IgG-treated rats reached 100% incidence while no incidence was observed in the abatacept-treated group. Serum anti-collagen antibody levels correlated well with the paw swelling data where abatacept administration resulted in 90% inhibition of collagen-specific antibodies. We also found that abatacept decreased the expression of many of the circulating cytokines and chemokines that were upregulated in diseased animals. The micro-CT data revealed that abatacept treatment promotes the bone from destruction as the knees and ankles of these rats appear to be normal.

**Conclusion** Abatacept, a selective co-stimulation modulator, significantly inhibited the onset and progression of disease in a rat collagen-induced arthritis model. In these studies, paw swelling, collagen-specific antibodies and bone destruction were all inhibited by the treatment.

### P5

**The transcription T-bet is required for optimal proinflammatory trafficking of CD4+ T cells**

**RM Rao1, GM Lord2, H Choe3, AH Lichtman4, FW Luscinskas1, LH Gimble1**

1Center of Excellence in Vascular Biology, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA; 2Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA; 3Department of Pediatrics, Children’s Hospital, Boston, Massachusetts, USA


**Background** The transcription factor T-bet is a critical regulator of Th1 effector function. Animals deficient in T-bet are protected from a variety of inflammatory diseases, including systemic lupus erythematosus and inflammatory arthritis. An essential function of Th1 cells is the ability to traffic appropriately to sites of inflammation, which is largely dependent on the expression of specific selectin ligands and chemokine receptors. We therefore hypothesised that T-bet would modulate lymphocyte trafficking in vitro and in vivo by direct regulation of both selectin binding and chemokine function.

**Methods** Bab/c mice deficient in, or transgenic for, T-bet had been generated previously. T-bet–/– × DO11.10 TCR and T-bet+ × Ifn-γ+ mice were generated by backcrossing for >10 generations. CD4+ T cells were generated from primary lymph nodes from all these mice by positive selection and stimulation with appropriate antigen. Functional analysis used the following four methods: adoptive transfer into WT Bab/c mice, which were then injected with OVA, cells were harvested from the spleen, lymph node and peritoneum; selectin binding, interactions with immobilised P-selectin and E-selectin under conditions of laminar flow were examined in a parallel plate flow chamber; expression of selectin ligands, using flow cytometry, real-time PCR and 32P incorporation; and chemokine receptor expression and function, using flow cytometry, real-time PCR, transwell chemotaxis and endothelial binding under flow conditions.
Results Selective migration of T-bet+/− CD4+ T cells in a Th1-dependent model of peripheral inflammation was completely abrogated. Further investigation revealed that this effect was due to a 50% reduction in binding to P-selectin but not to VLA-4. The effect was seen in vitro and in vivo in fluorescent conditions AB, Göteborg, Sweden.

Conclusions These data establish that T-bet impairs a specific migratory program onto developing CD4+ cells via control of P-selectin binding and CXCR3 expression and function. Furthermore, as E-selectin and CCR5 binding are unimpaired, this reveals a level of control on trafficking of Th1 lymphocytes not recognised by previous paradigms.

Acknowledgements This work was supported by the Arthritis Research Campaign (R0600), the Medical Research Council (G108/380) and the National Institutes of Health (AI48126, HL36028, LS53993).

P6 Specificity of CD4 T-cell responses to aggrecan in BALB/c and DR1 transgenic mice

K Lowes1, AA von Delwisch2, N McKie3, DM Allmann2, JA Goodacre2, AD Rowan1, JH Robinson1

1Musculoskeletal Research Group, Clinical Medical Sciences, University of Newcastle upon Tyne, UK; 2Human Disease Immunogenetics Group, Imperial College School of Medicine, London, UK; 3Lancashire Postgraduate School of Medicine and Health, Preston, UK


Background It has been suggested that rheumatoid arthritis (RA) is initiated or perpetuated by CD4 T cells activated by presentation of joint antigens by susceptible MHC class II molecules including HLA-DR4 and DR1. A number of candidate antigens have been investigated including cartilage-derived type II collagen and aggrecan. Immunisation of susceptible strains of mice with aggrecan, including BALB/c (H-2d), induces autoimmune arthritis, providing an animal model of human RA [1]. Immunisation with peptides predicted to bind to HLA-DR1 also induces T-cell responses in BALB/c mice [2]. The auto- immune T-cell response focuses on only a few epitopes within restricted regions of aggrecan such as the G1, globular domain, for reasons that are poorly understood. One explanation is a failure of self-tolerance due to poor presentation of these aggrecan epitopes in the thymus, and presentation of the same epitopes in joints following release and processing of the normally sequestered aggrecan induced by early inflammatory events. T-cell responses have also been observed in RA patients mapping epitopes within the G1 domain.

Aim To characterise aggrecan-specific T-cell hybridomas from BALB/c (H-2d) and DR1 to investigate the mechanisms of antigen presentation of articular aggrecan CD4 T-cell epitopes of aggrecan.

Methods Aggrecan-specific T-cell hybridomas were generated from spleen cells of BALB/c (H-2d) and DR1×10101 transgenic mouse. Cultures of invasive and non-invasive aggrecan-specific T-cell hybridomas were measured by proliferation of CTL-2 indicator cells to T-cell hybridoma supernatants in the presence of titrated thymidine and expressed as counts per minute.

Results The specificity of most aggrecan-specific T-cell hybridomas mapped to the aggrecan G1 domain using synthetic peptides representing known H-2d-restricted or DR1-restricted CD4 T-cell epitopes. However, most cloned (and recloned) T-cell hybridomas recognised two of the H-2d-restricted epitopes (84–103 and 169–189) as well as two of the DR1-restricted epitopes (148–165 and 292–311). The same synthetic peptides were not recognised by H-2d-restricted and DR1-restricted T-cell hybridomas and unrelated specificities and were not mitogenic for spleen cells from BALB/c or DR1-tg mice. None of the T-cell hybridomas recognised aggrecan epitopes 68–82 or 201–213.

Conclusion We are investigating this unexpected pattern of cross-reactivity between a number of known arthritogenic epitopes of aggrecan using lymph node T-cell responses of peptide-immunised BALB/c and DR1-tg mice. In addition we are investigating the mechanisms of antigen presentation of these epitopes, which may shed light on why this particular region of aggrecan is antigenic for autoreactive T cells.

References

P7 The role of hypoxia in rheumatoid tendon disease

B Sivakumar1,2, N Kang1, P Taylor2, EM Paleolog2,3

1Restoration of Appearance of Function Trust, Northwood, UK; 2Kennedy Institute of Rheumatology, Faculty of Medicine, Imperial College, London, UK; 3Division of Surgery, Anaesthetics and Intensive Care, Faculty of Medicine, Imperial College, London, UK


Background Tendon disease is often the first presentation of rheumatoid arthritis (RA). Tendon inflammation and neovascularisation in RA is the result of both inflammatory and fibroproliferative processes. Several studies have demonstrated that hypoxia and neovascularisation are involved in both inflammatory and fibroproliferative processes. In vivo oxygen tension measurements were taken intra-operatively using an established microelectrode technique. Readings were taken from tendon and joint synovium. Tissue oxygen tension was measured from areas of oxygen sampling for immunohistochemical analysis of CD31 expression, which is a marker of hypoxia

Methods Patients undergoing elective hand surgery for RA were recruited into the study. In vivo oxygen tension measurements were taken intra-operatively using an established microelectrode technique. Readings were taken from tendon and joint synovium. Tissue oxygen tension was measured using the microelectrode technique. Tissue oxygen tension was measured from areas of oxygen sampling for immunohistochemical analysis of CD31 expression, which is a marker of hypoxia.

Results We observed profound hypoxia in the synovium of RA tendons and joints in vivo. Tendon synovium was completely abrogated in vivo, compared to joints from the non-invasive synovium. Tissue oxygen tension was measured using the microelectrode technique. Tissue oxygen tension was compared to the synovium of the non-invasive synovium. Tissue oxygen tension was measured from areas of oxygen sampling for immunohistochemical analysis of CD31 expression, which is a marker of hypoxia.

Conclusion Tendon hypoxia is a feature of rheumatoid tenosynovitis. Key cytokines are regulated by hypoxia in this disease process. HIF-2α may represent the link between hypoxia and VEGF-driven angiogenesis in rheumatoid tendon disease.

Acknowledgements BM is a Royal College of Surgeons of England Research Fellow. The Kennedy Institute of Rheumatology receives a core grant from arc.

P8 Short-fibre modification facilitates adenovirus-mediated gene delivery in rheumatoid arthritis synovioctyes and synovium: role of RGD and non-RGD binding integrins

M-L Toh1, S-H Hong1, L Franqueville1, L Lindholm2, P Boulanger3, P Miossec1

1Department of Immunology and Rheumatology, Mixed Unit Civil Hospital of Lyon-Biomerieux, Edouard Herriot Hospital, Lyon, France; 2Laboratory of Virology and Viral Pathogenesis, CNRS UMR-5537, Faculty of Medicine RTH Laenec, Lyon, France; 3Department of Medical Microbiology and Immunology, University of Göttingen, and Got-A-Gene R&D, Göttingen, Sweden


Objective Adenovirus (Ad5) receptors other than Cocksackie-ad receptor have not been well explored in rheumatoid arthritis (RA) human fibroblast-like synoviocytes (FLS). Defineing these receptors may enable development of improved Ad5 vectors to specific synovial targets. As Cocksackie-ad receptor is absent in RA FLS, we investigated the efficacy and receptor usage of fibre-modified Ad5 vectors for gene delivery in vitro and in vivo.

Methods Short fibre modified vectors with seven fibre repeats (Ad5GFP-R7-knob, Ad5GFP-R7-RGD) were compared with wild-type (WT) 22 repeats.
Ad5GFP-R7-knob gene transduction was 25-fold higher than Ad5GFP-R7 (Suppl 1). Background Since the idiotypic network is an important mechanism for control-ling the immune repertoire, we tested anti-idiotypic modulation employing con-centrated specific natural polyclonal anti-dsDNA anti-idiotypic antibodies obtained from a commercial IVIG in the treatment of experimental systemic lupus erythematosus (SLE).

To address the specificity and efficacy of affinity purified IVIG, affinity purified on peptide mimetics of anti-dsDNA idiotypes, in vitro and in vivo, as treatment for experimental lupus.

Materials and methods Specific natural polyclonal anti-dsDNA anti-idiotypic antibodies were affinity purified from IVIG (OMRIX Biopharmaceutics Inc., Nes-Ze-land). Anti-dsDNA idiotypes were synthesized and used to replace the human anti-dsDNA idiotypes column. IVIG affinity purified on the synthetic peptides columns were determined as peptide-specific IVIG (psIVIG). The psIVIG compound was tested for specificity by ELISA and competition assays.

Results Each psIVG inhibited the binding of anti-dsDNA antibodies from 12 lupus patients, to dsDNA, differentially by 15% up to 46% or as a mix up to 87–94%. naïve mouse immunized with a branched peptide composed of the synthet-sic anti-dsDNA idiotypes induced the generation of elevated titers of anti-dsDNA. The anti-dsDNA generation was inhibited in the branched peptide immunized mice, following treatment with psIVIG. A cocktail of psIVIG was intro-duced to NZBxWFl1. The following clinical parameters were improved in the NZBxWFl1 psIVIG subjected mice: circulating anti-dsDNA antibodies, leukopenia, proteinuria and immunoglobulin deposits in the kidneys.

Conclusion We introduce herein an IVIG subtraction, specific for anti-dsDNA treatment for lupus patients, and discuss its efficacy and beneficial effect in sup-pression of humoral and clinical signs of SLE versus regular IVIG.

P11 Acceleration of apoptotic cells clearance by macrophages upon exposure to serum amyloid P component and its synthetic derivatives L Slutzky1, M Blank1, G Goddard1, M Fridkin1, Y Shoenfeld1
1Department of Medicine B and The Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel; 2Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel

Background Impaired clearance of apoptotic cellular debris by macrophages was recently suggested as a mechanism leading to the systemic pathogenesis of systemic lupus erythematosus patients. Serum Amyloid P component (SAP) is a plasma protein that binds apoptotic cells and macrophages. Objectives To investigate the ability of SAP protein and its synthetic peptide derivates to enhance the clearance of apoptotic cells by macrophages in vitro. Methods Macrophages were isolated from peripheral blood-cells of 38 healthy donors and the purity was confirmed by FACS analysis using C014-PE. Apopto-sis was induced in Jurkat cells using anti-Fas antibodies and confirmed by stain-ing with a caspACE® FITC-VAD-FMK. The apoptotic cells were introduced to macrophages in the presence/absence of SAP protein and SAP synthetic peptide derivates. Clearance of labeled apoptotic cells by macrophages, in vitro, was detected by FACS and analyzed under fluorescence microscope.

Results In the presence of SAP, the clearance of apoptotic cells increased twice (index 2.03) compared with the control (index 1). In the presence of SAP derivates synthetic peptide (marked as peptide 2B), an increase of 53% (index 1.53) was detected. A D-form of the SAP synthetic derivative peptide was used as a negative control and gave a clearance index of only 1.1 in comparison with the control. A significant correlation was found between the concentration of SAP protein and SAP synthetic peptide derivates and the clearance index.

Conclusion Herein we show the role of SAP and SAP-derived synthetic peptides in accelerating clearance of apoptotic cells by macrophages in vitro. Our results may pave the way for future development of SAP-derived synthetic peptides for apoptotic cell clearance improvement in systemic lupus erythematosus patients.
P12  
Close association between valvular heart disease and central nervous system manifestations in antiphospholipid syndrome  
I Krause1, S Lev1, A Fraser2, M Blank3, J Chapman4, Y Shoenfeld1,4  
1Research Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel; 2Department of Medicine B, Robin Medical Center, Bellinson Campus, Sackler Faculty of Medicine, Tel-Aviv University, Israel; 3Department of Immunology, Sheba Medical Center, Tel-Hashomer; 4Department of Medicine B, Sheba Medical Center, Tel-Hashomer, Israel  
Objectives Heart valve lesions and central nervous system (CNS) involvement are among the most common manifestations of antiphospholipid syndrome (APS). We evaluated possible inter-relations between these manifestations in a large group of APS patients.  
Methods Two hundred and eighty-four APS patients were retrospectively evaluated, 159 of whom had primary APS (PAPS). Cardiac–CNS associations were determined for the entire study population, and for subgroups of patients with PAPS or APS secondary to systemic lupus erythematosus (SLE).  
Results Significant associations were found between cardiac valvular vegetations and epilepsy ($P < 0.02$), and between cardiac valve thickening or dysfunction and migraine ($P = 0.002$). Subanalyses revealed that patients with PAPS had significant associations between cardiac valvular pathology and both epilepsy and migraine, while patients with APS secondary to SLE presented no such associations.  
Conclusions Our study points to potentially different biological behaviors in PAPS than in APS secondary to SLE. According to our results, the presence of cardiac valvular pathology may be a risk factor for several CNS involvements in PAPS.  

P13  
Elevated titers of anti-ribosomal-P antibodies in systemic lupus erythematosus  
G Zandman-Goddard1, B Gilburt1, S Bardechevski2, L Stojanovich1, P Langevitz2, Y Shoenfeld3  
1Center for Autoimmune Diseases and Department of Medicine B, Sheba Medical Center, Tel-Hashomer, Israel; 2Rheumatology Unit, Sackler Faculty of Medicine, Tel-Aviv University, Israel  
Objective Ribosomal P is located in the cytoplasm. The detection of antibodies is to the 60 kDa fraction. Anti-ribosomal P antibodies are highly specific for systemic lupus erythematosus (SLE), and are detected at a 15–20% frequency according to the literature. Elevated anti-ribosomal P titers correlate with disease activity and are specifically associated with neuropsychiatric disease such as psychosis/depression, and coexist with anti-dsDNA antibodies. The aim of our study was to evaluate the frequency of anti-ribosomal P antibody titers and the correlation with manifestations in SLE patients.  
Methods Sera samples from 174 individuals were evaluated for titers of anti-ribosomal P antibodies: 77 samples from SLE patients, 22 patients with antiphospholipid syndrome (APS), 20 patients with familial Mediterranean fever, 12 patients with infections, and 43 healthy controls. Anti-ribosomal P antibody titers were tested by ELISA. Manifestations of SLE at the time of serum sampling were determined by the SLEDAI score.  
Results Six SLE patients (11%) harbored elevated anti-ribosomal P antibody titers. Five SLE patients were females, mean age 44.3 years (range, 18–73 years old), and the mean SLEDAI mean score was 7 (range, 3–10) indicating moderate disease. Elevated titers of anti-dsDNA were detected in 50% of SLE patients with elevated anti-ribosomal P antibodies. One patient had secondary APS. One patient with elevated titers of anti-ribosomal had renal disease and psychosis. Three patients had a rash, while none of the patients had arthritis or leukopenia. Anti-ribosomal P titers were not elevated in patients with primary APS, familial Mediterranean fever, infections, or in healthy controls.  
Conclusion The prevalence of elevated titers of anti-ribosomal P antibodies was restricted to SLE patients. No correlation with a specific manifestation was found.  

P14  
Human type II collagen is processed in lysosomal compartments of macrophages for presentation of the glycosylated arthritogenic epitope hCII259–273 to CD4 T cells in HLA-DR1 transgenic mice  
A von Delwig1, DM Altman2, JD Isaacs3, R Holmdahl4, N Mckee5, JH Robinson5  
1Musculoskeletal Research Group, University of Newcastle upon Tyne, UK; 2Human Disease Immunogenetics Group, Imperial College School of Medicine, London, UK; 3Section for Medical Immunology Research, Lund University, Lund, Sweden  
Background Post-translational modification of human type II collagen (hCII) in the form of hydroxylation of Pro and Lys residues and glycosylation of some hydroxylated Lys residues has been shown to correlate with hCII arthritogenicity in susceptible strains of mice [1,2]. At the epitope level, O-linked glycosylation of Lys264, located within the arthritogenic region hCII259–273, has been implicated in the creation of neoepitopes recognized by arthritogenic T cells [3]. Macrophages and to lesser extent primed B cells have been implicated in processing hCII for presentation of hCII259–273 epitope to specific T cells [4,5], whereas Langerhans dendritic cells are unable to process CII [6]. Macrophages may thus play a pivotal role in T cell survival during chronic arthritis. However, no information is available on the mechanisms of antigen processing of the glycosylated arthritogenic epitope, although it is likely to be crucial for an understanding of the activation of autoimmune T cells in rheumatoid arthritis.  
Objective We investigated the mechanisms of intracellular processing of hCII for presentation of the glycosylated epitope hCII259–273 to CD4 T cells in macrophages from HLA-DR1-tg transgenic mice.  
Methods HLA-DRB*0101 C57BL/6J-tg transgenic mice (designated HLA-DR1-tg) were developed by backcrossing HLA-DRB*0101 Aα* mice onto a MHC class II-deficient background. T-cell hybridomas specific for the glycosylated and non-glycosylated hCII259–273 epitope were developed to study antigen presentation of the glycosylated epitope by bone marrow macrophages used as antigen-presenting cells. Subcellular fractions of macrophages were used as a source of enzyme activity to digest hCII at pH 4.5 in the presence and absence of enzyme inhibitors to localize stages of lysosomal/endosomal compartments and to identify the families of enzymes involved.  
Results HLA-DR1-tg mice lacking mouse MHC class II were susceptible to collagen-induced arthritis. Macrophages from DR1-tg mice processed intact hCII for presentation of the glycosylated epitope hCII259–273 to T-cell hybridomas. T-cell hybridomas specific for the glycosylated peptide did not cross-react with the non-glycosylated peptide. Intracellular processing of hCII for presentation of the glycosylated epitope was prevented by inhibitors of serine-proteases, cysteine-proteases, aspartic-proteases and metallo-proteases or agents that raise endosomal pH, suggesting a requirement for extensive lysosomal processing. Lysosome-enriched subcellular fractions of macrophages were identified as the main organelles involved in processing and presentation of the glycosylated epitope from hCII, as these compartments contained: proteolytic enzymes of the serine-protease and cysteine-protease families that could generate the glycosylated hCII epitope; the glycosylated hCII epitope itself generated by intracellular processing of hCII; peptide-receptive HLA-DR1 molecules; and complexes of HLA-DR1 molecules with the glycosylated and non-glycosylated hCII259–273 epitopes.  
Conclusion We showed stringent conditions for intracellular lysosomal processing of hCII for presentation of the glycosylated epitope by HLA-DR1-tg macrophages to CD4 T cells, which may explain the lack of tolerance to glycosylated collagen and induction of arthritis in HLA-DR1-tg mice.  
References  
Acknowledgements Supported by grant MP/R0819 from the Arthritis Research Campaign UK.  

P15  
Does the burden of inflammation determined prospectively in patients with early inflammatory arthritis deter the progression of atherosclerosis?  
WY Al-Shenh1, S Skehan2, E Hefferan3, F Hughes4, DJ Veale1,1  
1Department of Rheumatology, UCD, Dublin, Ireland; 2Department of Radiology, UCD, Dublin, Ireland  
Background Accelerated atherosclerosis accounts for the increased mortality seen in patients with established rheumatoid arthritis (RA). Recent research has
shown that RA is associated with an increase in the carotid intimal medial thickness (IMT). To date, there is no prospective study in RA that examines this question and none that includes an inflammatory disease control. 

**Objectives** To evaluate prospectively the burden of inflammation in a cohort of patients with early inflammatory arthritis, including RA and psoriatic arthritis (PsA). To correlate inflammatory burden with IMT in this cohort and to compare with normal age-matched control subjects.

**Methods** RA and PsA patients with disease duration of more than 5 years were selected from the early arthritis clinic database for further study. Controls without inflammatory conditions were recruited from the general clinic. Men older than 40 years and women older than 50 years were excluded. Patients with known predisposing risks for ischaemic heart disease were also excluded. At the time of clinical assessment blood samples were collected for erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) together with fasting lipid samples, and carotid artery ultrasound was performed at the same time. The mean IMT was then calculated by averaging the values at three points, 1 cm above, at, and 1 cm below the area of maximal IMT for each carotid artery.

**Results** To date, 61 patients (29 RA, 26 PsA and six control subjects) have been reviewed. Twenty-one (72%) of the RA patients compared with 11 (42%) of the PsA patients had an increased IMT (normal IMT <0.5 cm). Mean ± standard deviation IMT values in the RA cohort (0.6 ± 0.14) and in the PsA cohort (0.5 ± 0.15) were significantly greater than controls (P = 0.003, P = 0.03, respectively). IMT values in the RA cohort were greater than in PsA (P = 0.017). There was a significant correlation between IMT and age in the RA cohort. However, mean age in the three groups was not different and no correlation between IMT and age was evident in the PsA or the control group. The area under the curve (AUC) ESR correlated with the AUC CRP in the group as a whole and in both RA and PsA separately. No correlation was found between the AUC for ESR or CRP and IMT in the different subgroups or in patients with an increased IMT.

**Conclusions** Patients with inflammatory arthritis (RA > PsA) are at a greater risk of developing atherosclerosis compared with control subjects. No correlation has been found to date between IMT values and the burden of inflammation as measured by CRP or ESR over time. Some additional mechanism of accelerated atherosclerosis in inflammation, yet to be determined, may well apply. The results are preliminary and recruitment with additional analysis is ongoing.

**P16**

**Altered composition of CD97 splice variants in rheumatoid synovial tissue**

FA van Gaalen1, TCM van der Pauw Kraan2, RGHH Nilsen3, TWJ Huizinga4, CL Verwei5

1Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; 2Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands; 3Department of Orthopaedic Surgery, Leiden University Medical Center, Leiden, The Netherlands


The intimal lining of synovial tissue consists of fibroblast-like synoviocytes (type A synoviocytes) and macrophages (type B synoviocytes). These cells are able to interact through the CD97/CD55 receptor ligand system. The CD97 receptor is a heterodimer receptor composed of an alpha and a beta subunit. The CD97alpha subunit may exist as three isoforms due to alternative spliced transcripts, each having a different affinity for CD55. When comparing synoviun of rheumatoid arthritis (RA) patients with synoviun of patients with osteoarthritis (OA), no increase in the level of total of CD97alpha or in the level of CD97beta transcripts was found. However, in RA synoviun a relative increased expression of CD97 transcripts encoding isoforms with an increased affinity for CD55 (CD97alpha2 and CD97alpha3 mRNA) was detected. A difference in CD97 splice variants between RA and OA tissues could not be attributed to differences in composition of cells as in both tissues the majority of CD97- cells were CD14+ macrophages/monocytes – 93% in RA and 94% in OA, respectively. These data indicate that during inflammation CD97 splicing is regulated, and we propose that this is likely to affect trafficking and functioning of CD97-positive leukocytes.

**P17**

**Improvement of T-cell function in rheumatoid arthritis (RA) patients in clinical remission is associated with the recovery of IL-7 expression and depends on a familial history of RA**

F Ponchel, AK Brown, SL Field, L Hensor, P Emery, JD Isaacs

Molecular Medicine Unit and Rheumatology Research Unit, The University of Leeds, UK


**Background** Rheumatoid arthritis (RA) is a chronic, inflammatory disease with a number of phenotypic and functional T-cell defects. We previously demonstrated abnormal differentiation and hyperproliferation of RA patient T cells [1], in relation with inflammation and associated with reduced thymic activity as measured by T-cell receptor excision circle (TREC) content. However, it is still not clear whether these dysfunctions are a primary feature of RA or only secondary to the inflammatory disease state. Therefore we aimed to identify RA patients in clinical remission in whom systemic inflammation was controlled.

**Methods** Patients were defined as ‘in remission’ when they had controlled disease, with no change of activity for at least 6 months, C-reactive protein below 15, no swollen or tender joints and on stable treatment (with or without therapy).

**Results** The TREC content in CD4+ T cells was by real-time PCR. IL-7 quantification was by ELISA. Proliferation assay in response to mitogen, IL-2, TCR stimulation or recall antigen.

**Conclusion** RA patients in clinical remission are clearly separated in two groups, according to their ability to express IL-7 and the associated consequences on thymic activity and T-cell responses. This ability was dependent on the age of the patients at disease onset. This was only associated with a maternal family history of RA and suggests that genetic anticipation may be involved.

**Reference**


**P18**

**T-bet expression in rheumatoid arthritis patients with early, disease-modifying anti-rheumatic drug naïve disease is low and correlates with low levels of IL-7 and T-cell dysfunctions**

F Ponchel, AK Brown, SL Field, M Quinn, P Conaghan, P Emery, JD Isaacs

Molecular Medicine Unit and Rheumatology Research Unit, The University of Leeds, UK


**Background** Rheumatoid arthritis (RA) exact pathogenesis remains uncertain, although autoimmune processes appear to play a role, and RA is often referred to as a Th1-driven disease. However, it is well known that RA patients have a reduced capacity to produce IL-2 and interferon gamma (IFN-γ). IL-7 is an important cytokine during early events leading naïve T cells towards Th1 polarisation. We have associated low levels of circulating IL-7 with reduced thymic T-cell development and T-cell functions in the periphery. The origin of IL-7 in the circulation is not clear and stomal cells in the bone marrow, liver, gut and lymph nodes are potential production sources. The only cytokines known to regulate the expression of IL-7 in different tissues are IFN-γ (bone marrow), transforming growth factor beta (TGF-β) (skin) and both IL-1 and tumour necrosis factor alpha (TNF-α) (synovium). We therefore investigated the relationship between levels of circulating IL-7, a Th1 (IFN-γ) and a Th2 (TGF-β) cytokine, a proinflammatory cytokine (TNF-α) and two transcription factors essential for T-cell polarisation (T-bet and GATA3).

**Methods** Patients ‘in remission’ were defined as having controlled disease, with no change of activity for at least 6 months, C-reactive protein below 15, no swollen or tender joints and on stable treatment (with or without therapy).

**Results** We selected 10 patients, with either low or high levels of circulating IL-7. Levels of IFN-γ, TGF-β and TNF-α were measured. High levels of IL-7 were significantly associated with higher levels of IFN-γ (P = 0.04) and a tendency for lower levels of TGF-β but no difference was found for TNF-α. Furthermore, there was a
direct correlation between levels of IL-7 and IFN-γ ($R = 0.650$, $P = 0.005$). It is established that a high ratio of expression between T-bet and GATA3 defined a tendency towards Th1 polarisation. T-bet levels of expression were significantly higher in patients with high IL-7 ($P < 0.0001$) and we found a positive correlation between the two ($R = 0.600$, $P = 0.001$). Similar results and correlation were found using the ratio of T-bet to GATA3 expression ($P < 0.0001$ and $R = 0.700$, $P = 0.002$). These results were confirmed in a cohort of 10 patients with active, early, DMARD naïve disease.

**Conclusion** These results confirm that Th1 polarisation is impaired in RA. In addition, they suggest that either the Th1 cytokines regulate the levels of circulating IL-7 or that the transcription factors regulating Th1 polarisation also regulate the expression of IL-7. Further studies on the mode of regulation for IL-7 expression in the circulation are necessary to understand how this cytokine may participate to the pathogenesis of RA.

**P19**

The signalling signature downstream of the notch receptor in CD4+CD25+ regulatory T cells in RA defines anergic cells: insight into resistance to anti-tumour necrosis factor therapies

**MH Buch**, K Snow, S Field, P Emery, J Isaacs, F Ponchel

1Academic Unit of Musculoskeletal Disease, University of Leeds, UK; 2Molecular Medicine Unit, University of Leeds, UK; 3Department of Rheumatology, University of Newcastle, UK


**Background** We have previously reported on the abnormal expression of the dif-ferent members of the Jagged/Notch signalling pathway in early rheumatoid arthritis (RA) patients and Deltex and Dlx are two main signalling molecules resulting from the transduction of notch signals. We have shown that signalling through the Jagged/Notch pathway is involved in the development of an anergic phenotype in a T-cell clone model in vitro. We have also used this model to establish a Notch signalling signature characterising a T-cell suppression reaction. We analysed the Notch signalling signature of effecter CD4+ T cells and CD4+CD25+ regulatory T cells in RA patients and compared it with healthy controls.

**Methods** The HA1.7 CD4+T-cell clone develops an anergic phenotype associated with high CD25 expression when stimulated with its cognate peptide in the absence of co-stimulation. These cells were used in a suppression assay of fresh HA1.7 (CD25+) cells, activated by anti-CD3/CD28 antibodies in proliferation assays. Real-time PCR for the quantification of gene expression was undertaken. CD4+CD25+ T cells and CD4+CD25+ regulatory T cells were sorted using flow cytometry from 50 ml blood from five RA patients with early, disease-modifying anti-rheumatic drug naive disease and seven healthy controls. Gene expression was quantified by real-time PCR.

**Results** During a suppression reaction of fresh HA1.7 cells (CD25+) by anergic HA1.7 expressing high levels of CD25, the expression of HES1 was induced; however, Deltex was inhibited. This signature is unique and differs from either an activation (downregulation of both) or an anergy signalling signature (upregulation of both). Results from a similar quantification in RA patients, suggest that CD4+CD25+ regulatory T cells in RA have the signature of anergic cells with high levels of both HES1 and Deltex, whereas control regulatory cells display a signature comparable with previously published data (low HES1, high Deltex) [1]. Preliminary results in RA patients, pre and post TNF-blockade, suggest that the response to therapy is associated with a normalisation of the Notch signature post treatment to resemble the signature of control activated regulatory T cells (upregulated HES1 and downregulated Deltex).

**Conclusions** CD4+CD25+ regulatory T cells in RA appear anergic and may therefore not be able to suppress an undesirable auto-immune reaction very early in the RA disease process. Altogether, our results on the abnormal baseline expression of Jagged/Notch molecules and these atypical signalling signatures suggest that the Jagged/Notch pathway may be involved in the pathogenesis of RA.

**Reference**


**P20**

Citrullinated α enolase, a novel citrullinated autoantigen in rheumatoid arthritis, upregulated by chronic inflammation

**A Kinloch, V Tatzer, R Wait, D Penson, S Sacre, P Donatiens, D Moyes, P Taylor, PJ Venables**

Inflammation & Immunity, Kennedy Institute of Rheumatology, Imperial College London, UK


**Introduction** Antibodies to citrullinated proteins are the most specific serological marker for rheumatoid arthritis (RA). They are associated with severity of disease and may occur years before clinical manifestations. It is unclear whether antibo-odies to citrullinated proteins react with any citrullinated protein or whether there are specific citrullinated proteins driving the autoimmune response. In this study we use the HL60 cell line as a substrate for identifying autoantigens in myelomono-cytic cells, the major cell type present in the rheumatoid joint.

**Method** Citrullinated autoantigens were sought by immunoblotting with a screening panel of four RA and one healthy control sera, using lysates of HL60 cells, untreated or differentiated to monocytes or granulocytes. Each lysate was incubated with or without peptide arginine deiminase in vitro. Reactive bands were identified using two-dimensional gel electrophoresis and MALDI TOF microsequencing with α enolase antibodies to purified α enolase, including control and peptide arginine deiminase. Antibodies to citrullinated α enolase, of which seven also reacted with the uncitrullinated form. Six (15%) normal sera reacted with both forms. α Enolase was demonstrated in the subsyn-oovium and vascular endothelial cells in all synovial membrane biopsies. This was confirmed by immunoblotting where a protein in RA synovocyte lysates, co-migrating with purified α enolase, reacted with anti-α enolase antibody. Stimulation of macrophages with lipopolysaccharide or tumour necrosis factor alpha upregulated and induced secretion of α enolase. Secretion was inhibited with monensin.

**Conclusions** In this study, nearly one-half of the RA sera reacted with citrulli-nated α enolase. This is a high frequency given the relative insensitivity of immunoblotting. We suggest that using a more refined ELISA-based assay, both diagnostic sensitivity and specificity will increase. The finding of antibody, together with abundant expression of antigen in the joint (which is amplified with inflammatory stimuli) makes citrullinated α enolase a candidate autoantigen for driving the chronic immune response in RA.

**Acknowledgment** This work was supported by the Arthritis Research Campaign (arc).

**P21**

Abatacept (CTLA4-Ig) modulates human T-cell proliferation and cytokine production but does not affect lipopolysaccharide-induced tumor necrosis factor alpha production by monocytes

**PM Davis, SG Nadler, KA Rouleau, SJ Suchard**

Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, USA


**Background and objectives** Activated T cells play a central role in the inflammatory cascade leading to the joint inflammation and destruction characteristic of rheuma-toid arthritis (RA). The cytokines secreted by activated T cells are thought to both ini-tiate and propagate the immunologically driven inflammation associated with RA. Abatacept, the first of a new class of agents for the treatment of RA that selectively modulates the co-stimulatory signal required for full T-cell activation, was evaluated for its ability to regulate human T-cell proliferation and cytokine production in vitro. The effect of abatacept on lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-α) from monocytes was evaluated to distinguish the impact of this agent on innate versus adaptive, antigen-specific immune responses.

**Methods** T cells were isolated from normal healthy human volunteers. The effect of abatacept on antigen-dependent T-cell activation was evaluated using either an irradiated human B-cell line (PM-LCL) as the antigen-presenting cells (APCs) for a primary mixed lymphocyte reaction (MLR), or autologous EB-PBMCs as APCs.
for a recall response to tetanus toxoid (TT). Cytokines were measured at various times post activation, with proliferation determined on day 5. Monocytes were iso-
lated by elutriation, challenged with LPS and TNF-α levels measured at 6 hours. Chi-locus-specific fusion protein was included as a non-specific fusion protein control. Results Abactcept significantly downmodulated T-cell proliferation, in both primary and recall responses, at concentrations between 0.3 and 100 μg/ml, with maximal inhibition (−80–90%) observed at ~3–10 μg/ml. These concentrations are below the abactcept trough plasma levels observed in patients receiving a clinically effective dose [1]. Under conditions of maximal inhibition of proliferation, and similar to trough plasma levels in patients (30 μg/ml), abactcept also inhib-
ited IL-2, TNF-α and interferon gamma secretion in both primary and TT-depen-
dent recall responses. However, the extent, kinetics and rank order of cytokine inhibition by abactcept was somewhat different between primary and recall responses. In contrast, abactcept did not inhibit LPS-induced TNF-α production in primary human monocytes, demonstrating that its action is restricted to antigen-dependent T-cell responses. Conclusion Abactcept, a selective co-stimulation modulator, significantly inhib-
ited the activation (as measured by cytokine production) and proliferation of human T cells in the context of a primary MLR or TT-dependent memory response. This inhibition occurred at concentrations below the serum C
min levels observed in patients receiving a clinically effective dose of abactcept [1] (10 mg/kg monthly), consistent with suppression of T-cell activation in vivo. There was no effect of abactcept on LPS-stimulated TNF-α production in monocytes indicating that this agent may largely preserve innate immune responses. Reference 1. Kremer JM, Westhoven S, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, et al.: Treatment of rheuma-

P22 Intra-articular gene therapy blocking NF-κB using adeno-
associated virus type 5 ameliorates adjuvant arthritis in rats J Adriaansen1, SW Tassis1, N Hajji1, A Bakker1, MJ Vervoordeldonk1, PP Tak1
1Academic Medical Center, Amsterdam, The Netherlands; 2Amsterdam Molecular Therapeutics, Amsterdam, The Netherlands
Objective NF-κB is highly activated in synovium of RA patients, and can induce transcription of proinflammatory cytokines, adhesion molecules, and inducible nitric oxide, among others. Phosphorylation of the inhibitor of NF-κB proteins is an important step in NF-κB/Rel activation and is regulated by IκB kinase (IκK). The IκK complex consists of at least three subunits, including IκKα and IκKβ (also called IKK1 and IKK2) and the regulatory subunit IκKγ. In an initial study in Lewis rats with adjuvant arthritis (AA) adeno-associated dominant-negative IκK2 (Ad.IKK2dn) significantly ameliorated the severity of disease as evidenced by decreased paw swelling compared with Ad.GFP-treated rats [1]. However, adeno-associated vectors are known to be very immunogenic, compromising stable long-term expression of the transgene. Adeno-associated virus (AAV) is considered the most promising vector for gene therapy in RA. In a comparative serotype study we found that direct injec-
tion of Ad.IKK2dn into the ankle joints of rats with AA resulted in the highest synovial transduction, with good expression of the transgene at the protein level until the end of the study, followed by AAV2. In the present study we investigated the effect of inhibiting NF-κB in AA in rats using AAV-mediated intra-articular gene therapy. For this purpose we used the following vectors: AAV5 containing the IKK2dk2 (AAV5.IKK2dk2) or AAV2 containing the IκB-suppressor gene (AAV2.IκB Sr). Methods AAV5.IKK2dk2 (2.5 x 1010vp), AAV2.IκB Sr (2.5 x 1010vp) or AAV5/ AAV2.GFP were injected into the right ankle joints of rats with AA on day 11 after adjuvant immunization. Subsequently, the effect of both genes on paw swelling was measured by water displacement plethysmometry. Animals were sacrificed 2 weeks after intra-articular injection and joints were collected for analysis. Bone degradation was examined using X-rays of the ankle joints and histology was per-
S12
Arthritis Research & Therapy Vol 7 Suppl 1 Abstracts of the 25th European Workshop for Rheumatology Research
Acknowledgement SWT received funding from the Dutch Arthritis Foundation.
Cytokine release in response to one species of HERV-K113 RNA from different cells

<table>
<thead>
<tr>
<th>Tumor necrosis factor (ng/ml)</th>
<th>IL-6 (ng/ml)</th>
<th>IP-10 (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macrophage and K113 RNA</td>
<td>5.46</td>
<td>0.234</td>
</tr>
<tr>
<td>Macrophage and R848 (positive control)</td>
<td>7.58</td>
<td>0.155</td>
</tr>
<tr>
<td>Macrophage and control RNA (negative control)</td>
<td>0.04</td>
<td>0.0</td>
</tr>
<tr>
<td>Dendritic cell and K113 RNA</td>
<td>4.45</td>
<td>3.75</td>
</tr>
<tr>
<td>Dendritic cell and R848 (positive control)</td>
<td>6.49</td>
<td>13.57</td>
</tr>
<tr>
<td>Dendritic cell and control RNA (negative control)</td>
<td>0.095</td>
<td>0.458</td>
</tr>
</tbody>
</table>

P25

Anti-tumour necrosis factor alpha treatment in patients affected by rheumatoid arthritis with anti-Ro/SSA antibodies

I Cavazzana, F Franceschini, E Danielli, P Airò, R Cattaneo
Rheumatology and Clinical Immunology Unit and Chair, Spedali Civili, Brescia, Italy

Background Anti-tumour necrosis factor alpha (anti-TNF-α) treatment could induce the onset of new autoantibodies [1,2] or clinical features of other autoimmune diseases than rheumatoid arthritis (RA) [2].

Aim To analyse the efficacy and safety of anti-TNF-α treatment in six patients affected by RA with anti-Ro/SSA antibodies and to evaluate the clinical and laboratory changes during the treatment.

Patients and methods Antinuclear antibodies (IF) on HEp-2 cells, anti-dsDNA (Farr assay), antinuclear and anti-ENA (CIE) were evaluated before the treatment and every 6–12 months. Anti-Ro/SSA antibodies were confirmed by ELISA, using recombinant 52 and 60 kDa Ro proteins (Pharmacia).

Results Six patients had anti-Ro/SSA antibodies before anti-TNFα treatment. Anti-Ro/SSA was detected in four sera using both CIE and ELISA, while two sera showed anti-60 kDa Ro antibodies only by ELISA. Six patients (mean age, 58 years; standard deviation [SD], 9.8) were affected by long-standing RA (mean duration, 7 years; range, 5–22 years), not responding to common disease-modifying anti-rheumatic drugs (mean, 5 disease-modifying anti-rheumatic drugs; SD, 2.3). All the patients were treated for a mean of 31 months (SD, 20.4 months), four subjects with Infliximab and two with Etanercept.

Before the treatment the patients showed active arthritis with a mean of 25.3 tender joints (SD, 2.16), 17.3 swollen joints (SD, 8.6) and Disease Activity Score (DAS) of 5.5 (SD, 1.04); after 6, 12, 18, and 24 months all the patients showed a rapid and sustained improvement with reduction of DAS value (see Table 1).

All the patients were affected by Sjögren syndrome (SS), associated to RA, clinically stable during the treatment. One subject was also affected by primary biliary cirrhosis, which remained clinically and histologically stable. Three patients developed anti-dsDNA at low titre after 6 months and a fourth after 12 months of treatment. Only one patient developed skin lesions after 6 months of Infliximab, clinically and histologically similar to subacute cutaneous lupus with IgM deposits at basal membrane. No patients developed aCL, while the titre of anti-Ro antibodies by ELISA was stable during the treatment. One subject, affected by RA and HCV hepatitis, stopped the etanercept treatment due to severe increase of hepatic enzymes.

Table 1

Clinical response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies

<table>
<thead>
<tr>
<th>Mean Disease Activity Score 44</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>At onset</td>
<td>5.56</td>
</tr>
<tr>
<td>6th month</td>
<td>3.38</td>
</tr>
<tr>
<td>12th month</td>
<td>3.41</td>
</tr>
<tr>
<td>18th month</td>
<td>3.33</td>
</tr>
<tr>
<td>24th month</td>
<td>2.88</td>
</tr>
</tbody>
</table>

Conclusions Anti-TNF treatment in RA-SS patients with anti-Ro/SSA showed a good and sustained efficacy until the 24th month. Four patients (66.7%) showed anti-dsDNA after 6–12 months, while only one developed subacute cutaneous lupus-like symptoms. No other autoantibodies nor an increase of the anti-Ro titre were observed.

References

P26

Ha-Ras/ERK1-2 pathway is responsible for oxygen species generation in scleroderma fibroblasts

S Svegliati1, MM Luchetti1, P Paroncini1, A DiCarlo1, F Bevilacqua1, N Campelli1, E Avvedimento2, A Gabrielli1
1Istituto di Clinica Medica Generale, Epatologia ed Immunologia Clinica, Università Politecnica delle Marche, Ancona, Italy; 2Dipartimento di Biologia e Patologia cellulare e Molecolare, Università Federico II, Napoli, Italy

Background Reactive oxygen species (ROS) are involved in scleroderma (SSc) fibroblast activation, proliferation and type I collagen gene expression [1]. In order to understand the signal trasduction pathway involved in ROS generation by SSc fibroblasts, we have assessed the role of Ha-Ras and Ki-Ras proteins and that of their downstream effectors.

Materials and methods Intracellular ROS were evaluated with 2′,7′-dichlorofluorescein diacetate (DCHF-DA 10 μM). For Ha-Ras and Ki-Ras protein expression whole cell lysates were immunoprecipitated with specific antibodies and subjected to SDS-PAGE or cells were fixed in paraformaldehyde (4%) and observed by confocal microscopy. SSc skin fibroblasts were transiently transfected with the dominant negative form of Ha-Ras (H17Ras) or with the empty vector using the Effectene Transfection reagents (BioRad).

Results Quiescent SSc fibroblasts contain an altered ratio between the two Ras isoforms showing a selective increase of the mass and the activity of Ha-Ras protein when compared with normal controls. Moreover ERK1-2 are constitutively phosphorilated in quiescent SSc fibroblasts. Inhibition of either Ras, ERK1-2, ROS with specific inhibitor or trasfecting with the negative Ras variant reverse this phenotype back to normal and reduce collagen overproduction by SSc cells.

Conclusions These results suggest that ROS production in SSc fibroblasts is linked and ultimately dependent on increased Ha-Ras signalling via ERK1-2. These events are responsible for the characteristic cellular phenotype of scleroderma fibroblasts and explain some of the clinical features of the disease. Moreover, these data provide evidence for the use of Ras inhibitors in the treatment of the disease.

Reference

P27

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept

X Baraliakos1, J Davis2, W Tsuji3, J Braun1
1Rheumazentrum Ruhrgebiet, Herne, Germany; 2Division of Rheumatology, University of California, San Francisco, California, USA; 3Armen Inc., Thousand Oaks, California, USA

Objective To assess spinal inflammation by magnetic resonance imaging (MRI) before and after treatment with the tumor necrosis factor (TNF) receptor fusion protein etanercept compared with placebo.

Methods MRI examinations of the lower thoracic and lumbar spine of 40 patients with active ankylosing spondylitis (AS) were performed as part of the recently published randomized controlled trial at four different timepoints: baseline (BL), after 12 weeks (FU1), 24 weeks (FU2) and 48 weeks (FU3). Nineteen patients received etanercept twice weekly, 2 x 25 mg subcutaneously, for 1 year and 21 patients received placebo for 6 months (until FU2) before switching to etanercept. The patients’ mean age was 39.7 years, 75% male, 89% HLA-B27-positive mean disease duration was 13 years. MRI examinations included T1-weighted sequences before (T1) and after application of gadolinium-diethylenetriamine-pentaacetic-acid (T1/Gd-DTPA) and T2-weighted fat-saturated (T2-FS) sequences. MRI examinations were scored by a modified ASRMRI score using predefined vertebral units as a basis.
Results After 12 weeks, spinal inflammation (T2-FS) regressed by 54% (1.33 ± 1.06 at TP1, P = 0.0002) in the etanercept group, but worsened by 13% in the placebo group (0.94 at BL and 1.07 at TP1, P = 0.05). After switching to etanercept, patients improved similarly, T1/Gd-DTPA MRI sequences performed equally well. About 60% of all active lesions at BL were detected in the thoracic spine. There were no significant changes in the chronicity score.

Conclusions Treatment with etanercept of patients with active AS results in regression of spinal inflammation as assessed by spinal MRI. Inclusion of the thoracic spine in MRI examinations of AS patients may be of particular importance.

P28 Two-year follow-up results after re-administration of etanercept in active ankylosing spondylitis X Baraliakos1, J Brandt1, J Listing2, H Haibel3, HM Rudwaleit2, J Sieper3, J Braun1

1Rheumazentrum Ruhrgebiet, Herne, Germany; 2German Rheumatism Research Center, Epidemiology Department, Berlin, Germany; 3Department of Gastroenterology/Rheumatology, Charité, Medical University Berlin, Campus Benjamin Franklin, Germany


Objectives The tumor necrosis factor alpha (TNF-α) receptor fusion protein etanercept has proven short-term efficacy in patients with active ankylosing spondylitis (AS). The results of continuous treatment with etanercept over 1 year were reported previously. Here we report the experience with the second year of follow-up.

Methods Overall, 23 out of 30 AS patients (77%) who had participated in the initial placebo-controlled phase of the trial were included in this 2-year extension, where patients with active disease were treated with etanercept (2 × 25 mg subcutaneously twice a week). Disease-modifying anti-rheumatic drugs and steroids were not allowed. The clinical response was assessed by standard assessment tools for disease activity (Bath AS Disease Activity Index [BASDAI]), function (Bath AS Functional Index) and mobility (Bath AS Metrology Index). The primary outcome of this trial was efficacy on disease activity after 2 years of continuous treatment with etanercept in AS patients, compared with patient status at baseline (BL).

Results Of the 30 initial patients, 21 (70%) completed year 2. At week 102, 54% of the patients had maintained a 50% improvement of BASDAI, and 9/21 (43%) were in a state of partial remission according to the ASAS criteria. The mean BASDAI score remained stable (2.6 ± 2.2 at week 54 and 2.7 ± 2.4 at week 102) in the second study year. Similarly, all other clinical parameters showed no change during year 2 with significant improvement compared with BL. Two patients experienced serious adverse events leading to discontinuation of therapy.

Conclusions This study confirms the efficacy and safety of etanercept in the treatment of patients with active AS without simultaneous administration of disease-modifying anti-rheumatic drugs or steroids over 2 years of continuous treatment.

P29 Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years X Baraliakos1, J Brandt1, J Listing2, J Sieper3, J Braun1

1Rheumatology Medical Center Ruhrgebiet, Herne, Germany; 2German Rheumatism Research Center, Berlin, Germany; 3University Medicine Berlin, Campus Benjamin Franklin, Germany


Objective Infliximab, a monoclonal antibody against tumor necrosis factor α (TNF-α), is approved in Europe for the treatment of patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. This report provides analyses from a 3-year extension study, as a follow-up to both the 1-year and 2-year open label extensions of the original 3-month randomized controlled trial of infliximab in patients with AS.

Methods Of the 49 patients with AS who completed the second year of the study, 46 continued treatment with infliximab 5 mg/kg every 6 weeks for week 156. The Bath AS Disease Activity Index (BASDAI), the Bath AS Functional Index, the Bath AS Metrology Index, patient’s and physician’s global assessment, quality of life (Short Form-36), C-reactive protein, and erythrocyte sedimentation rate were assessed throughout the study period.

Results The improvement of signs and symptoms observed in the majority of the patients during the first and second year was sustained throughout the third year of the study. Forty-three patients (87%) of the 49 patients enrolled at baseline and 93% of the patients who started the third year) completed week 156. A BASDAI 50% improvement was achieved by 26 of 43 patients (60%) at week 156. The score of other efficacy assessments were similar to the values observed at weeks 54 and 102. Median C-reactive protein levels remained low (< 1.5 mg/l at week 156). There were no relevant side effects and no discontinuation because of drug-related adverse events during the third year of the study.

Conclusions Patients with AS receiving infliximab for 3 years showed durable clinical response without loss of efficacy. Long-term infliximab treatment was well tolerated by patients in this study.

P30 Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab X Baraliakos1, J Listing2, J Brandt1, M Rudwaleit2, J Sieper3, J Braun1

1Rheumazentrum Ruhrgebiet, Herne, Germany; 2German Rheumatism Research Center, Berlin, Germany; 3Charité, Medical University of Berlin, Campus Benjamin Franklin, Department of Rheumatology, Germany


Objectives To analyze the clinical response and the time to relapse after withdrawal of continuous long-term infliximab therapy in patients with ankylosing spondylitis (AS).

Methods After 3 years of infliximab therapy, all AS patients (n = 42) discontinued treatment (TP1) and were visited regularly in order to assess the time to relapse (TP2) for 1 year. Relapse was defined as an increase to a Bath AS Disease Activity Index (BASDAI) value and physician’s global assessment ≥ 4 according to the ASAS recommendations.

Results After 52 weeks, 41 of the 42 patients (97.6%) had to be reinfused because of relapse. The mean change of the BASDAI between TP1 and TP2 was 3.6 ± 1.7, and for the physician’s global assessment was 4.4 ± 1.8 (both P < 0.001). The mean time to relapse was 17.5 weeks (± 7.9 weeks, range 7–45 weeks). Ten patients (24%) showed a relapse within 12 weeks and 38 patients (90.5%) within 36 weeks. After 52 weeks, only one patient had remained in ongoing remission without anti-tumor necrosis factor therapy. Patients who were in partial remission and those with normal C-reactive protein levels at baseline had longer mean time to relapse after discontinuation. Treatment with infliximab was safe and resulted in clinical improvement similar to the state before withdrawal in all patients.

Conclusions Discontinuation of long-term therapy with infliximab led to relapse of disease activity in all but one patient after different time periods. Remission and low C-reactive protein levels at the time of withdrawal were associated with longer flare free periods. Retreatment with infliximab was safe and efficacious.

P31 Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab X Baraliakos1, J Listing2, M Rudwaleit2, J Brandt1, J Sieper3, J Braun1

1Rheumazentrum Ruhrgebiet, Herne, Germany; 2German Rheumatism Research Center, Berlin, Germany; 3Rheumatology, Charité, Campus Benjamin Franklin, Berlin, Germany


Background Anti-tumor necrosis factor therapy is clinically efficacious in patients with active ankylosing spondylitis (AS) and leads to improvement of spinal inflammation, as assessed by magnetic resonance imaging. It is unclear whether anti-tumor necrosis factor therapy has influence on chronic spinal changes in AS.

Objective To analyze the effect of infliximab on the radiographic course of AS.

Methods Complete sets of lateral radiographs of the cervical and the lumbar spine were available from 82 patients from two sources: 41 patients (group 1) had been treated with infliximab (5 mg/kg/6 weeks) as part of a recent randomized controlled trial, and 41 patients (group 2) were part of the early German AS cohort (GESPIC), without controlled interventions. Radiographs were performed at baseline and after 2 years and were scored by the modified SASSS.

Results Patients in the infliximab group were older, had a longer disease duration and more radiographic damage at baseline. The mean modified SASSS change was 0.4 (± 2.7) and 0.7 (± 3.4) for group 1 and group 2, respectively (P = not significant). Radiographic damage at baseline was a predictor for more radiographic progression. Patients with baseline damage who were treated with infliximab showed a trend for less radiographic progression. There were no correlations between clinical parameters and radiographic progression.

Conclusions AS patients treated with infliximab showed somewhat less radiographic progression after 2 years. Patients with prevalent radiographic damage are prone to develop more damage over time. Infliximab may decelerate radiographic progression in such patients. Larger studies are needed to prove that anti-tumor necrosis factor therapy inhibits structural damage.

Acknowledgement This abstract is eligible for application for a postgraduate student fellowship.
Oxygen radical production determines chondrocyte death and regulates matrix metalloproteinase-mediated matrix degradation during interferon gamma-accelerated immune complex arthritis

PLEM van Lent1, KCAM Nabbe1, AEM Holthuysen1, JK Kolfs1, SM Holland2, WB van den Berg1
1Department of Rheumatology, UMCN Nijmegen, The Netherlands; 2Department of Pediatrics, University of Pittsburgh, Pennsylvania, USA; 3Host Defense, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA


Objective In earlier studies we found that FCγRII determines chondrocyte death and matrix metalloproteinase (MMP)-mediated cartilage destruction during interferon gamma (IFN-γ)-regulated immune complex (IC)-mediated arthritis [1]. As binding of ICs to FCγRII leads to oxygen radical production, we now investigate the contribution of oxygen radicals to induction of both parameters of cartilage destruction using P47phox knockout mice. These mice have a defect in NADPH-oxidase activation and fail to produce oxygen radicals.

Methods IFN-γ were expressed in knee joints of P47phox–/– and their wildtype (WT) controls by local injection of adenoviral IFN-γ construct. One day thereafter a passive IC-mediated arthritis was induced. Chondrocyte death and MMP-mediated cartilage destruction were measured in various layers of the knee joint using histology of total joint knees. Neoeptopes induced by MMPs were detected using immunolocalisation and anti-VDIPEN antibodies. Synovium was isolated and mRNA levels of MMPs/ tissue inhibitor of metalloproteinases (TIMPs) were determined using quantitative RT-PCR.

Results High levels of IFN-γ were found 1 day after injection of the IFN-γ adenoviral construct in knee joints of P47phox–/– and WT controls, and resulted in a high and comparable upregulation of FCγRII up to day 7 in both groups. Induction of IC-mediated arthritis in P47phox–/– and WT controls had no effect on MMP-3 and MMP-13 expression at day 3 and day 7. At day 7, macrophages formed the dominant cell type. When compared with WT controls, RNA levels of MMP-3 and MMP-13, which are crucial in cartilage destruction within this model, were elevated in inflamed synovia of P47phox–/– whereas TIMP-3, a crucial inhibitor of MMP-3, was completely absent. Nevertheless, MMP-mediated cartilage destruction was significantly lower in P47phox–/– at day 7 (between 30–60%). Moreover chondrocyte death that was evident in arthritic WT controls (20–60% at day 3 and 30–80% at day 7) was completely blocked in P47phox–/–.

Conclusion During IFN-γ-regulated IC-mediated arthritis, oxygen radicals, which are strongly induced after FCγRII stimulation, determine chondrocyte death and largely mediate MMP-mediated cartilage destruction.


P33

In systemic sclerosis, levels of tissue kallikrein are related to microvascular changes assayed by videocapillaroscopy and immunohistochemistry

A Del Rosso1, AF Milia1, LI Manneschi2, O Distel1, S Guiducci1, A Pignone1, S Gay1, MM Cerini1
1Department of Medicine, Division of Rheumatology, University of Florence, Italy; 2Department of Anatomy, Histology and Forensic Medicine, University of Florence, Italy; 3Center of Experimental Rheumatology, University Hospital of Zurich, Switzerland


Objective In systemic sclerosis (SSc), characterised by microvascular changes leading to ischemia and impaired angiogenesis, the lack of an angiogenic response to hypoxia may be due to inappropriate synthesis of angiogenic and angiostatic factors. Tissue kallikrein (t-kallikrein) is a potent angiogenic agent regulating the kallikrein kinin system with kallistatin as its natural inhibitor. T-kallikrein is synthesised by endothelial and vascular smooth muscle cells as well as inflammatory cells.

Aim To evaluate, in SSc patients: t-kallikrein and kallistatin levels and their correlation with clinical features and parameters of microvascular involvement; and t-kallikrein expression in the skin of SSc patients.

Methods Serum levels of t-kallikrein and kallistatin (ELISA) were assayed in 43 SSc patients, also evaluated for subsets (dSSc, 11 patients; lSSc, 32 patients), clinical and immunological features and microvascular involvement (ulcers, telangiectasias, nailfold videocapillaroscopy). Expression of t-kallikrein (immunohistochemistry) was evaluated in biopsies taken from the involved skin of the forearm of six SSc patients (two lSSc and four dSSc) and six controls.

Results Circulating levels of t-kallikrein were higher in SSc patients than in controls (n = 39) (P < 0.001). No differences in t-kallikrein were detected between lSSc and dSSc. T-kallikrein levels were higher in patients with early (five patients) and active (31 patients) capillaroscopic patterns than in those with a late pattern (seven patients) (P = 0.018 and 0.023). Patients with giant capillaries and capillary microhemorrhages (35 patients) had significantly higher t-kallikrein levels than patients with architectural derangement (8 patients) (P = 0.04). Neither differences in kallistatin levels were detected between SSc patients and controls nor between lSSc and dSSc. In control skin samples, t-kallikrein immunoreactivity was shown in endothelial and smooth muscle cells and pericytes of microvessels. In SSc skin, immunoreaction for t-kallikrein was found in microvascular endothelial cells and in perivascular inflammatory infiltrates present in the papillary dermis near to the dermo-epidermal junction. In dSSc skin, the few remaining vessels showed no immunoreactivity for t-kallikrein, except for the vessels near sweat glands and nerves.

Conclusions Our findings indicate that both t-kallikrein levels and t-kallikrein skin expression are related to typical SSc microvascular changes as assayed by nailfold videocapillaroscopy and by immunohistochemistry of skin biopsies.

P34

A complete phylogenetic analysis coupling expression data from EST databases. An example with a family of genes: the peptidyl arginine deiminase genes

N Balandraud, P Gouret, E Danchin, M Blanc, D Zinn, P Pontarotti
EA 3781 Evolution, Genome, Environment, Université de Provence, Marseille, France


Background For functional annotation, similarity-based approaches [1] do not take into account all the information from comparative and evolutionary biology. They do not differentiate between orthologs and paralogs among homologs and, furthermore, the closest BLAST is often not the nearest neighbour [2]. Phylogenetic approaches taking into account duplication and speciation events are necessary to solve these problems. But they do not blend any data from transcriptional behaviour. Nevertheless, orthologs can have very similar ‘molecular function’ but undergo a different ‘macroscopic function’ because of a transcriptional shift. Growing data for gene expression profiling are available in various databases concerning normal or pathological tissues (Expressed Sequence Tags [ESTs] from NR, TIGR, GeneNote, Gepis, etc.). Some works recently examined the correlation between evolution (duplication and speciation) of genes and expression divergence within and between species [3,4], and some examine the expression profile between orthologous genes in sequenced species [5].

Methods We performed a phylogenetic analysis of a protein family, using EST databases. This allowed us to enlarge the dataset of species containing homologs and consequently to improve the reconstruction of the genes’ evolutionary history. We then extracted all the transcriptional data contained in EST databases, to decipher the gene expression pattern. Because gene annotation is currently labour intensive, we used a locally developed platform dedicated to phylogenetic annotation (named FIGENIX) [6]. We validated this approach on a family of genes possibly implied in rheumatoid arthritis; the peptidyl arginine deiminase (PADI) genes.

Results We show here a phylogenetic annotation with an enlarged dataset including EST contigs and expression data. It allowed us to integrate more functional data for analysis of a set of genes and permits us to give a transcriptional footprint of the gene. Our analysis showed that the PADI-2 paralog group have kept the ancestral molecular function coupled with a probable ancestral expression profile. These classified data permitted us to perform an updated footprint of the transcriptional data for each paralog group from this protein family.

Conclusion We believe this method announces a new way to annotate uncharacterized ESTs. More than classical phylogeny, it allows highlighting of the transcriptional shift between paralogs, and is thus a good tool to improve annotation. It showed that functional shift can occur in differential tissue expression rather than in biochemical function of the protein.

This method of analysis is at its beginning and has to be extended to all kinds of expression database, including databases where expression data are normalized such as UniGene. In the future it cannot be ignored in annotating new unknown ESTs, underlined by DNA microarray assays for example.

References

Acknowledgement This work is supported by the French Society of Rheumatology (FRR).

P35
Expression of innate immune receptors in the immunopathologic lesion of primary Sjogren’s syndrome: preliminary results
E Bourazopoulou, EK Kapsogeorgou, JRoutsias, DA Liakos, HM Moutsopoulos, AG Tzioufas
Department of Pathophysiology, School of Medicine, National University of Athens, Greece

Background Toll-like receptors (TLRs) have a crucial role in early host defence against invading pathogens. They recognize specific molecular patterns that are present in microbial and viral components, whereas several endogenous molecules seem to be placed among their expanding group of ligands. The CD91 receptor (low-density lipoprotein receptor-related protein [LRP1] or alpha 2-macroglobulin receptor [A2MR]) is a multifunctional receptor that recognizes hsp-chaperoned peptides, which are processed and presented by the MHC class I and MHC class II molecules. So far, there is an increasing evidence that the receptors of innate immunity also play an important role in acquired immunity.

Objective The objective of our study was to evaluate the expression of TLRs and CD91 in minor salivary gland (MSG) biopsy tissues and non-neoplastic salivary gland epithelial cell lines obtained from patients with primary Sjogren’s syndrome (pSS).

Methods At the mRNA level, the expression of TLR2, TLR4, TLR7, TLR9 and CD91 was examined in a non-neoplastic salivary gland epithelial cell line from a patient with pSS by means of RT-PCR. Protein expression of TLR2, TLR4, and CD91 was studied by immunohistochemistry in MSG biopsy tissues from 12 patients with pSS and nine control patients with non-specific sialadenitis.

Results RT-PCR analysis revealed transcriptional activation of TLR2, TLR4, TLR7, TLR9 and CD91 genes in the epithelial cell line of pSS patient. In MSG biopsy tissues, abundant expression of CD91 was observed in ductal cells of both pSS and control tissues, but also in the foci lymphocytic infiltrates of pSS patients. TLR2 and TLR4 protein expression was localized in single, scattered cells, both in pSS patients and, to a lesser extent, in control patients, showing a distinct staining pattern.

Conclusion The presence of CD91 and TLRs in the immunopathologic lesion of Sjogren’s syndrome provides preliminary evidence, suggesting their possible role in innate immune responses within the lesion.

P36
The association of different B27 subtypes with the peptide loading complex
JC Goodall, L Ellis, JSH Gaston
Department of Medicine, Addenbrookes Hospital, University of Cambridge, UK

Background The molecular basis for the strong association of HLA-B27 with ankylosing spondylitis (AS) has not been elucidated. A number of B27 alleles including B*2704 and B*2705 are associated with increased susceptibility to AS; in contrast, the alleles B*2706 and B*2709 are not associated with AS. These alleles differ in amino acid regions that have been shown to influence the interaction with tapasin, an accessory molecule that plays a critical role in incorporating HLA class I into the peptide loading complex (PLC). Our aim was to determine whether B27 subtypes differ in their association with the PLC.

Methods The 221 line that is negative for HLA class I alleles B, A and C was transfected with B*2704, 05, 06 and 09 expression constructs, and stable long-term transfectants with equivalent HLA-B27 expression were selected. The PLC was immunoprecipitated using the anti-TAP antibody 148.3 (provided by R Tampe) and magnetic anti-immunoglobulin microbeads. Non-specific binding of HLA class I was determined by immunoprecipitation with an isotype control mAb. Following reducing SDS-PAGE and western blotting of the eluted proteins, the co-precipitation of HLA-B27 was detected by probing the immunoblots with the anti-HLA class I mAb, HC10, followed by HRP-linked secondary antibodies and visualized using enhanced chemiluminescence. Detection of TAP and tapasin was achieved by stripping bound mAbs and reprobing the immunoblots with RING4C (provided by P Cresswell) or ‘Giles’ (provided by T Elliott) polyclonal antisera, respectively.

Results Only HLA-B*2704, 05 and 09 were found to be readily detectable above background on the immunoblot; suggesting that they were co-precipitated by the anti-TAP mAb and therefore incorporated into the PLC. Despite expressing equivalent quantities of HLA class I heavy chain to the other B27 subtypes, HLA-B*2706 was unique in that it was not detectable above background levels. The inability to detect B*2706 was not due to different efficiencies in immunoprecipitation of the PLC since equivalent quantities of TAP and tapasin were immunoprecipitated from the cell lysates of all B27 subtypes.

Conclusions We have shown that B*2706 differs from the other B27 subtypes in that it cannot be detected within the PLC. B*2706 differs from B*2704 at amino acid positions 114 and 116, and we suggest that these amino acid differences confer the PLC independence of this allele. PLC independence may play a role in contributing protection from arthritis by a number of potential mechanisms such as conferring an inability to bind an atherogenic peptide that is only efficiently bound in the context of the PLC. Alternatively, lack of association with the PLC could also modify an event downstream of peptide loading that may protect from disease susceptibility.

P37
Functional regulatory immune responses against human cartilage glycoprotein-39 in health versus proinflammatory responses in rheumatoid arthritis
JHM van Bilsen1, H van Dongen1, LR Lard1, EIH van der Voort1, DG Elferink2, AM Bakker1, AMM Miltenburg1, TWJ Huizinga1, RRP de Vries2, REM Toes1
1Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; 2Department of Immunohematology and Blood Transfusion, Leiden University Center, Leiden, The Netherlands; 3NV Organon, Oss, The Netherlands

The class of immune response against autoantigens could profoundly influence the onset and/or outcome of autoimmune diseases. Until now, there is only limited information on the antigen-specific balance between proinflammatory and regulatory responses in humans. Here we analyzed the natural immune response against a candidate autoantigen in rheumatoid arthritis, Human Cartilage gp-39 (HC gp-39).

Peripheral blood mononuclear cells from healthy individuals reacted against HC gp-39 with the production of IL-10, but not interferon gamma (Fig. 1). Ex vivo assays indicated that the naturally occurring HC gp-39-specific immune response in bulk is powerful enough to suppress antigen-specific recall responses, demonstrating that, rather than being unresponsive, the HC gp-39-directed immune response in healthy individuals shows a strong bias towards a regulatory phenotype. Moreover, CD4+ T-cell lines directed against HC gp-39 expressed CD25, GITR and Foxp3 molecules and were capable of suppressing antigen-specific T-cell responses. Cell–cell contact was required for this suppression. As opposed to healthy individuals, the HC gp-39-directed immune response in 50% of patients with rheumatoid arthritis exhibits polarization towards a proinflammatory Th1 phenotype and is significantly less powerful in suppressing antigen-specific recall responses.

Together these findings indicate that the presence of HC gp-39-specific immune responses in healthy individuals may have an inhibitory effect on inflammatory responses in areas where HC gp-39 is present. Furthermore, these data indicate that the class of HC gp-39-directed immune response in RA patients has shifted from an anti-inflammatory towards a proinflammatory phenotype.

Figure 1

Human Cartilage gp-39 (HC gp-39)-specific immune reactivity in healthy donors. (a) Peripheral blood mononuclear cells from healthy donors (n = 31) react against HC gp-39 by production of IL-10 but not interferon gamma (IFN-γ). (b) ‘Control’ recall antigen-induced responses are dominated by IFN-γ production.

Acknowledgements This work was supported by The Dutch Arthritis Association. REMT is supported by a Vidi Grant from the Netherlands Organization for Scientific Research. HyD and LRL are supported by The Netherlands Organization for Health Research and Development.
P38 Differential survival of leucocyte subsets by synovial, bone marrow and skin fibroblasts: site-specific rescue of CD4+ T cells versus activation-induced rescue of neutrophils
AF Diler1, G Parsonage1, AMCT Thomas2, SJ Curnow1, A Akbar1, M Salmon1, CD Buckley1
1Rheumatology Research Group, MRC Centre for Immune Regulation, University of Birmingham; 2Royal Orthopaedic Hospital, Birmingham, UK; 2Department of Immunology and Molecular Pathology, UCL, London, UK Arthritis Res Ther 2005, 7(Suppl 1):P38 (DOI 10.1186/ar1559)
Background Chronic inflammatory disease is characterised by predilection for certain sites, the molecular basis of which remains obscure. We investigated the role that fibroblasts play in governing the survival (persistence) as well as the type of infiltrate (predominantly neutrophil versus lymphocyte) using a leucocyte–fibroblast co-culture model. We used matched synovial, bone marrow and skin fibroblasts to test the hypothesis that a fibroblast-derived, stromal area post code identifies microenvironments that can support differential leucocyte accumulation.
Methods Matched synovial (SFb), bone marrow (BMFb) and dermal fibroblast (DFb) lines were established from eight patients satisfying ACR criteria for rheumatoid arthritis undergoing total hip or knee arthroplasty. Activated peripheral blood CD4+ T cells prepared by negative depletion and neutrophils prepared by density gradient centrifugation were co-cultured with fibroblasts. Survival, apoptosis and proliferation were assessed using total cell counts and active caspase 3 staining (T cells) or DiOC6 staining (neutrophils).
Results Site-specific survival of CD4+ T cells was observed in all eight sets of matched samples: at 3 days, DFb maintained better T-cell survival than culture in medium alone (40 ± 1.2% mean ± standard error) compared with 25.4 ± 1.4% (P < 0.05). However, both SFb and BMFb maintained even better T-cell survival compared with DFb: 58.8 ± 1.2% (P < 0.001 versus DFb) and 51.4 ± 2% (P < 0.005 versus DFb). Fibroblast pre-activation with a wide range of proinflammatory cytokines (IL-2, interferon gamma, IL-4, IL-10, tumour necrosis factor alpha) significantly increased neutrophil survival: SFb 51.2 ± 6.1%, BMFb 51.1 ± 5.5%, DFb 50.6 ± 4.7%, versus control 16.2 ± 3.3%, P < 0.001. Fibroblast conditioned media reconstituted the survival effect, indicating that a soluble survival factor(s) as opposed to cell–cell contact mechanism is involved in neutrophil survival.
Conclusions Fibroblasts differentially regulate leucocyte subset survival in both a site-dependent and activation-dependent manner. Our results provide an alternative explanation for site-specific differences in the pattern of T-cell and neutrophil accumulation in different chronic inflammatory diseases.

P39 Regulatory T-cell defect in the arthritis-susceptible DBA/1 mouse
SP Fairchild1, M Schenk1, R Doffinger2, FC Hall1
1Department of Clinical Medicine, University of Cambridge, UK; 2Department of Clinical Immunology and Biochemistry, Addenbrooke’s Hospital, Cambridge, UK Arthritis Res Ther 2005, 7(Suppl 1):P39 (DOI 10.1186/ar1560)
Background DBA/1 mice are susceptible to collagen-induced arthritis and to low-grade spontaneous inflammatory arthritis in elderly males. CD4+CD25+ T cells have been implicated in the suppression of arthritis in the susceptible DBA/1 strain [1,2] and in patients with rheumatoid arthritis [3]. We have studied the function of the CD4+CD25+ T-cell subset in DBA/1 and arthritis-non-susceptible C57Bl/6 male mice.
Methods The frequencies of CD4+CD25+ T cells were assessed in lymph nodes and the spleen of DBA/1 and C57Bl/6 mice by FACS analysis. Spleens were harvested from adult male DBA/1 and BALB/c mice. CD4+CD25+ and CD4+CD25- T cells were purified using Miltenyi reagents and a VarioMACS. Proliferation assays in response to either Concanavalin A (1 µg/ml) or soluble anti-CD3 (0.1–10 µg/ml) were performed using 5x104 CD4+CD25- cells with 1µCi irradiated adherent splenocytes as antigen-presenting cells. Co-culture of CD4+CD25+ and CD4+CD25- T cells in a 1:1 ratio was used to assess suppression. Cytokine (IL-2, IL-10) and AIM-1 expression gamma, IL-4, IL-10, tumour necrosis factor alpha, IL-6, IL-17, IL-15) were measured in the tissue culture supernatant after 36 hours incubation. Proliferation was measured by 3H-thymidine incorporation. Suppression ratios (SRs) were calculated as follows: SR = (response from CD4+CD25-/CD4+CD25+ T-cell coculture) / (response from CD4+CD25- T cells alone). SRs in DBA/1 and C57Bl/6 mice were compared using Student’s t-test.
Results The frequency of CD4+CD25+ T cells was comparable in the spleen and lymph nodes of DBA/1 and C57Bl/6 mice. SRs were higher (i.e. less suppression) in proliferation assays from DBA/1 mice compared with C57Bl/6 mice, which were stimulated with anti-CD3 (P = 0.03). DBA/1 cultures were generally associated with higher cytokine levels. Cytokine SRs were higher (i.e. less suppression) for DBA/1 compared with C57Bl/6 cultures for IL-6 and IL-17. SRs were lower (i.e. more suppression) for DBA/1 compared with C57Bl/6 cultures for IL-4 and IL-10.
Conclusions The arthritis-susceptible DBA/1 mouse strain appears to have a functional defect in the CD4+ CD25+ T-cell compartment. IL-4 and IL-10 are efficiently suppressed by CD4+CD25+ T cells. Suppression of IL-6 and IL-17 appears to be defective. This may partly explain the susceptibility of DBA/1 mice to erosive arthritis.
Reference

P40 Heme oxygenase 1 regulates osteoclastogenesis
J Zwerina1, S Hayer1, K Rodlitch1, J Radda1, O Hoffmann2, JS Smolen1, G Schett1
1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria; 2Institute for Pharmacy, University of Vienna, Austria Arthritis Res Ther 2005, 7(Suppl 1):P40 (DOI 10.1186/ar1561)
Heme oxygenase 1 (HO-1) plays an important role in vascular disease, transplanation and inflammation. In animal models of acute and chronic inflammation, induction of HO-1 has anti-inflammatory and cytoprotective properties. Since inflammation is an important trigger of osteoclastogenesis, we hypothesized that HO-1 might play a role in osteoclastogenesis.
When HO-1 was induced by hemin in vitro, a significant dose-dependent inhibitory effect on osteoclastogenesis was observed. Hemin primarily inhibited differentiation of mononuclear osteoclast precursors to osteoclasts. These effects were based on a downregulation of the expression of c-fms and RANK, the receptors for monocyte-colony stimulating factor and RANKL, whereas MAP kinase, NF-kB or Akt signalling were not affected. In vivo, HO-1 induction prevented endotoxin-induced calvarial bone resorption. Furthermore, assessment of synovial tissue from rheumatoid arthritis (RA) patients showed expression of HO-1 in monocytes and fibroblasts, whereas osteoclasts were rarely HO-1 positive. To further assess the role of HO-1 activity in RA patients, we correlated the presence of local bone erosions with serum bilirubin levels. We observed significant higher bilirubin levels in non-erosive than in erosive RA patients. Thus, an increase of HO-1 expression is anti-osteoclastogenic in vitro and might protect from increased bone resorption in vivo.
Acknowledgement This study was supported by the START price of the Austrian Science Fund (FS).

P41 How does tumour necrosis factor uncouple T-cell receptor-induced IL-2 gene expression in murine T cells?
JM Clark, K Aleksyadis, M Panesar, AP Cope
The Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College London, UK Arthritis Res Ther 2005, 7(Suppl 1):P41 (DOI 10.1186/ar1562)
Background T-cell receptor (TCR)-induced IL-2 expression is suppressed at the level of mRNA and protein following chronic culture of T cells with tumour necrosis factor (TNF) at picomolar concentrations, an effect that is reversible upon removal of TNF. This TCR hyporesponsiveness is reminiscent of that of T cells recovered from inflamed sites such as the rheumatoid synovium. We have found that, although chronic TNF attenuates TCR expression and TCR-proximal signalling, IL-2 expression is suppressed regardless of whether cells are stimulated via the TCR, or with phorbol ester and calcium ionophore to activate the MAPK and NFAT pathways directly. Suppression therefore occurs independently of TCR-proximal effects of TNF [1,2].
Objectives We are studying the mechanisms by which chronic TNF suppresses TCR responses in the CD4+ mouse T-cell hybridoma clone, 11A2. We have compared the stability of induced IL-2 mRNA, and the regulation of transcription factors important for IL-2 gene expression, in control and TNF-treated cells; and we have recently begun to study effects of chronic TNF on chromatin remodelling across the IL-2 proximal promoter (pI-2), which precedes initiation of transcription, using the chromatin accessibility real-time PCR (CHART-PCR) assay [3].
Methods Cells were grown in the presence or absence of 2.5 ng/ml murine TNF for 8 days. Washed cells were stimulated with either plate-bound anti-CD3e, or phorbol 12-myristate 13-acetate (PMMA) and ionomycin, for 4 hours.

Available online http://arthritis-research.com/supplements/7/S17
mRNA stability assay Actinomycin D was added and cells harvested over a 4-hour time-course. Total RNA was extracted and probed for IL-2 mRNA by ribonuclease protection assay.

Transcription factor regulation Whole cell lysates were probed for NF-xB and IxB family proteins by immunoblot.

Chromatin remodelling Nuclei were isolated and subjected to limited nuclease digestion. DNA was extracted and quantitative analysis of target sequences within pIL-2 carried out by real-time PCR. An increase in the threshold cycle (Ct) of a target sequence PCR product from activated cells was indicative of stimulation-induced chromatin remodelling.

Results IL-2 mRNA induced via TCR was unstable (t1/2 < 30 min), whereas PMA and ionomycin stabilised IL-2 mRNA strongly (t1/2 > 2 hours). However, the initial rate of decay was similar in control and TNF-treated cells, suggesting that reduced expression in TNF-treated cells was not due to decreased stability of IL-2 mRNA.

c-Rel, IxB, and IxB were regulated differently in control and TNF-treated cells: expression of IxB was comparatively enhanced, while that of c-Rel and IxB(B) was attenuated in TNF-treated cells. These altered responses may affect the ability of TNF-treated cells to remodel IL-2 productively through NF-xB consensus binding upon cell stimulation [4]. This hypothesis is now being tested by CHART-PCR.

Conclusions Chronic culture of murine T cells in TNF does not alter the stability of IL-2 mRNA induced via TCR, or by PMA and ionomycin, in those cells. However, altered regulation of NF-xB expression and activity in TNF-treated cells may contribute to poor inducibility of IL-2 through effects on stimulus-induced changes in chromatin conformation across pIL-2.

References

P42
The invasiveness of fibroblast-like synoviocytes is of relevance for the rate of joint destruction in patients with rheumatoid arthritis and is a patient characteristic

TCA Tolboom1, AHH van der Heim-van Mill2, RGHN Nelissen3, FC Breeveld4, REM Toes5, TWJ Huizinga6
1Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; 2Department of Orthopedics, Leiden University Medical Center, Leiden, The Netherlands

Objective Rheumatoid arthritis (RA) is characterized by inflammation of synovial joints and degradation of these joints. Fibroblast-like synoviocytes (FLS) are thought to play a role, because they can invade normal human cartilage in SCID mice [1] and matrigel in vitro [2]. This study was undertaken to investigate the association of these in vitro characteristics with the disease characteristics in patients with RA.

Methods Synovial tissue samples of 72 RA and 50 osteoarthritis patients were obtained; from seven patients with RA, samples of different joints were collected. The FLS invasiveness in Matrigel matrix was studied; the intra-individual and inter-individual differences were compared. The radiological scores of the X-rays of the hands and feet of the patients with the FLS that exhibit the most extreme differences in in vitro ingrowth (most invasive and least invasive FLS) were determined with the Sharp–van der Heijde method to determine the relationship between in vitro invasion data and clinical data.

Results FLS from patients with RA are more invasive than FLS from patients with osteoarthritis (P < 0.001). The intra-individual variation in FLS invasion was much less than the inter-individual variation (P = 0.028; mean difference ± standard deviation, 1204 ± 298 and 3476 ± 2387 for intra-individual and inter-individual variation, respectively), showing that the level of FLS invasion is a patient characteristic. The mean Sharp score of X-rays of the hands and feet of the patients with the most invasive disease was 22.3 ± 0.0, whereas for patients with the least invasive disease, which was much lower as compared with 22.3 ± 0.0 (per year of disease duration (n = 8) for the patients with the most invasive disease (P < 0.001).

Conclusion The ex vivo behaviour of FLS is a patient characteristic given the small intra-individual variation, and is highly correlated with the rate of joint destruction in patients with RA. This suggests that the ex vivo invasive behaviour of FLS from patients with RA is of relevance for the rate of joint destruction in patients with RA.

References

Acknowledgements TCAAT and AMDtvdH-M contributed equally to this work.

P43
A role for IL-7 in regulating CD4+CD25high regulatory T cells

CA Lawson1,2, AK Brown1,3, SL Field1, C Burgoyne1, P Emery1, JD Isaacs1, F Ponchel1,2
1Department of Rheumatology, University of Leeds, UK; 2Molecular Medicine Unit, University of Leeds, UK; 3Department of Rheumatology, University of Newcastle, UK

Background Despite the accumulation of evidence that CD4+CD25high regulatory T cells play an important role in the prevention of autoimmune disease, little is known about how they are regulated in vivo. There are thought to be at least two mechanisms for the generation of regulatory T cells: naturally occurring CD4+CD25high regulatory T cells derive from the thymus, and peripherally-induced regulatory cells arise under tolerogenic conditions. Recently, cytokine activation requirements for CD4+CD25high regulatory T-cell function were associated with IL-7, as well as IL-2 and IL-4. We examined a cohort of patients with rheumatoid arthritis whose disease was well controlled, Serum IL-7 levels were measured by ELISA. Quantification of the CD4+CD25+ T-cell subset was performed using flow cytometry. Thymic activity was evaluated by real-time PCR quantification of T-cell receptor excision circles in CD4+ T cells. Thymidinate incorporation assays were used to assess the response of CD4+CD25+ T cells to IL-7 stimulation, and also their ability to suppress the proliferation of CD4+CD25- T cells in response to phytohaemagglutinin in co-culture.

Methods Peripheral blood samples were taken from patients with rheumatoid arthritis whose disease was well controlled. Serum IL-7 levels were measured by ELISA. Quantification of the CD4+CD25+ T-cell subset was performed using flow cytometry. Thymic activity was evaluated by real-time PCR quantification of T-cell receptor excision circles in CD4+ T cells. Thymidinate incorporation assays were used to assess the response of CD4+CD25+ T cells to IL-7 stimulation, and also their ability to suppress the proliferation of CD4+CD25- T cells in response to phytohaemagglutinin in co-culture.

Results Circulating levels of IL-7 positively correlated with the frequency of circulating CD4+CD25high T cells (n = 47, R = 0.647, P < 0.0001). This appeared to result from an increased production of these cells by the thymus. High levels of circulating IL-7 in vivo were associated with increased suppressor functions of CD4+CD25high T cells in vitro (n = 5, mean 79% suppression by cells from patients with high IL-7 levels, and 39% suppression by cells from patients with low IL-7 levels). In patients with low circulating IL-7 levels, adding exogenous IL-7 to co-cultures appeared to increase suppression.

Conclusions Our data suggest that IL-7 has a role in regulating CD4+CD25high T-cell number and function. Circulating IL-7 levels are low in active rheumatoid arthritis, and this may be a contributory factor to the reduced size and suppressor function of the CD4+CD25high regulatory T-cell population in this disease.

P44
Results of the Consensus Finding Study Group on Autoantibodies (March 2003–March 2004)

D Hamann1, P Charles2, M Renz3, HP Seelig4, A Wilk5, RJT Smeenk5
1Department of Autoimmune Diseases, Sanquin Diagnostic Services at CLB, Amsterdam, The Netherlands; 2Department of Rheumatology, Kennedy Institute and Hammersmith Hospitals, London, UK; 3Laboratory Prof. HP Seelig, Dr R Seelig and Colleagues, Karlsruhe, Germany; 4Department of Autoimmunology, Statens Serum Institut, Copenhagen, Denmark

The European Consensus Finding Study Group on Autoantibodies is currently formed by 43 European laboratories involved in the field of serological diagnostics in rheumatic diseases. The aim of this group is to work towards achieving common consensus in this field: a laboratory result should be the same, wherever the result is obtained.

The Steering Committee of the Consensus Finding Study Group tested 24 candidate sera that had been contributed by the participating laboratories. Ten sera were selected for the annual serum round. This year, special emphasis was put on anti-DNA antibody testing. For this purpose four sera were included that contained different specificities of anti-DNA (Table 1). The remaining six sera were positive for a variety of autoantibodies (Table 1).
Table 1
Summary of results for 10 distributed sera

| Serum Detected antibodies Comments |
|-----------------------------------|---------------------------------|
| 1 dsDNA Only C. luciliae positive |
| 2 SS-A 52 kDa + 60 kDa, SS-B Good consensus |
| 3 SS-A 52 kDa, SCL-70 SS-A 60 kDa only found by minority |
| 4 PR-3 ANCA Very few incorrect results |
| 5 SS-B SS-A found by ELISA, counterimmunoelectrophoresis and immunoblot mostly negative |
| 6 U1-RNP, A and C protein 7OK negative, good consensus |
| 7 Centromere (CENP-B) Good consensus |
| 8 ssDNA Perfect consensus |
| 9 dsDNA No consensus |
| 10 dsDNA Good consensus |

For the first time, a dedicated computer program was used to allow more easy data entry and statistical analysis. Next to the 10 sera, a CD-ROM containing 20 HEP-2 cell staining patterns was dispatched to the participating laboratories. The CD-ROM also contained the spreadsheets to be filled in by the participants. Results were returned by 38 out of 43 participating laboratories. The data were discussed at a satellite meeting during the 24th European Workshop on Rheumatology Research in Berlin and were published on the website of the Sanquin Blood Supply Foundation in Amsterdam (via a link distributed to the participants). In depth analysis of individual results compared with the consensus were sent to the participants.

In general, the participants reached a high degree of consensus for most of the samples. The results for anti-dsDNA were very promising. A perfect consensus was reached for the absence of dsDNA antibodies in an anti-ssDNA specific serum (serum 8). The absence of false positive results showed that assays measuring anti-dsDNA antibodies have been improved such as to exclude detection of anti-ssDNA. Serum 9 was obtained from a rheumatoid arthritis patient who had been treated with anti-tumour necrosis factor alpha (Infliximab) and developed anti-ssDNA antibodies, yet showed no clinical signs of systemic lupus erythematosus. Using different assays, divergent results were obtained. Most laboratories found anti-dsDNA antibodies by the indirect immunofluorescence technique (substrate C. luciliae), whereas anti-ssDNA ELISAs were negative. For this sample most commercial Farr assays showed positive reactions. Detailed analysis of the serum in Amsterdam showed the presence of low avidity IgM and IgG antibodies to dsDNA. In order to understand the cause of the discrepancies the influence of choice of assay will be studied in more detail.

Divergent results, depending on the method for detection, were also found for antibodies to SS-A. Obviously, ELISA-based techniques were more sensitive. Unfortunately, most ELISAs do not distinguish between anti-SS-A 52 and anti-SS-A 60 antibodies. The clinical relevance of the lower limit of detection has to be established in the future. We will include a more detailed method analysis in the next rounds.

There was general agreement among the participating laboratories that these Consensus Rounds should be continued, including the HEP-2 cell pattern recognition CD-ROM effort. It was decided to focus next round on anti-phospholipid antibodies. For information about the study group please contact Ruud Smeenk (r.smeenk@sanquin.nl).

P45
Effects of overexpression of PAD4 enzyme in mouse synovium
AJW Zendman1, WAM Horstman1, AJ Amtz2, MB Bennink2, ER Vossenaar3, WI van Venrooij4, WB van den Berg2, FAJ van de Loo2, GJM Pruijn1
1Department of Biochemistry 161, Radboud University Nijmegen, The Netherlands; 2Department of Experimental Rheumatology, University Medical Center St Radboud, Nijmegen, The Netherlands


Background Autoantibodies directed against citrullinated proteins (e.g. anti-CCP) can be detected in rheumatoid arthritis (RA) patients with very high specificity. The antibodies are present already years before the first clinical symptoms and their presence predicts the development of erosive disease. Citrullinated proteins, the target of anti-CCP antibodies, are formed by post-translational deamina- tion of arginine residues, catalyzed by peptidylarginine deiminase enzymes (PADs). PAD enzymes are expressed by cells present in the inflamed joints of RA patients. These data are the basis of our hypothesis that protein citrullination by PAD is intimately involved in the development of RA.

Objective To investigate the effect of PAD4 overexpression in synovium of naive mice and in mouse models of arthritis.

Methods An adenoviral delivery tool for local expression of mouse PAD4 was successfully constructed. Using this adenoviral construct, PAD4 overexpression was effectuated in cells present in the synovial cavity after intraarticular injection. Effects of PAD4 overexpression in mice with or without co-induction of arthritis (streptococcal cell wall arthritis) were investigated using routine scoring of arthritic features (e.g. swelling) and histology. The presence of citrulline-specific antibodies was measured by ELISA using a synthetic citrullinated peptide (CCP1) and a noncitrullinated control peptide.

Results In all naive mice (C57/B16, n = 12) we were able to effectively overexpress PAD4 in the synovial tissue, lasting at least 1 week. This overexpression resulted in the generation of citrullinated proteins in vivo. In mice receiving a control adenovirus no citrullinated proteins were observed. The overexpression did not induce inflammation. Similar experiments in streptococcal cell wall (SCW)-induced mice (C57/B6 + SCW, n = 8) showed a prolonged expression of citrullinated proteins when the knees were preloaded with PAD4 (compared with control adenovirus-treated SCW mice, n = 8), but this did not affect the level of inflammation or tissue damage. Importantly, overexpression of PAD4 did not lead to the production of citrulline-specific autoantibodies in these mice.

Conclusion Adenoviral expression constructs can successfully be used to introduce PAD enzymes in mouse synovium. Overexpression of PAD4 results in the production of synovial citrullinated proteins, but did not cause additional inflammation in mice nor did it cause an immune response to citrullinated proteins. Generating anti-CCP-positive mice will be crucial in studying the effect of specific immune complexes on arthritic phenomena in mouse models of arthritis.

Acknowledgements This work was financially supported by the Netherlands Foundation for Chemical Research and the Netherlands Technology Foundation, the European League against Rheumatism and the Netherlands Foundation for Medical Research.

P46
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
1JD Isaacs, 2AJ Clarke, 3BL Hazleman, 4G Hale, 5H Waldmann, 6DPM Symmons
1School of Clinical Medical Sciences, University of Newcastle upon Tyne, UK; 2ARC Epidemiology Unit, University of Manchester, UK; 3Department of Rheumatology, Addenbrooke’s Hospital NHS Trust, Cambridge, UK; 4Dunn School of Pathology, University of Oxford, UK


Background In the early 1990s, we used the monoclonal antibody alemtuzumab (MabCampath, Schering AG, Berlin, Germany) to treat patients with refractory rheumatoid arthritis. This treatment provided temporary relief of symptoms but was associated with long-term lymphopenia, particularly of T lymphocytes [1]. We continue to follow these patients to exclude any adverse effects of their long-term lymphopenia.

Objective The objective of the current study was to compare 10-year mortality in this patient cohort with mortality in a control patient cohort.

Methods Fifty-three rheumatoid arthritis patients that received alemtuzumab (median dose, 172 mg; range, 1–420 mg) between 1991 and 1994 (cases) were monitored via the Office for National Statistics Central Registry, to ensure notifica- tion of death. A retrospective, matched-cohort study of mortality was performed with 102 control subjects selected from the European League Against Rheumatism database. This database comprises patients with rheumatic disorders who have received immunosuppressive drugs, usually cyclophosphamide or azathioprine.

Results Median (range) duration of follow-up was 10.28 (1.27–12.15) years for cases and 10.35 (1.18–12.14) years for controls. There were 20 deaths among the cases compared with 37 among the controls. This provided a mortality rate of 0.045 deaths per person per year for the cases and 0.041 deaths per person per year for the controls. The mortality ratio was 1.10 (95% confidence interval, 0.61–1.90). There was no significant difference in survival between the two groups (P = 0.73, log-rank test). Figure 1 illustrates Kaplan–Meier survival plots for cases and controls. The causes of death in the cases reflected those expected in a hospital-based rheumatoid arthritis cohort. Median time (range) from treatment to death for cases was 5.9 (1.3–11.7) years. Mortality did not differ according to total dose of alemtuzumab or the number of courses received.

Conclusions Despite long-term lymphopenia, there was no excess mortality in recipients of alemtuzumab at a median follow-up of 10.3 years from treatment.


Acknowledgements This work was supported by Ilex Oncology, Inc. and the Arthritis Research Campaign

Available online http://arthritis-research.com/supplements/7/S1
The hypoxia marker EF-5 was applied in mice with the collagen-induced arthritis (CIA) model. Using the hypoxia marker EF-5, we found that in mice with CIA, synovial tissues from active disease were associated with relapse. Using a regression analysis, we revealed that the frequency of inflammation-related cells was highly significant in predicting relapse, being correct in 78% of cases ($P = 0.025$). Neither the presence of rheumatoid factor or nodule improved this model.

**Results**

The abnormal differentiation patterns observed in active disease were mainly characterized by a high frequency of inflammation-related cells. Its complete absence in health and accumulation in disease remission also suggests a primary defect in T-cell differentiation pathways in RA.

**Conclusions**

These results suggest that the hyper-reactivity of the inflammatory subset is associated with disease activity; however, its persistence in the absence of inflammation suggests a primary defect possibly in activation-induced cell death. The second subset appears fairly inactive, but more work is necessary to fully characterize these cells. Its complete absence in health and accumulation in disease remission also suggests a primary defect in T-cell differentiation pathways in RA.
Identification of the EGF-TM7 receptor EMR2 and its ligand dermatan sulphate in rheumatoid synovial tissue

EN Kop1, MJ Kwakkenbos2, JDZ Teske1, MC Kraan1, TJ Smets1, M Stacey3, H-H Lin1, J Hamann2, PP Tak1
1Division of Clinical Immunology and Rheumatology, Academic Medical Center, Amsterdam, The Netherlands; 2Laboratory of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands; 3Sir William Dunn School of Pathology, University of Oxford, UK


Introduction EMR2 is a member of the EGF-TM7 family closely related to CD97. Chondroitin sulphates have recently been identified as ligands for EMR2 and CD97. Chondroitin sulphates have been implicated in the pathogenesis of rheumatoid arthritis (RA). The objective of this study is to determine the expression of EMR2 and the distribution of EMR2 and CD97 ligands in RA synovial tissue.

Methods Synovial tissue samples were obtained by arthroscopy from patients with RA (n = 19), inflammatory osteoarthritis (n = 13), and reactive arthritis (n = 13). Immunohistologic staining was performed with EMR2 mAb and stained synovial tissue sections were analysed by digital image analysis. Co-expression of EMR2 with lineage and activation markers was determined by double immuno-fluorescence microscopy. To evaluate the expression of EMR2 and CD97 ligands in RA synovium, binding assays using fluorescent beads loaded with EMR2-Fc or CD97-Fc constructs were performed.

Results EMR2 expression in the synovial sublining was significantly higher in RA compared with disease controls. Most EMR2-positive cells were macrophages and dendritic cells, expressing co-stimulatory molecules and tumour necrosis factor alpha. Dermatan sulphate was shown to be the ligand of the largest isoform of EMR2 and CD97 in rheumatoid synovium. In addition, the smaller isoforms of CD97, but not EMR2, bound CD55 on fibroblast-like synoviocytes.

Conclusion The EGF-TM7 receptor EMR2 and CD97 are abundantly expressed on myeloid cells in synovial tissue of RA patients where they encounter their ligands dermatan sulphate and CD55. These interactions might facilitate the retention of activated macrophages in the synovium.

Prevalence and specificity of autoantibodies to defensins in sera of patients with systemic autoimmune diseases

AG Terzoglou, JG Routsias, AG Tzioufas, HM Moutsopoulos
Department of Pathophysiology, School of Medicine, University of Athens, Greece


Background Defensins are small positively charged peptides (29–47 amino acids) that have highly conserved sequences among species and play a role in host defense against bacteria and viruses. There are two categories of defensins: A-defensins are secreted from human neutrophils, and B-defensins are produced from the epithelial cells. Each peptide contains six cystein amino acid residues, connected with disulfide bonds. The physicochemical properties of defensins are similar with the properties of another molecule, B2-glycoprotein I (B2-GPI), the major target of the autoimmune response against defensins in patients with antiphospholipid syndrome (APS).

Objective We investigated whether sera from patients with APS as well as primary Sjögren Syndrome (pSS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) contain autoantibodies that react with defensins.

Methods We synthesized the linear peptides NH2-Ac-YCYPAPACAGGERRYGTOYQGR-LWAFCC-OH and NH2-GIPvTVCXSGACHPFOPRKYQICTGLPGTC-COKK-OH, corresponding to the amino acid sequences of the mature forms of A1 (deA1) and B2 (deB2) defensins, respectively. These peptides were oxidized, in order for the disulfide bonds of the native molecules to be created, and subsequently lyophilized. The peptides were dissolved in water and they were tested in ELISA experiments against sera from patients with APS (n = 24), pSS (n = 24), SLE (n = 16), and RA (n = 8). Additionally, sera from normal individuals were tested. Homologous inhibition experiments were performed in order to examine the specificity of the immune response against defensins.

Results None from the tested sera reacted against the deA1. Sera from patients with systemic autoimmune diseases contained autoantibodies to defensins as follows: 21% of patients with APS and 25%, 31%, and 12% of the sera from the patients with pSS, SLE, and RA, respectively, gave a positive reaction against the same peptide. The normal sera reacted with the peptides at all. In the inhibition experiments the deB2 peptide, when it was used as soluble inhibitor, inhibited the binding of the antibodies at the plate-bound deB2 by 64%.

Discussion Defensins are components of the innate immune system and share common physiochemical properties with the B2-GPI molecule. A rather small proportion of sera from patients with systemic autoimmune diseases contain antibodies that react specifically with the deB2 peptide. The presence of these autoantibodies is not disease specific and their pathogenic significance, if any, remains to be elucidated.

Tumor necrosis factor alpha reverses the immunosuppressive properties of mesenchymal stem cells in collagen-induced arthritis

F Djouadi1, P Plenc1, C Bony1, F Apparailly1, J Corgensen1,2, D Noé1
1INSERM U475, Montpellier, France; 2Department of Immuno-rheumatology, Lapeyronie Hospital, Montpellier, France


Background Mesenchymal stem cells (MSCs) are bone-marrow-derived progenitors that have been widely investigated for their potential for differentiation towards multiple lineages, such as osteocytes and chondrocytes. Recently, we and others showed that MSCs exhibit immunosuppressive properties inducing in vivo tolerance of T lymphocytes towards allogeneic cells. Moreover, these cells can be easily genetically modified to express ectopic molecules, such as anti-inflammatory cytokines.

Objective Here, we investigated whether naïve and IL-10-expressing MSCs could display an inhibitory effect towards self-reactive T lymphocytes in vitro and have a biological effect in the murine model of collagen-induced arthritis (CIA).

Methods We used the murine C3H10T1/2 cell line (C3 MSCs) in the CIA murine model of RA. We injected various doses of MSC at immunization or at boost and evaluated the clinical and immunological parameters. Immunosuppressive properties of MSC were determined in vitro in mixed lymphocyte reactions.

Results We evaluated the potential immunosuppressive role of MSCs in the CIA model and showed that MSCs did not display any benefit whatever the day of cell injection (day 0 or day 21) and the numbers of MSCs (106 or 4 × 106). Both clinical and immunological analyses argued for the accentuation of the Th1 helper response. Using luciferase-expressing MSCs, we were unable to detect labeled cells in the articular environment of the knee, suggesting that worsening of the symptoms was unlikely due to the homing of MSCs in the joints. Experiments in vitro showed that addition of tumor necrosis factor alpha was sufficient to reverse the immunosuppressive effect of MSCs on T-cell proliferation and this observation was associated with an increase of IL-6 secretion.

Conclusion Here, we demonstrated that the immunosuppressive properties of MSCs did not provide any clinical benefit in CIA. Our data suggest that environmental parameters, in particular inflammation, may influence the immunosuppressive properties of MSCs.

Neutralizing IL-17 during re-activation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and IL-1

M Koenders, E Lubberts, LAB Joosten, WB van den Berg
Department of Rheumatology, Experimental Rheumatology and Advanced Therapeutics, Radboud University Medical Center Nijmegen, The Netherlands


Background Rheumatoid arthritis is characterized by an intermittent course of the disease with alternate periods of remission and relapse. T cells, and in particular the T-cell cytokine IL-17, are expected to be involved in this flare-up of arthritis.

Objective To study the role of T-cell IL-17 in flare-up of experimental arthritis.

Methods Antigen-induced arthritis was induced in C57Bl/6 mice by immunizing and boosting with mBSA/complete Freund’s adjuvant, and subsequent intra-articular injection of 60 µg mBSA. At week 4 of arthritis, 2 µg mBSA was injected into the arthritic joint to induce a flare-up of the smouldering inflammation. To study the role of IL-17 in this flare-up, neutralizing rabbit-anti-mouse-IL-17 antibody (or control antibodies) were injected 2 hours prior to antigen rechallenge.

Results Quantitative PCR at various time points after arthritis induction showed that IL-17 mRNA expression was already upregulated at day 1, increased more at day 2 and day 7, and clearly diminished at day 21. After antigen rechallenge, IL-17 mRNA expression rapidly increased, peaking at 4 hours with a 25-fold upregulation compared with naive mice.

Neutralizing IL-17 significantly prevented joint swelling, as measured by 99mTc uptake at day 1 (Fig. 1a). Arthritic knee joints were isolated at day 4, and histological analysis showed significantly suppressed joint inflammation (Fig. 1b) and cartilage proteoglycan depletion in the anti-IL-17-treated group.

Blocking IL-17 also clearly protected arthritic mice against bone erosions (Fig. 1c). Cathepsin K staining showed reduced osteoclast-like activity, and quantitative PCR showed reduced RANKL mRNA expression in the anti-IL-17-treated group. The degree of bone erosions strongly correlated with the severity of joint inflammation, suggesting that neutralizing IL-17 reduces bone erosion by suppressing joint inflammation.

Interestingly, mice treated with anti-IL-17 antibodies showed reduced protein levels of IL-1β, tumor necrosis factor alpha, and the cytokine-induced neutrophil chemotactant KC, suggesting that IL-17 acts as an upstream mediator in destructive joint inflammation during flare-up of experimental arthritis.
Objective To test the hypothesis that RA bone-marrow-derived B cells express TLR9 protein that could be detected via intracellular staining and flow cytometric analysis. Importantly, these TLR9 are functional. CpG-ODN, but not control GpC-ODN, in a dose-dependent manner enhanced the expression of activation markers (CD86 and CD54) on B cells in BMMC cultured in vitro. The specificity of CpG-ODN triggered expression of CD86 was confirmed in experiments where cells cultured in the presence of chloroquine, a known inhibitor of TLR9-triggered signal transduction, failed to respond to CpG-ODN. Moreover, CpG-ODN triggers bone marrow B-cell proliferation in vitro, as judged by enhanced expression of proliferation marker Ki-67 and a diminished level of CFSE dye. Interestingly, our preliminary data indicate the presence of bacterial DNA in several samples of bone marrow tissues isolated from RA patients. We could amplify DNA encoding bacterial 16S-ribosomal RNA in one bone marrow plasma and three BMMC out of five analyzed samples.

Conclusions Our results indicate that CpG oligodeoxynucleotides, the potent agonists of TLR9, modulate the activity of B cells from bone marrow of RA patients via induction of costimulatory and adhesion molecules (CD86, CD54) expression, and via cell proliferation. Thus, our data suggest that bone marrow of RA patients may represent an important secondary lymphoid organ that actively participates in the pathogenesis of RA.

P54

Functional Toll-like receptor 9 modulates the activity of bone marrow B cells isolated from rheumatoid arthritis patients

W Rudnicka1, E Warnawin1, M Buler1, T Burakowski1, M Bik1, E Kontry1, C Michalak1, P Malyk1, W Maslinski1

1Department of Pathophysiology and Immunology, Institute of Rheumatology, Warsaw, Poland; 2Clinic of Orthopedic Surgery, Institute of Rheumatology, Warsaw, Poland


Background Toll-like receptors (TLRs), a family of pathogen recognition receptors, represent an important component of the innate immune system that also contributes to the development of acquired immunity. TLR9 expressed in the cytoplasm of several cell types including B cells, and recognize and are activated by unmethylated CpG-rich, pathogen-derived DNA sequences. This CpG stimulation triggers B-cell proliferation and promotes Th1 response. Moreover, DNA containing CpG-rich motifs, acting as polyclonal stimuli, participates in the maintenance of serological memory by human memory B cells. Recent data indicate that bone marrow in rheumatoid arthritis (RA) patients may actively participate in the pathogenesis of RA as a secondary lymphoid organ via overproduction of proinflammatory cytokines and a site of effective antigen presentation.

Objective To test the hypothesis that RA bone-marrow-derived B cells express functional TLR9.

Methods Bone marrow mononuclear cells (BMMC) were isolated from RA bone marrow samples obtained during joint replacement surgery. The expression of TLR9 protein on B lymphocytes, gated as CD19-positive cells in BMMC preparation, was assessed by intracellular staining and flow cytometric analysis. BMMC were stimulated in vitro with agonistic (CpG-ODN) or control (GpC-ODN) oligodeoxynucleotides (15–30 μg/ml). In blocking experiments chloroquine (2–3 μg/ml) was added to the culture 50 min before stimulus. The expression of activation markers CD86 and CD54 on B lymphocytes (CD19+) were analyzed after 48 and 72 hours in culture using flow cytometry. Ki-67 and CFSE staining (flow cytometry) was applied to evaluate B-cell proliferation after 72 and 120 hours of culture with oligodeoxynucleotides. The concentrations of oligodeoxynucleotides and chloroquine used in experiments were not toxic to BMMC as judged by colorimetric lactate dehydrogenase assay. The presence of bacterial DNA in bone marrow plasma and BMMC was evaluated by DNA extraction and PCR amplification. Primers used for PCR recognize highly conserved regions of the euubacterial 16S-ribosomal RNA gene.

Results RA bone-marrow-derived B lymphocytes express TLR9 protein that could be detected via intracellular staining and flow cytometric analysis. Importantly, these TLR9 are functional. CpG-ODN, but not control GpC-ODN, in a dose-dependent manner enhanced the expression of activation markers (CD86 and CD54) on B cells in BMMC cultured in vitro. The specificity of CpG-ODN triggered expression of CD86 was confirmed in experiments where cells cultured in the presence of chloroquine, a known inhibitor of TLR9-triggered signal transduction, failed to respond to CpG-ODN. Moreover, CpG-ODN triggers bone marrow B-cell proliferation in vitro, as judged by enhanced expression of proliferation marker Ki-67 and a diminished level of CFSE dye. Interestingly, our preliminary data indicate the presence of bacterial DNA in several samples of bone marrow tissues isolated from RA patients. We could amplify DNA encoding bacterial 16S-ribosomal RNA in one bone marrow plasma and three BMMC out of five analyzed samples.

Conclusions Our results indicate that CpG oligodeoxynucleotides, the potent agonists of TLR9, modulate the activity of B cells from bone marrow of RA patients via induction of costimulatory and adhesion molecules (CD86, CD54) expression, and via cell proliferation. Thus, our data suggest that bone marrow of RA patients may represent an important secondary lymphoid organ that actively participates in the pathogenesis of RA.
Conclusion These findings suggest that treatment of CIA with BiP is mediated at least in part by induction of IL-4-dependent regulatory T cells.

References

Acknowledgement Research was funded by Immune Regulation Ltd (GSP, VMC and MBS are shareholders in the company).

P56
High-dose chemotherapy and syngeneic stem cell transplantation in a patient with refractory rheumatoid arthritis: poor response associated with persistence of synovial abnormalities
M van Oosterhout1, RJ Verburg1, EWN Levarht1, D Moolenaar2, I Bajema2, RY Barge3, WE Fibbe3, JM van Laar1
1Department of Rheumatology, Leiden University Medical Center, The Netherlands; 2Department of Pathology, Leiden University Medical Center, The Netherlands; 3Department of Hematology, Leiden University Medical Center, The Netherlands Arthritis Res Ther 2005, 7(Suppl 1):P56 (DOI 10.1186/ar1577)

Background High-dose chemotherapy (HDC) and stem cell transplantation (SCT) is an experimental treatment option for patients with refractory rheumatoid arthritis (RA). The re-infusion of stem cells with a possible intrinsic cell defect may be the cause for disease relapse due to increased sensitivity to disease-modifying anti-rheumatic drugs (DMARDs). This can be avoided by a syngeneic transplantation with healthy stem cells from an identical sibling.

Objectives We treated a 44-year-old woman, who had seropositive, erosive RA, with HDC and syngeneic SCT from her healthy identical twin sister. The patient had undergone multiple joint operations and had become refractory to conventional DMARDs, etanercept and infliximab.

Methods Outcome measures were DAS28, rheumatoid factor titer (lgM), need for DMARD therapy and synovial inflammation for which tissue was obtained at baseline, 2, 3 and 6 months through knee arthroscopy. Stem cells from the donor were mobilized with filgrastim and collected by leukapheresis on day –1 and 0. HDC consisted of cyclophosphamide (total dose 13.4 g intravenously) combined with 1 mg/kg prednisone. On day 0 an unmanipulated graft containing 182 × 106 leukocytes, containing 769 × 103 monocytes, containing 769 × 103 lymphocytes, containing 769 × 103 neutrophils and plasma cells were mobilized with filgrastim and collected by leukapheresis on day –1 and 0. Baseline, 2, 3 and 6 months through knee arthroscopy. Stem cells from the donor were collected by leukapheresis on day 0.

Results Before conditioning, infliximab, methotrexate and prednisone were discontinued and the patient was discharged on day 14 without joint complaints. After 1 month disease activity flared accompanied by an acute phase response. Despite maintenance therapy with 10 mg prednisone and re-institution of methotrexate up to 22.5 mg/week she had continued active disease up to 1 year after SCT (Fig. 1). Synovial biopsies at all time points showed a marked infiltration of neutrophils and plasma cells, even 2 months after HDC. Immunohistological staining showed infiltration of activated T cells (CD8+), B cells (CD19+) and plasma cells (CD138+).

Discussion HDC and syngeneic SCT did not result in remission of RA. The persistence of RF, anti-CCP (IgG) and plasma cells in the synovial tissue suggests host plasma cells were not eradicated by cyclophosphamide, nor replaced by donor plasma cells (rheumatoid factor and anti-CCP negative).

P57
Expression of IL-18 in muscle tissue of patients with treatment-resistant idiopathic inflammatory myopathies
IE Lundberg1, S Barbarossi1, AK Ulf gren1, JG Gracie2, IB McNees2
1Rheumatology Unit, Department of Medicine, Karolinska Institutet at Karolinska University Hospital, Solna, Stockholm, Sweden; 2Centre for Rheumatic Diseases, University of Glasgow, Glasgow, UK Arthritis Res Ther 2005, 7(Suppl 1):P57 (DOI 10.1186/ar1578)

Background Idiopathic inflammatory myopathies, myositis, are characterized by infiltrates of T lymphocytes and macrophages in muscle tissue. Some patients with myositis are very resistant to immunosuppressive treatment. Thus new therapies are urgently required. An increased knowledge of the key molecular mechanisms in myositis would be important for development of new targeted therapies for these patients. IL-18 is a pleiotropic cytokine with proinflammatory and immunoregulatory effects. It has been shown to play an important pathogenic role in various autoimmune disorders (e.g. rheumatoid arthritis and Sjögren's syndrome). Whether IL-18 has a role in disease mechanism in myositis is not known.

Objective To study the expression of IL-18 in muscle tissue of patients with idiopathic inflammatory myopathies.

Methods Thirteen treatment-resistant patients, six polymyositis, four dermatomyositis, one juvenile dermatomyositis, and two inclusion body myositis with signs of active muscle inflammation, were included in our study. Muscle biopsies were investigated by immunohistochemistry using monoclonal antibodies against IL-18.

Results Intracellular IL-18 expression was detected in all patients with polymyositis, one juvenile dermatomyositis, and two inclusion body myositis with signs of active muscle inflammation, were included in our study. Muscle biopsies were investigated by immunohistochemistry using monoclonal antibodies against IL-18.

Conclusion This is the first study to demonstrate IL-18 expression at the protein level in muscle tissue from patients with idiopathic inflammatory myopathies. This was a consistent finding in mononuclear inflammatory cells in all three subsets of patients with treatment-resistant disease. These results suggest that IL-18 could have a role in the immunopathogenesis of myositis.

P58
Evaluation of chondrocyte micromass culture for the study of cartilage degradation
MG Morgan, X Xu, AD Rowan, TE Cawston

Background An understanding of the mechanisms involved in cartilage degradation that occur in rheumatoid arthritis and osteoarthritis is essential for the development of treatments to block disease progression. Culturing chondrocytes to synthesize a cartilage matrix would ideally provide a cartilage matrix of consistent composition that would reproducibly respond to different stimuli. When cultured in monolayers, chondrocytes convert to a fibroblastic morphology and gradually lose their native phenotype, no longer able to synthesize type II collagen and aggrecan. However, when chondrocytes are cultured at a high density in the presence of growth factors, the chondrocytes regain their native phenotype and synthesize a cartilage matrix that would ideally provide a cartilage matrix of consistent composition.

Methods Chondrocytes extracted from bovine nasal cartilage were passaged several times to produce substantial cell stocks. Harvested cells were resuspended at 2 × 105 cells/ml and seeded in the centre of each well of a 48-well plate (20 μl/well). Cultures were maintained in a serum-free medium with or without ITS (insulin, transferrin and selenium), ascorbic acid, and transforming growth factor-β.

Figure 1

Available online http://arthritis-research.com/supplements/7/S1
growth factor beta 1 (TGFB1) for 14–21 days. Histological analysis of the micromass cultures examined the presence of proteoglycans and type II collagen. The effects of cytokine stimulation with IL-1, oncostatin M (OSM), and the combination of both cytokines on matrix degradation were tested by analysing proteoglycan and collagen release. Collagenase activity was measured by bioassay.

Results Both ITS and ascorbic acid were necessary for maximum collagen incorporation into micromass cultures. Collagen and proteoglycan incorporation increased with increasing TGFB1 concentration and increasing culture duration, maximum incorporation detected when TGFB1 was used at 30 ng/ml and cultures were maintained for 21 days. Histology showed that both proteoglycans and type II collagen were present throughout the chondrocyte micromass matrix. When micromass cultures were stimulated with IL-1, OSM and IL-1/OSM for 14 days, proteoglycan release was greater compared with control, but there was no difference for collagen release (see Fig. 1). Active collagenase levels were negligible, although high levels of pro-collagenase were detected.

Conclusion The chondrocyte micromass cultures synthesized a matrix that contained proteoglycan and type II collagen. The micromass culture may serve as a good model for studying proteoglycan but not collagen degradation.

Reference

Acknowledgment This work was funded by GlaxoSmithKline.

P59
A link between complement activation and anti-SSA in immune complex-induced cytokine production in systemic lupus erythematosus

L Mathsson, E Ahlin, H Storforss, J Rönnelid
Unit of Clinical Immunology, Uppsala University, Uppsala, Sweden


Background We have earlier shown that polyethylene glycol (PEG)-precipitated immune complexes (IC) from systemic lupus erythematosus (SLE) patients can induce IL-10 and IL-6 production from peripheral blood mononuclear cells. SLE is associated with IC-induced classical complement activation. Autoantibodies together with autoantigens released from apoptotic cells partly explain the IC formation. We therefore wanted to investigate how complement activation and levels of autoantibodies correlate to the amount of circulating IC and IC-induced cytokine production.

Others have previously shown an inverse correlation between IL-10 and IL-12 in SLE and we have shown that the degree of complement activation affects IC-induced IL-10 and IL-12 in different ways. A second aim was to investigate the effect of SLE IC on the production of IL-10 and IL-12.

Methods In total 195 SLE samples were investigated. Levels of autoantibodies (anti-nuclear antibodies, anti-DNA, SSA, SSB, RNP and Sm) were known for 116/195 samples. In a first study we investigated 19 patients with paired serum samples obtained at different occasions and mostly showing activation of the classical complement pathway. Here we primarily wanted to evaluate the effect of disease activity on IC-induced cytokine production. In a second study 78 samples with normal classical complement function and known autoantibody status were studied. Samples were PEG-precipitated and 10% PEG precipitates were added to serum-free cultures of normal peripheral blood mononuclear cells, and the levels of IL-10, IL-6 and IL-12/p40 were measured in the supernatants after 20 hours. Classical complement pathway function, levels of C2, C3b and circulating IC were measured in all samples.

Results In paired analysis, increased complement activation (lowered classical function and raised C3b/C3 ratio) was associated with increased IL-10 production (r = 0.046). For IL-6 there was a parallel but non-significant trend. Decreased C3 levels were also associated with increased IL-12 production (r = 0.03). When investigating these complement-activating sera in cross-section we found increased IL-10 levels in ENA+ (P = 0.03) and DNA+ samples (P = 0.046) compared with ENA- and DNA- samples with the largest impact of anti-SSA/SSB (P = 0.02). The same pattern was found for IL-6. In sera with normal complement levels there was no association between antibody status and IL-10 production, but IL-12 levels were increased in ENA+ cultures (P = 0.01) and linked to anti-SSA/SSB (P < 0.0001). There was no association to anti-DNA.

Concluding IC in serum and PEG IC-induced IL-10 production correlated in samples from active SLE (r = 0.55, P = 0.003), and we therefore used circulating IC as a surrogate marker for IC-induced IL-10 production in statistical evaluation of all sera with known antibody status. In analysis of variance with circulating IC as a dependent variable we found a strong interaction between decreased complement function and the occurrence of ENA, especially anti-SSA (complement P < 0.0001, anti-SSA P = 0.0001, interaction P = 0.002). Anti-DNA showed no association.

Conclusion We have found a link between classical complement activation, levels of circulating IC and induction of the cytokines IL-10, IL-6 and IL-12 with strong interaction between complement activation and presence of autoantibodies, notably anti-SSA. We hypothesize that, in quiescent SLE, autoantibodies circulate in monomeric form. In active SLE apoptotic cells release SSA forming IC with circulating anti-SSA, with subsequent induction of cytokines like IL-10.

PEG-precipitated SLE IC induce the production of IL-10 and IL-12 with parallel patterns depending on complement and autoantibodies. Inverse regulation of IL-10 and IL-12 in SLE therefore does not seem to depend on SLE-specific IC.

P60
The value of serum type II collagen epitope measurement in assessing early clinical response to treatment with anti-tumour necrosis factor alpha therapy in rheumatoid arthritis

RH Mullan1, T Lobanok1, C Walsh1, L King2, O Fitzgerald3, B Bresnihan1, U Fearon1, R Poole4, DJ Veale1
1University College Dublin, Ireland; 2Shriners Hospital, Cedar Avenue, Montreal, PQ, Canada; 3Ibex Pharmaceuticals, Montreal, PQ, Canada


Introduction Current guidelines on the use of anti-tumour necrosis factor alpha (anti-TNF-α) therapies in rheumatoid arthritis (RA) recommend a 3-month trial of the drug before a clinical assessment of treatment efficacy can be made. The serum epitope of the type II collagen propeptide CPII correlated with type II collagen synthesis, and is elevated in RA. The collagen cleavage neo-epitope C2C is specific for the destruction of type II collagen by the collagenases MMP-1, MMP-8 and MMP-13. Previously we have shown that the ratio of C2C/CPII is increased in osteoarthritis and correlates with cartilage destruction. The current pilot study assessed the utility of serum measurement of C2C and CPII in predicting early response to treatment with anti-TNF-α therapy in a group of 20 RA patients.

Method Twenty patients were assessed before commencement of either infliximab (n = 8) or etanercept (n = 15) therapy, and at 1-month and 3-month time points. After therapy was commenced, measurements of 28 swollen and tender joint counts for DAS28 score, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were taken at the time of each assessment. Additional serum was collected for measurement of CPII and C2C by ELISA. The change in serum levels of ESR, CRP, C2C, CPII and a ratio of C2C/CPII between 0 and 1 month was calculated, and then correlated with clinical outcomes at 3 months to assess their predictive value, using the Spearman Rank Correlation Coefficient.

Results The median DAS28 score fell from 6.20 to 3.74 following 3 months of treatment (P = 0.0004, Wilcoxon Sign Rank Test). The change in C2C/CPII at 1 month of therapy was more closely associated with the change in swollen joint count at 3 months (P = 0.16) than either CRP (P = 0.62) or ESR (P = 0.84). The change in C2C/CPII at 1 month was more closely associated with tender joint count at 3 months (P = 0.19) than either the ESR (P = 0.59) or CRP (P = 0.52). One-month changes in C2G and CPII when used individually were not predictive of swollen joint count at 3 months (P = 0.55 and P = 0.74, respectively) or tender joint count at 3 months (P = 0.4 and P = 0.8, respectively).

Conclusion The ratio of C2C/CPII appears to offer a better method of predicting early response to biological therapy than the standard acute phase markers CRP.

Figure 1
Cytokine Stimulated Release of Chondrocyte Micromass Matrix Components

The effect on proteoglycan and collagen release when bovine nasal chondrocyte micromass cultured for 14 days in serum-free medium supplemented with 25 ng/ml transforming growth factor beta 1 and then stimulated for 14 days with IL-1 (1 ng/ml), oncostatin M (OSM) (10 ng/ml) and IL-1/OSM combination (1/10 ng/ml). A significant difference with control was identified by Student’s t test, *** P < 0.005.
P61
Oncostatin M in rheumatoid arthritis: a key cytokine acts synergistically with other proinflammatory cytokines to promote human cartilage loss
U Fearon1, R Mullan1, R Poole2, T Markham3, O FitzGerald1, B Bresnihan1, DJ Veale1

1St Vincents University Hospital & The Conway Institute, Dublin, Ireland;
2Shirrins Hospital and McGill University, Montreal, Canada

Introduction Oncostatin M (OSM), an IL-6 type cytokine, is raised in the rheumatoid arthritis (RA) joint and correlates with markers of inflammation and cartilage destruction. This study explores the mechanistic role of OSM in cell adhesion, angiogenesis and matrix degradation.

Methods Microvascular endothelial cells (EC), primary RA synovial fibroblasts (SFC), synovial explant culture and RASFC/cartilage co-cultures were stimulated with OSM (20 ng/ml) ± IL-1 (5 ng/ml). Cell proliferation, cell adhesion molecule expression, tubule formation, cell migration and matrix degradation were assessed by proliferation, flow cytometry, matrigel angiogenesis and ELISA assays.

Results OSM stimulated EC/RASFC (basal = 0.9/0.56 to 1.56/1.94; P < 0.05, day 4) alone but demonstrated a synergistic effect in the presence of IL-1 (P < 0.01). OSM and IL-1 increased intercellular adhesion molecule expression, with no effect on vascular cell adhesion molecule or platelet endothelial cell adhesion molecule. OSM had an additive effect with IL-1 on intercellular adhesion molecule expression (P < 0.05). OSM increased EC tube formation (basal = 20 ± 1.5 to 47 ± 3.7; mean ± standard error, P < 0.01), and increased EC migration (basal = 1.265 ± 0.115 to 1.87 ± 0.187; P < 0.05). OSM synergistically increased TIMP-1 production in EC, SFC and synovial explants in the presence of IL-1, with no effect on αvβ3 or urokinase (−type plasminogen activator) receptor expression. OSM and IL-1 stimulated MMP-1 and MMP-13 expression in cartilage and SFC alone (P < 0.05) but had a significant threefold synergistic induction when cultured together (P < 0.01). Cartilage sections stained with safranin-O demonstrated almost complete depletion of proteoglycan expression in RASFC/cartilage co-cultures following 4 weeks incubation with IL-1/OSM.

This was reflected in the supernatants where IL-1 and OSM together synergistically increased GAG release from a basal level of 3.5–9.1 (μg GAG/mg cartilage weight) compared with either IL-1 or OSM alone.

Conclusion OSM plays a critical role in RASFC activation and cartilage invasion, also promoting angiogenesis. Its ability to act synergistically with other proinflammatory cytokines such as IL-1 further supports a key role for OSM in RA.

P62
Methotrexate, through adenosine release, downregulates tumor necrosis factor alpha-induced synovial fibroblast IL-15 expression and proliferation
E Miranda, M Benito, A Balsa, E Martin-Mola
Department of Rheumatology, Hospital La Paz, Madrid, Spain


Background Tumor necrosis factor alpha (TNF-α) is found at high concentrations in the rheumatoid joint and induces upregulation of synovial fibroblast IL-15, a cytokine known to induce fibroblast proliferation through an autocrine loop. The mechanism of action of low-dose oral methotrexate (MTX) is not well understood. By inhibiting AICAR transformylase, MTX has been described to induce the extracellular release of the potent anti-inflammatory autacoid adenosine. Objective To test the effect of MTX on TNF-α-induced synovial fibroblast IL-15 expression and proliferation.

Methods Synovial fibroblasts (Sfib) isolated from surgical specimens of rheumatoid arthritis (RA) patients (n = 10) were cultured in six-well plates. Sfib were stimulated with 10 ng/ml TNF-α and pretreated for 2 hours with medium or MTX at varying doses (0, 0.01, 0.1, 1, 10 μM) in the presence or absence of adenosine deaminase, DPCPX (adenosine A1 receptor antagonist) or DMXPA (adenosine A2 receptor antagonist). Surface and intracellular IL-15 protein were determined by immunofluorescence and flow cytometry. IL-15 mRNA was measured by real-time quantitative RT-PCR in a LightCycler instrument (Roche). Sfib proliferation was evaluated using the alamar blue bioassay.

Results TNF-α induced an upregulation of intracellular and surface IL-15 protein expression and of IL-15 mRNA, together with an increased Sfib proliferation rate. Sfib proliferation was significantly inhibited by a neutralizing anti-IL-15 monoclonal antibody but not by an isotype control antibody. In the presence of MTX, TNF-α-induced IL-15 upregulation and Sfib proliferation were reduced by 40–65% in a dose-dependent manner. Adenosine deaminase reversed the effects of MTX as did addition of DMXPA but not DPCPX 1 hour prior to MTX.

Conclusion MTX interferes with TNF-α-induced synovial fibroblast IL-15 upregulation and proliferation. This effect seems to be mediated through adenosine release and adenosine A2 receptor engagement. This may be a mechanism by which MTX controls the aggressive behavior of synovial fibroblasts in RA.

Acknowledgements This work was supported by Ministerio de Educación y Ciencia Programa Ramón y Cajal (EM) and Ministerio de Educación y Ciencia grant SAF 2003-01670 (EM and MB).

P63
Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrin
I Auger1, M Sebag2, C Vincent2, S Guis1, L Nogueira3, B Svesson3, A Cantagrel4, G Serre2, J Rouzier1

1INSERM UMR 639, Medical School and Rheumatology Ward, La Conception Hospital, Marseille, France; 2CNRS-Toulouse III University UMR 5165, Purpan Hospital, Toulouse, France; 3Rheumatology Ward, Helsingborg Lasarett AB, Helsingborg, Sweden; 4Toulouse III University EA 2405 and Rheumatology Ward, Rangueil Hospital, Toulouse, France


Rheumatoid arthritis (RA), a chronic inflammatory joint disease, develops in patients expressing particular HLA-DR alleles. RA patients’ sera contain antibod-
ies to a post-translationally modified form of fibrin on which arginyl residues are transformed in citrulline.

We tested whether HLA-DR alleles influence the production of anti-citrullinated fibrin antibodies in RA patient sera and whether the replacement of arginyl residues by citrulyl residues on fibrin peptides could modify their binding to RA-associated HLA-DR molecules and their recognition by T cells in RA patients and controls.

We found that RA-associated HLA-DR alleles are also associated with presence of anti-citrullinated fibrin antibodies in RA patient sera. Multiple peptides from the alpha and beta chain of fibrin are capable to bind many HLA-DR alleles. RA-associated HLA-DR alleles are good fibrin peptide binders. However, citrullination does not influ-
ence fibrin peptide binding to HLA-DR or fibrin peptide recognition by T cells. Finally, peripheral blood T cells that recognize native or citrullinated fibrin peptides are common in RA patients and very uncommon in normal controls. These results suggest that citrullination of fibrin has nothing to do with peptide/HLA-DR/T cell interaction and is merely involved in the definition of B-cell epitopes.

P64
Bone marrow as a secondary lymphoid organ: mature T-cell subsets in bone marrow from rheumatoid arthritis and osteoarthritis patients
E Warnawin1, T Burakowski1, I Jung2, P Maldyby3, W Maslinski1

1Department of Pathophysiology and Immunology, Institute of Rheumatology, Warsaw, Poland; 2Clinic of Orthopedic Surgery, Institute of Rheumatology, Warsaw, Poland


Introduction Recent data indicate that bone marrow plays an important role not only as a primary lymphoid organ responsible for haemopoiesis, but also as a sec-

ondary lymphoid organ with capability of antigen presentation exceeding that of lymph nodes. Although in chronic inflammatory/immune disease, like rheumatoid arthritis (RA), bone marrow participates in the initiation and/or perpetuation of the disease, there is little information about the real number of lymphocyte subpopu-
lations in the bone marrow of these patients and how they can be modulated by T-cell growth factors. IL-15 acting through IL-15 receptors (including high-affinity IL-15R alpha chain) is a key cytokine influencing the development of natural killer cells in bone marrow, and proliferation and maintenance of the memory CD3+ cell pool. However, there is no information about the levels of IL-15 in bone marrow.

Objectives To compare the real cell numbers within lymphocyte subsets in bone marrow isolated from RA and osteoarthritis (OA) patients. To measure the levels of soluble IL-15 and surface-expressed IL-15R alpha in bone marrow plasma and cells, respectively. To analyze the presence of memory and actively proliferating T cells in the bone marrow.

Available online http://arthritis-research.com/supplements/7/S1
The molecular pathogenesis of rheumatoid arthritis (RA) is still poorly understood. Cells obtained from RA bone marrow (6.1 ± 2.8 versus 3.2 ± 1.8 x 10^6/ml bone marrow, P = 0.008). In contrast, only 42% of B (CD19+) cells present in OA were present in RA bone marrow (2.0 ± 0.9 versus 0.85 ± 0.3 cells x 10^6/ml bone marrow, P = 0.02). Interestingly, both CD3+CD4+ and CD3+CD8+ cells obtained from RA patients expressed a significantly higher level of CD45RO (P = 0.002 and P = 0.001, respectively), measured as the mean fluorescence intensity, than in OA. In addition, there was a tendency (although not statistically significant, P = 0.08) for a higher percentage of CD3+CD8+CD45RO+ cells in bone marrow from RA patients in comparison with OA patients (38.7% versus 28.1%). Interestingly, lymphocytes isolated from RA patients expressed a significantly higher level of surface IL-15R alpha chain (P = 0.01), indicating their activation status. Cells isolated from RA bone marrow bound significantly more Ki-67 than cells isolated from OA bone marrow, indicating that RA cells proliferated more vigorously. There were elevated levels of IL-15 in bone marrow plasma from RA in comparison with OA patients (1304.5 ± 956.3 pg/ml and 760 ± 238.7 pg/ml, respectively, P = 0.01).

Conclusion Lymphocytes obtained from RA patients expressed higher levels of IL-15R when compared to those lymphocytes obtained from OA patients. It is likely that locally overproduced IL-15 is responsible for the elevated number of T cells in RA bone marrow. Higher density of CD45RO memory marker expressed on T cells from RA patients further supports the role of IL-15 as a known growth factor for memory T cells. A significantly lower B-cell number in RA than in OA suggests that these cells actively emigrate from RA bone marrow to peripheral blood and affected joints. Distinct subpopulations of mature lymphocytes present in bone marrow from RA and OA patients indicate that the bone marrow acts as a secondary lymphoid organ that actively contributes to the pathogenesis of RA.

P65 Signaling pathways involved in TRAIL-induced rheumatoid arthritis synovial fibroblast proliferation J Morel1,2, R Audo2, B Combe1,2

1CHU Lapeyronie, Montpellier, France; 2INSERM U454, Montpellier, France Arthritis Res Ther 2005, 7(Suppl 1):P65 (DOI 10.1186/ar1586) Tumor necrosis factor alpha-related apoptosis inducing ligand (TRAIL) is a proapoptotic factor that can also induce cell proliferation. The role of TRAIL in rheumatoid arthritis (RA) is still unclear. Previously, we reported that TRAIL induces RA fibroblast-like synoviocytes (FLS) proliferation. We now investigate the intracellular mechanisms involved in TRAIL-induced cell proliferation. Therefore, we tested the effect of TRAIL on signaling pathways including MAP kinases (p38 and ERK1/2) and PI3 kinase/Akt, known to control cell proliferation. For all these experiments, the concentration of TRAIL used to stimulate cells was 0.5 nM. TRAIL induced p38 MAP kinase but with a lower intensity in comparison with tumor necrosis factor alpha (TNF-α) (n = 3). TRAIL also induced ERK1/2 and Akt phosphorylation in RA FLS in a time-dependent manner, showing maximum activation between 5 and 10 min by western blot (n = 3). This kinetic and intensity of ERK and Akt activation were similar to positive control TNF-α (n = 3). The transcription factor NF-κB plays a major role in cell survival and is activated by MAP kinases and Akt. When NF-κB is activated, it translocates from the cytoplasm to the nucleus. We examined NF-κB translocation into the nucleus of RA FLS following TRAIL stimulation using immunofluorescence. RA FLS treated with TRAIL did not induce a nuclear uptake of NF-κB (n = 3). The percentages of RA FLS positive NF-κB translocation was increased from 43.7 ± 0.9% to 89.2 ± 2.3% when stimulated with TRAIL. For the positive control IL-1β, this percentage increased to 97.9 ± 1.1%. This result was confirmed by western blot. To determine the implication of MAP kinases, NF-κB, and Akt in TRAIL-induced proliferation, we therefore tested different specific signaling inhibitors including PI3 kinase inhibitor LY294002, ERK1/2 inhibitor PD98059, and p38 inhibitor SB203580. RA FLS cultured with the specific inhibitors at different concentrations showed that MeSO vehicle control for 1 hour and were then stimulated with TRAIL. Proliferation was assessed according to the level of incorporated tritiated thymidine. ERK1/2 inhibitor PD98059 and p38 inhibitor SB203580 significantly downregulated TRAIL-induced proliferation in a dose-dependent manner (n = 3). PI3 kinase inhibitor LY294002 almost completely blocked proliferation promoted by TRAIL. These results highlight the main role of Akt in TRAIL-mediated proliferation.

P66 Local IL-18 gene transfer prevents severe joint destruction in murine collagen-induced arthritis by induction of IL-4 and osteoprotegerin

LAB Joosten, RL Smeets, Mt Koenders, MMA Helsen, B Oppers-Walgren, FJ van de Loo, E Lubberts, WB van den Berg Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, University Medical Center Nijmegen, The Netherlands Arthritis Res Ther 2005, 7(Suppl 1):P66 (DOI 10.1186/ar1587) Introduction IL-18 is a member of the IL-1 family of proteins that exerts proinflammatory effects and is a pivotal cytokine for the development of T-cell-mediated immune responses. IL-18 can promote both the Th1 and Th2 pathways. Recent studies indicated IL-18 as an important stimulator of chronic inflammation in human diseases such as rheumatoid arthritis, Crohn’s disease and several allergic disorders. Objective To investigate the aggravating effect of local IL-18 overexpression on both joint inflammation and joint destruction in murine collagen-induced arthritis. Methods Collagen-induced arthritis was induced in DBA-1 mice by intradermal injection of 100 μg bovine type II collagen in FCA. At day 21 the mice were boosted with 100 μg type II collagen. IL-18 gene transfer was performed on day 21 by a particular injection of 1 × 10^10 pfu AdIL-18 and 1 × 10^10 pfu Ad5del70.3. Histopathology was examined at days 5 and 12 after AdIL-18 injection. Bone destruction was investigated using X-ray analysis. In addition, both systemic and local cytokine levels were determined in sera and pateilas washouts, using a multiplex bead array (Luminex Technology). Osteoprotegerin levels were examined by ELISA.

Results Here we report that overexpression of IL-18 in knee joints of collagen type II primed DBA-1 mice resulted in aggravation of joint inflammation. Enhanced influx of proinflammatory cells, predominantly polymorphonuclear cells, was seen already at day 5 in both synovial tissue and the joint cavity. At day 12 extensive severe joint inflammation was seen in the AdIL-18 injected knee joint, whereas the Ad5del70.3-injected or saline-injected mice showed modest joint inflammation. Of high interest, although severe joint inflammation developed after IL-18 gene transfer, no signs of joint destruction were noted at day 12 after IL-18 overexpression. Histopathological and X-ray analysis revealed that both cartilage and bone destruction were completely prevented after intra-articular IL-18 exposure during collagen-induced arthritis. In addition, we found that local overexpression of IL-18 resulted in elevated levels for IL-4 in both serum (29 ± 14 versus 4 ± 3 pg/ml) and in synovial tissue washouts (1240 ± 220 versus 24 ± 7 pg/ml) when compared with Ad5del70.3. Remarkably high levels of osteoprotegerin were found in synovial tissue washouts at day 12 after IL-18 gene transfer compared with Ad5del70.3 vector (1570 ± 270 versus 210 ± 20 pg/ml). Local IL-10 levels were strongly enhanced whereas IL-15 levels were significantly reduced after IL-18 gene transfer. Conclusion The present study clearly demonstrated that local IL-18 overexpression accelerates joint inflammation, but prevents development of severe cartilage and bone destruction. High levels of both IL-4 and osteoprotegerin indicate establishment of a non-destructive type 2 inflammation. These data suggest that IL-18 may have a dual role in chronic destructive arthritis and that therapies based on local IL-18 blockade might be inadequate in rheumatoid arthritis.

P67 Gene expression profiling provides a link between high inflammatory synovitis and myofibroblast-like synoviocytes TCG Timmer1, PV Kasperkovitz1, LGM van Baarsen2, P-T Tak3, TWJ Huizinga4, TCTM van der Pouw Kraan1, CL Verweij1

1Department of Molecular Cell Biology and Immunology, VUMC, Amsterdam, The Netherlands; 2Division of Clinical Immunology and Rheumatology, AMC, Amsterdam, The Netherlands; 3Department of Rheumatology, LUMC, Leiden, The Netherlands Arthritis Res Ther 2005, 7(Suppl 1):P67 (DOI 10.1186/ar1588) Objective The molecular pathogenesis of rheumatoid arthritis (RA) is still poorly understood. Given the heterogeneity in gene expression patterns and cellular distribution between RA synovial tissue, we determined whether this variability is also reflected at the level of fibroblast-like synoviocytes (FLS) cultured from those tissues. Methods Gene expression profiles in FLS from 19 RA synovial tissues were analyzed using cDNA microarrays and hierarchical cluster analysis. To validate the subclassification, we performed prediction analysis and principal component
P69
Expression of Toll-like receptor (TLR) 2, TLR3, TLR4 and TLR7 is increased in rheumatoid arthritis synovium and regulates cytokine production by dendritic cells upon stimulation of TLR specific pathways.

MF Roelofs, LAB Joosten, S Abdollahi-Roodsaz, AWT van Lieshout, MF Roelofs, LAB Joosten, S Abdollahi-Roodsaz, AWT van Lieshout, MF Roelofs, LAB Joosten, S Abdollahi-Roodsaz, AWT van Lieshout, MF Roelofs, LAB Joosten, S Abdollahi-Roodsaz, AWT van Lieshout, MF Roelofs, LAB Joosten, S Abdollahi-Roodsaz, AWT van Lieshout, MF Roelofs, LAB Joosten, S Abdollahi-Roodsaz, AWT van Lieshout

Department of Rheumatology, Rheumatology Research and Advanced Therapeutics, University Medical Center Nijmegen, The Netherlands


Background Rheumatoid arthritis (RA) is a chronic autoimmune disease that is activated by 'pathogen associated molecular patterns' via toll-like receptors (TLRs). TLR3 and TLR7 are important in the recognition of viral RNA, whereas TLR2 and TLR4 are involved in the recognition of bacterial components and host-derived molecules, including heat shock proteins, fibronectin, hyaluronic acid. TLR and DC are critical in the regulation of immune responses.

Aim To determine the expression of TLR2, TLR3, TLR4 and TLR7 in synovial biopsies and to evaluate the potential differences in DC maturation and cytokine production upon TLR-mediated triggering of cells from RA patients and healthy controls.
Methods  The presence of TLR2, TLR3, TLR4 and TLR7 in synovial tissue, from RA patients, osteoarthritis patients and healthy controls was studied with immunohistochemistry techniques. Furthermore, monocyte-derived dendritic cells from RA patients and healthy controls were cultured for 6 days and subsequently stimulated via specific TLR pathways; TLR2 (pam3csk4), TLR3 (polyIC), TLR4 (LPS) and TLR7 (R848). We determined the expression of cell surface markers (CD14, CD80, CD83, CD86, MHCI and MHCIi) by flow cytometry and tumour necrosis factor alpha, IL-6, IL-10 and IL-12 production was measured by multiplex cytokine bead arrays.

Results  TLR2, TLR3, TLR4 and TLR7 expression was markedly increased in synovial tissue from RA patients, compared with synovial tissue from osteoarthritis patients and healthy controls. After stimulation via specific TLR pathways, flow cytometry showed a clear DC maturation upon stimulation via all TLR pathways without any difference between RA cells and cells from healthy controls. However, cytokine production by DC from RA and controls was clearly different. RA DC produced increased levels of the proinflammatory cytokines tumour necrosis factor alpha and IL-6 upon stimulation of TLR2 or TLR4. In contrast, such differences were not noted after TLR3 and TLR7 stimulation. Triggering of TLR3 and TLR7 pathways resulted in increased production of IL-12, which was equal between RA and control DC. Intriguingly, simultaneous stimulation of TLR3/4, TLR3/7 and TLR4/7 pathways resulted in a marked synergy with respect to the production of proinflammatory mediators.

Conclusion  These results point out that despite a comparable DC phenotype, RA cells produce higher cytokine levels upon stimulation of TLR2 and TLR4 compared with healthy controls. The combination of specific TLR stimulations resulted in a distinguished synergy in cytokine production. Here, we postulate the hypothesis that the persistence of viral material in synovial tissue triggers the TLR3 and TLR7 pathways, which subsequently results in inflammation and release of endogenous ligands, resulting in TLR4 stimulation that leads to a vicious circle of synovial inflammation.

P71  Post-transcriptional regulation of proinflammatory cytokines in arthritis using gene delivery of AU-rich element binding factors

M Khoury1, P Apparailly1, AR Clark2, P Pience3, D Noel4, C Jorgensen1,2

1INSERM U475, Université Montpellier I, Montpellier, France; 2CHU Lapeyronie, service ImmunoRhumatologie, Montpellier, France; 3Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College London, UK


Background  Monocytes and macrophages are abundant in rheumatoid synovial tissue and play a major role in the pathogenesis of rheumatoid arthritis (RA) by secreting proinflammatory cytokines such as tumour necrosis factor alpha (TNF-α). An innovative approach is based on the regulation of mRNA stability and degradation, which constitute a critical step in the control of gene expression rather than neutralization of the downstream protein. Stability and degradation of TNF-α mRNA are regulated by cis-acting sequences as AU-rich elements (AREs). Tristetraprolin (TTP), a class of Cys-Cys-Cys-His (CCCH) zinc finger proteins, was identified as the critical TNF-α ARE-binding protein. Importantly, TTP knockout mice develop inflammatory arthritis, dermatitis and myeloid hyperplasia, prevented by anti-TNF-α antibodies. A recent study suggested that a low TTP/TNF-α mRNA expression ratio could indicate failure of RA patients to produce adequate amounts of TTP in response to increased TNF-α production. Our aim is to investigate the therapeutic potential of gene expression of ARE-binding elements for anti-TNF-α therapies.

Methods  We used the THP1 human monocyte cell line known for a high lipopolysaccharide (LPS)-induced TNF-α secretion. An expression vector containing TTP gene driven by the CMV promoter was constructed. TTP expression was evaluated by western blot following transfection by electroporation (320 mV). The secretion of TNF-α by THP1 was assessed by ELISA before and after TTP transfection (1 µg/10⁶ cells), following LPS stimulation (50 ng/ml).

Results  A significant decrease in TNF-α expression was observed in the TTP-transfected THP1 cells, compared with a GFP mock control. This suppression increased over time and last at least 48 hours after LPS stimulation (23% at 3 hours and 37% at 24 hours).

Conclusion  These preliminary results support an important role of TTP in regulating TNF-α in monocytes and might be the new target for gene delivery in an anti-TNF-α strategy in RA. In vitro evaluation of this strategy in experimental models of RA will be tested.

P72  Arthroscopic lavage with methylprednisolone is superior compared with either treatment alone in patients with inflammatory arthritis of the knee: a randomized prospective trial

M van Oosterhout1, JK Sont2, I Bajema3, FC Breedveld4, JM van Laar1

1Department of Rheumatology, Leiden University Medical Center, The Netherlands; 2Department of Medical Decision Making, Leiden University Medical Center, The Netherlands; 3Department of Pathology, Leiden University Medical Center, The Netherlands


Background  Patients with recurring or persisting inflammatory arthritis of the knee despite anti-rheumatic therapies are frequently treated with intra-articular steroid injections. Lavage of a rheumatic joint may also be beneficial by removing synovial debris and proinflammatory substances from the joint. Only uncontrolled studies have been performed so far and none of these has studied local synovial features.

Objectives  To compare the therapeutic effect of three local interventions: arthroscopic lavage with steroid application (AL + st), arthroscopic lavage with placebo (AL + pl) and needle biopsy with steroids (NB + st, as a representative of joint injection). To study synovial tissue biopsies for predictive factors for the response to local therapy.

Methods  Arthroscopic lavage with 1 l saline was performed under local anaesthesia using 2 troCHANTERS. At the end of the procedure 80 mg methylprednisolone or placebo was instilled. Needle biopsy was performed under local anaesthesia with 1 trochanter and instillation of 80 mg methylprednisolone. In all patients synovial tissue specimens were obtained and histologically analyzed. Kaplan–Meier curves were constructed depicting the time until recurrence of arthritis. Cumulative incidences of recurrence were used to calculate relative risks (RRs) between treatment groups.

Results  Seventy-eight patients were equally randomized over the three interventions. AL + st was the best therapy with a median time until recurrence of 0.58 years, followed by NB + st (0.23 years) and AL + pl (0.08 years) (Fig. 1) The RR for recurrence compared with AL + st was 2.0 for NB + st (P = 0.03) and 4.7 for AL + pl (P < 0.001). Synovial tissue analysis showed a relation between infiltrating lymphocytes and outcome of AL + st; RR = 2.7 (P = 0.01) in patients with less infiltrating lymphocytes. The opposite was found for fibrosis; RR = 2.9 (P = 0.03) in patients with more fibrosis.

Conclusion  Joint lavage preceding steroid injection had a marked effect on time until recurrence when compared with joint lavage or steroid injection alone. The clinical effect was correlated with the presence of a lymphocytic infiltrate and the absence of fibrosis.

P73  Phenotypic, genotypic and functional characterization of mesenchymal stem cells from synovial membrane compared with bone marrow

F Djouadi1, D Noël2, G Usz2, T Haïli3, P Pience4, C Bomy4, F Apparailly1, C Jorgensen1,2

1INSERM U475, Montpellier, France; 2CNRS UMR 5124, University of Montpellier II, Montpellier, France; 3Charité Hospital, Berlin, Germany; 4Department of Immunology, Lapeyronie Hospital, Montpellier, France


Objective  Mesenchymal stem cells (MSC) are progenitor cells of mesodermal lineages that are present in different tissues such as the fat pads and the bone.
marrow (BM) but also in the cartilage and the synovial membrane (SM). The aim of this study was to better characterize BM-derived and SM-derived MSC and discriminate between the two tissue sources.

Methods BM-MSC and SM-MSC were compared for the expression of cell surface marker inducers and markers of HSC class I and class II molecules by interferon (IFN)-γ, IFN-γ, and IFN-γ. Functional characterization was assessed through their differentiation potential towards chondrocytes and osteoblasts using quantitative RT-PCR, and their immunosuppressive properties by mixed lymphocyte reaction and indoleamine 2,3-dioxygenase activity. Using macroarray technology, the expression of 28 genes was monitored in four samples from BM-derived and SM-derived MSC.

Results BM-derived and SM-derived MSC were shown to express CD44, CD73, and CD90 and CD105 in the same range and to respond to IFN stimulation. We showed that IFN-γ, IFN-α/β, and IFN-α are able to stimulate the expression of HSC markers, suggesting that both BM-MSC and SM-MSC are stem cells. Nevertheless, the macroarray analysis shows a statistically significant discrimination between SM-derived and BM-derived MSC, in particular inflammatory cytokines as IL6 and IL18B and upregulated in synovocytes compared with BM-MSC. Validation in terms of expression of specific proteins is being undertaken.

Conclusion Altogether, the data indicate that BM-MSC and SM-MSC shared multiple phenotypic and functional properties. However, the genomic signature permits one to discriminate the MSC originating from the two different tissues.

P74 Proinflammatory role for AT1 receptors in the rat synovium

AG Price, IC Lockhart, JS McLean, WR Ferrell

Departments of Biological Sciences, University of Paisley, UK; Centre for Rheumatic Diseases, Royal Inflammatory, Glasgow, UK


The increasing recognition that angiotensin II (Ang II) has proinflammatory roles suggests that it could contribute to chronic inflammatory conditions, such as rheumatoid arthritis (RA), but this requires investigation. Walsh and colleagues demonstrated the presence and upregulation of AT1 receptors [1] and angiotensin-converting enzyme [2] in the synovium of RA patients. The aim of this study was to determine the role of Ang II in rat knee joint pathophysiology and to investigate the anti-inflammatory potential of AT1 receptor antagonist losartan in models of arthritis. The second phase of this study was to determine the mechanism of any proinflammatory action of losartan. In vivo losartan has been reported to undergo hepatic first-pass metabolism [3], yielding two metabolites, EXP-3174 (β-hydroxy EXP-3179). The latter is structurally similar to the non-selective cyclooxygenase inhibitor indomethacin. Since the anti-inflammatory potential of cyclooxygenase inhibitors is well documented, we aimed to determine whether any anti-inflammatory benefit associated with losartan was attributable to AT1 receptor antagonism or inflammatory action on the prostanooid system.

In vitro experimental arthritis was induced under anaesthesia (halothane/O2/N2O/O) by intra-articular and peri-articular injection of Freund’s complete adjuvant in adult male Wistar rats (350 ± 20 g body weight, mean ± SEM, n = 6). Knee joint swelling was measured using callipers and expressed as the percentage change from pre-induction values. The anti-inflammatory potential of losartan (Merck & Co., USA) was tested both prophylactically and therapeutically. Prophylactically, losartan (15 mg/kg; subcutaneous) was given 1 hour prior to induction of arthritis and every 48 hours thereafter. Therapeutically, 12 days after the induction of arthritis, losartan (15 mg/kg; subcutaneous) was started and continued every 48 hours. The mechanism of action of losartan was investigated using EXP 3174 (Merck & Co.), given prophylactically (15 mg/kg; subcutaneous, maintenance every 48 hours) 1 hour prior to induction of arthritis (Freund’s complete adjuvant).

In vitro experiments US37 human monocytes at a logarithmic phase of growth were harvested and adjusted to 10^6 cells/ml in the presence of 10 nM phorbol 12-myristate 13-acetate for 3 days to differentiate into adherent macrophages. Cells were then quiesced for 24 hours before experiments commenced. Cells were then stimulated with lipopolysaccharide (50 ng/ml) incubated in the presence of medium (control), Ang II (10^−8 mol) or losartan (10^−7 mol to 10^−4 mol). Supernatants were collected and tumour necrosis factor alpha (TNF-α) levels measured by ELISA.

Prophylactic administration of losartan resulted in a significant reduction in knee joint swelling over 14 days (two-way analysis of variance [ANOVA], P < 0.00001; n = 6). The therapeutic losartan treatment reduced established knee swelling compared with vehicle control (two-way ANOVA, P = 0.00001; n = 7). Prophylactic administration of EXP-3174 also resulted in a reduced percentage increase in knee joint diameter, again found to be significant (two-way ANOVA, P < 0.00001; n = 6–9). Losartan inhibited TNF-α production from U937 cells in a dose-dependent manner (cf. LPS-treated cells; n = 5).

The anti-inflammatory benefit of both prophylactic and therapeutic losartan treatment suggests both an important role for Ang II in arthritis, and a novel therapeutic application for AT1 receptor antagonists. This anti-inflammatory action may be due to inhibition of TNF-α release from macrophages.

References


Acknowledgements This study was funded by University of Paisley Research Funds and Merck & Co, USA.
P76 Sustained downregulation of the TCRζ chain defines a transition from antigen mode to inflammation mode during terminal T-cell differentiation

Z Zhang, M Panesar, P Amjadi, A Foey, S Owen, F Dazzi, FM Brennan, AP Cope
The Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College London, UK


The molecular events that define early phases of activation and differentiation of effector T cells have been well characterised. Those events regulating terminal differentiation and effector function of chronically activated T cells at sites of inflammation, on the other hand, are less well understood. Using in vitro and in vivo models, we have explored the effects of the chronic inflammatory process on T-cell differentiation by investigating how tumour necrosis factor (TNF) regulates T-cell activation and effector responses. These studies have revealed that TNF-stimulated T cells resemble those derived from inflamed synovial joints since they express cell surface activation antigens, but are profoundly hyporesponsive to TCR engagement. Studies with mouse T cells suggest that this may be explained, at least in part, by the fact that TNF selectively targets the expression of the TCRζ chain. Loss of TCRζ expression perturbs the assembly, expression and stability of the TCR/CD3 complex leading to attenuation of membrane proximal tyrosine phosphorylation, intracellular calcium mobilisation and the transcription of cytokine genes upon TCR engagement, when compared with untreated T cells.

We have begun to investigate whether TCRζ expression could be used as a ‘biomarker’ of T-cell activation. Hyporesponsive T cells in human peripheral blood. Using a FACS-based assay, we have identified subsets of CD3+ T cells expressing low levels of TCRζ (hereafter termed TCRζdim) cells) in the peripheral blood of healthy donors, as well as patients with inflammatory arthritis. In vitro studies of peripheral blood lymphocytes from healthy donors define not only antigen-dependent downmodulation of TCRζ expression, which is transient, but also more sustained downregulation, which may arise through antigen-independ-ent mechanisms. Experiments reveal that, when compared with TCRζhigh cells, the TCRζdim population is enriched for cells expressing effector memory cell surface markers. While TCRζdim cells are hyporesponsive to TCR engagement, they retain effector potential, since a significant proportion are capable of produc-ing TNF-α and interferon gamma upon stimulation with phorbol ester and calcium ionophore. In contrast, the TCRζhigh subset is enriched for IL-10 producers. Furthermore, TCRζdim T cells are capable of activating monocytes through cell contact-dependent mechanisms. Together these data suggested that TCRζdim T cells may represent a subset of circulating effector memory cells in vivo.

Finally, we observed that TCRζdim T cells are enriched in inflamed joints of patients with inflammatory synovitis. Treatment of rheumatoid arthritis patients with anti-TNF (infliximab, 3 mg/kg) leads to significant accumulation of TCRζdim T cells in peripheral blood of a subset of patients. Indeed, the extent of accumulation at 14 weeks after starting treatment predicts the DAS28 clinical response at 30 weeks. We propose that sustained downregulation of the TCRζ chain defines a checkpoint where intracellular signals driving T-cell differentiation and effector responses switch from antigen mode to inflammation mode, where effector function may be largely antigen independent. As such this cell subset may represent a valid therapeutic cellular target.

Acknowledgments This work was funded by the Wellcome Trust and the Arthritis Research Campaign UK.

P77 Rheumatoid synovial fibroblasts activate endothelial cells and promote neutrophil recruitment in a flow based multicellular model of the rheumatoid pannus

E Smith1, F Lally1, F J Shaw1, GB Nash1, CD Buckley2, GE Rainger1
1Department of Physiology, The Medical School, University of Birmingham, UK; 2Department of Rheumatology, The Medical School, University of Birmingham, UK; 3Respiratory and Inflammation Research, AstaZeneca, Alderley Park, UK


In rheumatoid arthritis, leukocytes are recruited from the blood by vascular endothelial cells (EC) and accumulate in stromal tissue forming ectopic leukocyte aggregates that contribute to soft tissue remodelling and bone destruction. The signals that regulate the process of chronic leukocyte recruitment into the diseased joint are poorly defined; however, it is probable that cells of the tissue stroma that have undergone a disease-specific transition in phenotype contribute to inflammation by the inappropriate production of proinflammatory cytokines and chemokines [1,2]. Here we have used a novel co-culture model [3] to monitor the role of stromal cells in regulating the quality and quantity of leukocytes that enter the synovium. We tested the hypothesis that fibroblasts from the rheumatoid joint, but not fibroblasts from normal tissue (skin), have the ability to drive inflammation by activating EC and promoting the recruitment of neutrophils. EC were established in co-cultured with fibroblasts from the synovium (SF) or skin (SK) of RA patients on the opposite sides of porous transwell membranes. After 24 hours of EC conditioning, co-cultures were incorporated into a parallel plate leukocyte adhesion assay and the ability of EC to recruit flowing neutrophils determined. Neutrophils adhered efficiently to EC co-cultured with 5 × 106 SK (88.4 ± 12/mm1106 cells perfused) but not to EC cocultured with SF (12 ± 9/mm1106 cells perfused). Anti-P-selectin and anti-E-selectin antibodies markedly decreased neutrophil adhesion, and an anti-CD18 antibody (the β2 integrin) abolished neutrophil recruitment. The antibody blockade of the neutrophil chemokine receptor CXCR2 but not CXCR1 also abolished neutrophil recruit-ment. Supernatants collected from cocultures of EC/SF, but not from SF alone, activated EC to support neutrophil adhesion, indicating the presence of a soluble activating factor(s) generated exclusively in co-culture. EC/SF co-culture supernatants also contained a high concentration of IL-6 (2925.2 ± 521.2 pg/ml), and both IL-6 levels and neutrophil adhesion were reduced in a dose-dependent manner by the inclusion of hydrocortisone in the co-culture medium. An anti-IL-6 antibody also abolished neutrophil adhesion.

We propose that in the rheumatoid synovium, a previously unsuspected process of cross-talk involving IL-6 signalling occurs between synovial fibroblasts and vascular EC resulting in the upregulation of adhesion molecules and chemokines that support neutrophil recruitment. The observation that neutrophil adhesion in this coculture system can be inhibited by anti-IL-6 neutralising antibodies or hydrocortisone suggests that this novel in vitro model of the synovium faithfully mimics important in vivo processes involved in leukocyte accumulation within the syn-ovium. It also suggests that this new model can act as a useful screen for new anti-inflammatory therapies in rheumatoid arthritis.

References

P78 Impaired early B-cell tolerance in patients with rheumatoid arthritis

J Samuels1, Y-S Ng1, D Paget1, E Meffre1,2
1Laboratory of Biochemistry and Molecular Immunology, Hospital for Special Surgery, New York, New York, USA; 2Weill Medical College of Cornell University, New York, USA


Purpose Autoantibody production is a characteristic of most autoimmune dis-eases including rheumatoid arthritis (RA), but the stage of B-cell development at which B-cell tolerance is broken remains unknown. We previously established in healthy donors that most autoreactive developing B cells were removed either in the bone marrow or in the periphery, revealing two B-cell tolerance checkpoints. We aimed to determine whether the autoreactive B cells in RA evade one or both of these checkpoints. In addition, analysis of the antibody repertoire in RA might lead to potential insights about the mechanisms that may explain loss of B-cell tolerance.

Methods We obtained peripheral blood from four patients with clinically and soro-logically documented active RA, who had not yet received steroids, disease-modifying anti-rheumatic drugs or biologic therapy, or who had been off such regimens for at least 4 months. After isolating their peripheral B cells, we sorted, cloned and expressed in vitro antibodies from single new emigrant (CD19+CD10-IgM+IgC-D27+) and mature naive (CD19+CD10-IgM-IgC-D27+) B cells. In total, we examined by ELISA the specificity of 232 recombinant antibodies.

Results The antibody sequences in two of the patients showed a significant increase in the proportion of 11 amino-acid long CDR3s in Igk chains (previously described in RA synovium and blood), while the other two patients demonstrated an increase in Jk1 usage along with a shift towards more downstream Vk segments. This skewed Igk repertoire suggests that receptor editing, one of the mechanisms that ensures B-cell tolerance, is defective in those two patients. Despite the different antibody sequence patterns of our RA patients, all four patients showed significantly increased proportions of polyreactive antibodies in the new emigrant compartment (CD19+CD10-IgM+IgC-D27+) and mature naive (CD19+CD10-IgM-IgC-D27+) B cells. In total, we examined by ELISA the specificity of 232 recombinant antibodies.

References
Conclusions RA patients exhibit defective central and peripheral B-cell tolerance, which may favor the development of autoimmunity. We have also identified two distinct groups of RA patients based on their antibody sequences that suggest divergent mechanisms within the RA population — yet lead to a common phenotype.

P79 Characterization of the IL-12 family of cytokines in human dendritic cells infected with live Chlamydia trachomatis MK Matsyak, JSH Gaston University of Cambridge Clinical School, Department of Medicine, Addenbrooke’s Hospital, Cambridge, UK Arthritis Res Ther 2005, 7(Suppl 1):P79 (DOI 10.1186/ar1600)

Introduction Chlamydia trachomatis (CT) is a clinically important pathogen. In γ levels were not affected. CII-γ T cells [1,2]. Infected γ+2004, the effect inducing a decrease in the RANKL/OPG ratio was present in all biopsies with a characteristic pattern restricted to CD4+ cells from lymph node (LN) response was monitored by immunizing mice with 75 µg CII in adjuvant in hind paws. Some mice were administered 4 µg α-GalCer in the CII/adjuvant mixture at the same time. Nine days after immunization, CD4+ cells were purified from LN and cultured with CII and antigen-presenting cells. Proliferation was measured after 3 days by measuring BrDU incorporation, and IL-10 and IFN-γ levels were assessed by ELISA in the supernatants.

Results The number of NKT cells among leucocytes in the liver of DBA/1 mice was comparable to what is generally observed in C57Bl/6 and suggest a normal quantitative profile of NKT cells in DBA/1 mice. In contrast, in vivo NKT cell function was altered in DBA/1 mice since stimulation with α-GalCer (4 µg intraperitoneally) led to decreased IL-4 and IFN-γ levels in the serum 2 hours after the injection, as compared with C57Bl/6 mice (693 ± 154 pg/ml versus 1557 ± 137 g/ml IL-4 [P < 0.01] and 2077 ± 378 versus 4005 ± 581 IFN-γ [P < 0.02]). Treatment of CII with α-GalCer at day 0 induced a clear-cut diminution of clinical (ANOVA test, P = 0.001) and histological scores (1.1 ± 0.4 versus 1.85 ± 0.24, P < 0.05) of arthritis, as compared with the control group. Importantly, treatment of mice with an anti-IL-10 receptor abolished the protective effect of α-GalCer. The α-GalCer-induced protection was associated with the ability of CD4+ cells from CII-immunized and α-GalCer-treated DBA/1 mice to secrete larger amounts of IL-10 upon in vitro restimulation with CII, while IL-4 and IFN-γ levels were not affected. CII-induced proliferation was slightly reduced in LN CD4 cells from CII-immunized and α-GalCer-treated DBA/1 mice as compared with controls.

Conclusion These findings raise the possibility that NKT stimulation might induce a shift toward an anti-inflammatory Th2 status and could be used therapeutically to treat chronic autoimmune arthritis.

P81 Distinct patterns of RANKL/osteoprotegerin system modulation through anti-tumour necrosis factor and corticosteroid therapy in rheumatoid arthritis synovium Al Catrina1, D Makrygiannakis, E Af Klint1, SB Catrina, S Ernstam2, L Klareskog3, AK Ulfgren1

1Department of Rheumatology, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden; 2Department of Molecular Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden; 3Department of Rheumatology, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden Arthritis Res Ther 2005, 7(Suppl 1):P81 (DOI 10.1186/ar1602)

Background Anti-tumour necrosis factor (TNF) therapy with both etanercept and infliximab decreases radiographic progression of patients with rheumatoid arthritis (RA), while the effect of local corticosteroid injections, a routine adjuvant therapy in arthritis, on bone metabolism is still debated. Thus, we investigated the effect of both anti-TNF and local corticosteroid therapy on synovial expression of osteoprotegerin (OPG) and receptor activator of NF-κB ligand (RANKL). Methods OPG and RANKL were evaluated by immunohistochemistry in serial synovial biopsies obtained from 18 RA patients before and after 8 weeks of treatment with etanercept (nine patients) or infliximab (nine patients). Eighteen additional patients with arthritis that received a local corticosteroid injection were evaluated before and after 2 weeks of the injection. Biopsies were evaluated by double-blind semi-quantitative analysis and image analysis. The in vitro effect of TNF antagonists and corticosteroids (dexamethasone) on RANKL/OPG expression in osteoblasts was evaluated by western blot. Statistical analysis was performed using the Wilcoxon’s signed-rank test followed by Bonferroni correction.

Results OPG was present in all biopsies with a characteristic pattern restricted mainly to the endothelial cells and few mononuclear cells. RANKL was present mainly in the T-cell area and to a lesser extent on some endothelial cells, but absent in other mononuclear cells. Treatment with both infliximab and etanercept induced a synovial OPG expression. Neither infliximab nor etanercept induced RANKL expression following 8 weeks of treatment. The RANKL/OPG ratio decreased following therapy in both groups, the effect being more pronounced in the responders as compared with non-responders to therapy. Local corticosteroid treatment resulted in a similar change of the RANKL/OPG ratio through a different mechanism, with a significant decrease of the synovial RANKL and no changes in the OPG expression. In vitro both TNF antagonists and corticosteroids mimicked the in vivo effect inducing a decrease in the RANKL/OPG ratio in TNF-treated osteoblasts.
Therapy with both TNF antagonists and local corticosteroids modu-
lates the RANKL/OPG system, inhibiting bone destruction through distinct mechan-
isms. Thus, association of these two therapies may be beneficial in preventing bone erosions in RA.

P82

IL-1-driven cartilage and bone destruction are dependent on Toll-like receptors (TLR) 4, but not TLR2

S Abdollahi-Roei5, 6, ABJ Labo Joosten, M Mm Roefs, MMA Helsen,
B Oppers-Walgreen, CHM Arndtz, TRDJ Radstake, WB van den Berg
Rheumatology Research Laboratory and Advanced Therapeutics, University Medical Center Nijmegen, The Netherlands


Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by systemic, chronic joint inflammation. In spite of great efforts, the etiology of RA has not been completely elucidated to date. Toll-like receptors (TLRs) belong to the family of pattern recognition receptors and are involved in both innate and adaptive immune responses against microorganisms via recognition of pathogen-associated molecular patterns. In addition, TLRs have been reported to recognize several endogenous ligands, which are generated under stress conditions and cartilage damage. Triggering of TLRs results in the release of various proinflammatory cytokines such as IL-1. Tumor necrosis factor receptor alpha (IL-1) is one of the crucial cytokines in the pathogenesis of RA and is involved in Th1-mediated processes and cartilage and bone destruction. Therefore, TLRs may potentially be involved in either initiation or chronicity of arthritis.

Objective: To study the contribution of TLR2 and TLR4 in IL-1 driven joint inflammation, cartilage destruction and bone erosion.

Methods: C57BL/6 wild-type (WT), BL/6 TLR2 knockout (KO), C57BL/10 WT and BL/10 TLR4 KO mice were intra-articularly injected with 3 x 10^6 PFU mouse IL-1α adenoviral vector (AdmIL-1α) or control vector (Ad5del70-3). Inflammatory cell infiltration, cartilage proteoglycan (PG) depletion and cartilage and bone destruction were microscopically examined 7 days after virus injection.

Results: Prolonged expression of IL-1α in mice joints induced a severe arthritis in WT animals, exhibiting pathophysiologic changes resembling those in human RA. High amounts of inflammatory cells, predominantly polymorphonu-
clear cells, were present in the knee joint cavities of both WT and KO mice. Severe PG depletion, cartilage destruction and bone erosion were observed in WT mice, which did not differ from those in TLR2-deficient mice. Interestingly, in TLR4-deficient mice, cartilage PG depletion and destruction were significantly reduced. TLR4 KO mice showed also a marked reduction in bone erosion com-
pared with WT mice, although this reduction was not significant.

Conclusion: These data strongly suggest that TLR4 is involved in IL-1α-driven pathologic processes. Both cartilage and bone destruction were reduced in TLR4 KO mice, although joint inflammation was comparable with WT mice. This indicates the involvement of potential TLR4 ligands, generated by IL-1α-induced cartilage degradation, in chronic RA. Our data point out that TLR4 may be a novel therapeutic target in the treatment of RA.

Acknowledgements: Supported by the Dutch Arthritis Association. AdmIL-1β virus was a kind gift from Dr Carl D Richards from the Department of Pathology and Molecular Medicine, McMaster University, Ontario, Canada.

P83

Differential expression of multidrug resistance-related proteins on monocyte-derived macrophages from rheumatoid arthritis patients

R Oerlemans1, BAC Dijkmans1, J van der Heijden1, WF Lems1, A Reurs2, GL Scheffer2, RJ Schepers3, LA Aarden4, BAC Dijkmans1, G Jansen1

1Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands; 2Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands; 3Department of Immunopathology, Sanquin-Research, Amsterdam, The Netherlands


Background: Primary or acquired drug resistance is well recognized as a common cause of treatment failure of patients with cancer. From a rheumatoid arthritis (RA) treatment point of view, the issue of resistance to anti-rheumatic drugs (e.g disease-modifying anti-rheumatic drugs [DMARDs]) has not received much attention. A possible mechanism of drug resistance is overexpression of multidrug resistance (MDR)-related proteins. The objective of this study was to identify whether various MDR proteins are expressed on macrophages as potential target cells for DMARDs.

Methods: Monocyte-derived macrophages (MDM) were obtained from 15 RA patients (median age: 56 years, 13 females/two males) and eight healthy controls (median age: 51 years, four females/four males). Monocytes were isolated from peripheral blood mononuclear cells and differentiated into macrophages in the presence of macrophage-colony stimulating factor. Cytospins of MDMs were prepared for immunohistological analysis of the MDR-related proteins: P-glycoprotein, multidrug resistance associated protein (MRP) 1, MRP4, MRP5, breast cancer resistance protein (BCRP) and lung resistance protein (LRP). Staining intensities were scored as follows: (0), negative; (1), weakly positive; (2), positive; (3), strongly positive. The total score is depicted as the summation of percentiles of cells with intensities 0–3.

Results: MDMs of healthy controls and of RA patients stained strongly positive for macrophage markers CD68 and SA5. Except for MRP4, MDR protein expression was observed both in MDMs of healthy controls and RA patients. Results are shown as the median score with ranges (in parentheses) for MDR expression and a statistical evaluation (Mann–Whitney U test) for differential expression (Table 1).

Table 1

Multidrug resistance (MDR) protein expression in monocyte-derived macrophages from rheumatoid arthritis patients and healthy controls as median scores (ranges)

<table>
<thead>
<tr>
<th>MDR protein</th>
<th>Rheumatoid arthritis patients (n = 15)</th>
<th>Controls (n = 8)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCRP</td>
<td>1.04 (0.51–2.27)</td>
<td>0.63 (0.44–1.45)</td>
<td>0.043</td>
</tr>
<tr>
<td>LRP</td>
<td>0.87 (0.2–4.9)</td>
<td>0.64 (1.0–1.35)</td>
<td>0.876</td>
</tr>
<tr>
<td>MRP1</td>
<td>0.36 (0–1.03)</td>
<td>0.25 (0.09–1.01)</td>
<td>0.309</td>
</tr>
<tr>
<td>MRP5</td>
<td>0.31 (0–1.04)</td>
<td>0.12 (0.05–0.78)</td>
<td>0.238</td>
</tr>
<tr>
<td>P-glycoprotein</td>
<td>0.24 (0–1.05)</td>
<td>0.1 (0.05–1.06)</td>
<td>0.813</td>
</tr>
<tr>
<td>MRP4</td>
<td>&lt;0.05</td>
<td>&lt;0.05</td>
<td></td>
</tr>
</tbody>
</table>

Conclusions: MDR proteins, known to be involved in conferring drug resistance, are expressed on macrophages of RA patients. Beyond this, there seems to be a trend for a higher expression of MDR proteins on MDM from RA patients compared with healthy controls. Further studies are warranted to assess whether MDR is a clinically relevant issue in daily treatment of RA patients.

Acknowledgement: This study is supported by the Dutch Arthritis Association (Grant NRV-0341).

P84

Inhibition of tumour necrosis factor alpha production by activated T cells of rheumatoid arthritis patients by novel anti-folate drugs: an ex vivo pilot study

JW van der Heijden1, AH Gerards2, R Oerlemans1, WF Lems1, RJ Schepers3, LA Aarden4, BAC Dijkmans1, G Jansen1

1Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands; 2Wetland Hospital, Schiedam, The Netherlands; 3Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands; 4Department of Immunopathology, Sanquin-Research, Amsterdam, The Netherlands


Introduction: The folate antagonist methotrexate (MTX) is the ‘anchor-drug’ in the treatment of patients with rheumatoid arthritis (RA) [1]. The main target of MTX in intracellular folate metabolism is dihydrofolate reductase (DHFR) but several other targets have been described (e.g. thymidylate synthase (TS) and 5-aminopyrimidine-4-carboxamide ribonucleotide (AICAR)). At present the exact mechanism of action of MTX in RA still remains elusive [1]. Despite the potent anti-rheumatic capacity of MTX many patients (at least 50%) become resistant to MTX during long-lasting therapy. However, little is known about the mechanisms of resistance against MTX in RA patients [2]. From the field of oncology, where MTX is used against haematological malignancies, new anti-folate drugs were developed to circumvent MTX resistance [3]. These new folate antagonists have the following characteristics: are better transported through the reduced folate carrier, are retained intracellular more effi-
ciently by polyglutamation via polyglutamate synthetase, and/or have other targets in the folate pathway besides DHFR (e.g. TS).

Objective: To investigate whether two new-generation anti-folate drugs, PT523 (DHFR-inhibitor) and ZD1694 (TS-inhibitor), have equal or better anti-inflammatory activity compared with MTX based on their capacity to inhibit tumour necrosis factor alpha (TNF-α) production by activated T cells.

Methods: Whole blood from 11 RA patients and six healthy volunteers was incu-
bated ex vivo with MTX, PT523, ZD1694 and, as a control, the DMDAR sul-
phazaline (SSZ) after T-cell stimulation with α-CD3/CD28. Inhibition of TNF-α production was measured after 72 hours by ELISA [4].

The IC-50 values (defined as the drug concentration exerting 50% inhibition of TNF-α production) are used as a value for the anti-inflammatory capacity of the drug (Table 1).
Inhibition
In an α2004, 2001, = 11) (http://arthritis-research.com/supplements/7/S1
Blood 1999, This is the first study to show the expression of IL-1RI and IL-1RII in
setting, two novel anti-folate drugs designed to circum-
In chronic inflammatory diseases, IL-1 is known as an important
κ
Muscle biopsies from eight patients with polymyositis, three patients

IE Lundberg 1
C Grundtman
S Salomonsson
J Burton2
U Andersson3
IE Lundberg1
1Department of Rheumatology, Karolinska University Hospital Solna, Karolinska
Institutet, Stockholm, Sweden; 2Department of Woman and Child Health, Karolinska
University Hospital Solna, Karolinska Institutet, Stockholm, Sweden; 3Department of Rheumatology and IL-1
α
and IL-1RII expression were investigated by immunohistochemistry. IL-1RI and IL-1RII
were also investigated by confocal microscopy.

Results In patients with polymyositis and dermatomyositis, IL-1α was found to be
expressed in endothelial cells and inflammatory cells, and significantly increased
in symptomatic when compared with non-symptomatic muscle tissue. IL-1α was
not expressed in muscle tissue of healthy subjects. In patients, IL-1RI and IL-1RII
were strongly expressed in inflammatory cells, endothelial cells, in the membrane
of the muscle fiber, as well as in the nucleus of the muscle fiber of patients,
whereas in muscle tissue of healthy subjects only a scattered pattern of IL-1RI and
IL-1RII expression in a few endothelial cells and in a few of nuclei of the muscle
fiber could be observed. The membrane and nuclear expression were
confirmed by double stainings.

Discussion This is the first study to show the expression of IL-1RI and IL-1RII in the
cell nuclei and in the membrane of muscle fibers. Moreover, we have found
some marked differences between symptomatic and non-symptomatic muscle
tissue of patients and healthy subjects indicating a potentially important role of
IL-1 receptors in the pathogenesis of idiopathic inflammatory myopathies.

P86
Interleukin-1 receptor antagonist lentiviral gene transfer to
the murine knee joint ameliorates collagen-induced arthritis
FAJ van de Loo, LM Davelaev, OJ Amtz, MB Bennink, LB Joosten,
WB van den Berg
Rheumatology Research & Advanced Therapeutics, Department of
Rheumatology, University Medical Center Nijmegen, The Netherlands
Introduction The inflamed joints in rheumatoid arthritis patients are ideally suited
for gene therapy applications to acquire local production of potent anti-inflamma-
tory biomolecules. The need for precise and absolute targeting as for treating cancer
is not necessary in rheumatoid arthritis. However, the challenge is to obtain long-
term gene expression. For this purpose we used in this study HIV-based
lentiviruses (LV) for the stable transduction of the murine synovium.
Methods The coding sequence of murine interleukin-1 receptor antagonist
type II was inserted into the 3RLlucoptBgcsN3Rplp vector (cell-
inactivating vector was a gift from D Trono, Geneva, Switzerland) behind the
phosphoglycerate kinase-promoter. Vesticular stomatitis virus G envelope pseudotyped lentiviruses were produced by cotransfection of 293T-cells [1].
Recombinant lentiviruses were purified and titres were determined using the p24 ELISA (Murex HIV Antigen MAB, Abbott). Lentiviruses encoding for firefly
luciferase (Luc) were used for control. The lentiviruses were injected intra-articu-
larly into the murine knee joint. Synovial explants were taken to measure the
culture activity using a lumimeter. Mice immunized against bovine collagen-
type II received an intra-articularly injection of lentiviruses 1 day after the antigen
booster but without any visual signs of collagen-induced arthritis.
Results Naive C57B1/6 mice were injected with 300 ng (p24 value) of LV-Luc
into the knee joint. The Luc activity in the synovial biopsies increased steadily until
day 7 and remained at this level until the end of the experiment (day 21 after injection). Next we injected the same amount of LV-mlL-1Rα and LV-Luc into the
right knee joint of collagen-type II immunized mice just before onset of arthritis. At
day 31 after immunization all mice in the LV-IL-1Rα and LV-Luc-treated groups
developed clinical signs of severe arthritis in the paws. However, macroscopic
examination of the injected knees showed a significant reduction in joint inflam-
amation in all mice of the LV-mlL-1Rα group (arbitrary score [0–3] 0.55 ± 0.37) as
compared with the LV-Luc-treated mice (score 1.55 ± 0.53). Microscopic evalua-
tion confirmed the marked reduction in joint inflammation. Furthermore, the joint
that received LV-mlL-1Rα showed a marked reduction in bone destruction whereas
the extent of cartilage destruction was comparable with the LV-Luc-
treated knees during collagen-induced arthritis.
Conclusion We show for the first time that lentiviral-mediated local overexpres-
sion of IL-1Rα had a pronounced effect on the development of collagen-induced
arthritis in that particular knee joint. No protective effect was observed on the ipsi-
lateral or contralateral paws as we have demonstrated previously for IL-1Ra gene
transfer using adenoviral vectors [2,3]. The lentiviral transduction of the synovium
seems feasible and efficacious for treatment of arthritis.

References
leukin-1 receptor antagonist gene therapy results in efficient inhibition of
Effects of anti-rheumatic treatments on the prostaglandin E\(_2\), biosynthetic pathway in synovial tissue and synovial fluid cells from patients with rheumatoid arthritis


Department of Medicine, Rheumatology Unit, Karolinska Institute/Karolinska University Hospital, Stockholm, Sweden


Background Microsomal prostaglandin E synthase (mPGES-1) is upregulated in experimental arthritis and is markedly expressed in synovial tissue from patients with rheumatoid arthritis (RA), suggesting its important role in the pathogene-
sis of inflammatory arthritis. However, the effects of current anti-rheumatic thera-
pies on mPGES-1 expression have not been examined.

Objective To study the effects of anti-tumour necrosis factor (TNF) alpha blockers and glucocorticoids on prostaglandin (PG) E\(_2\) biosynthesis and mPGES-1 expres-
sion in synovial fluid mononuclear cells (SFMC) and synovial tissue from RA patients.

Methods Synovial tissues were obtained from 18 RA patients before and after treatment with TNF-blockers (infliximab and etanercept) and from 16 patients before and after intra-articular injection of steroids. SFMC were obtained from eight RA patients. In vitro effects of TNF-blockers and dexamethasone (Dex) on mPGES-1 expression in SFMC were examined by flow cytometry. PGE\(_2\) levels in culture supernatants were analyzed by enzyme immunoassay. Immunohisto-
logical analysis and double immunofluorescence were performed using antibody against mPGES-1, cyclooxygenase (COX) and CD163.

Results Treatment of SFMC with TNF-blockers or Dex decreased lipopolysac-
charide-induced mPGES-1 and COX-2 expression in CD14\(^+\) monocytes and PGE\(_2\) synthesis in culture supernatants. Double immunofluorescence revealed that mPGES-1 and COX-2 were co-localized in SFMC and in synovial tissue cells. Local treatment with steroids significantly reduced the mPGES-1, COX-2 and COX-1 expression in synovial tissue. However, neither mPGES-1 nor COX-2 expression in RA synovial tissues were significantly affected by anti-TNF therapy.

Conclusion In vitro, both TNF-blockers and Dex suppressed mPGES-1 in SFMC. In RA synovial tissue, local steroids but not TNF-blockade downregulate mPGES-1. These data provide support to the use of combination of TNF-blockade and glucocorticoids as therapeutic agents in RA.

Identification of a natural soluble form of the IL-18 receptor accessory protein as an immunomodulator in experimental arthritis

RL Smeets, OJ Amtz, MB Bennink, WB van den Berg, FAJ van de Loo

Experimental Rheumatology and Advanced Therapeutics, Department of Rheumatology, University Medical Center Nijmegen, The Netherlands


Background In the inflammatory process preceding erosive arthritis, IL-18 plays an important role. IL-18 is known to regulate immune responses by stimulating Th1 mat-
uration, and signaling is initiated through formation of a trimeric receptor complex, consisting of IL-18 bound to the IL-18R\(_\beta\) and its accessory receptor IL-18R\(_\alpha\).

Objective The aim of this study was to determine the physiological role of a recently described soluble form of the IL-18 receptor accessory protein (sIL-18R\(_\beta\)) in mice.

Methods Mice sIL-18R\(_\beta\) (genebank accession number AK053178) was cloned from murine lung cDNA and used for the generation of an adenoviral vector (Ad.Sl-18R\(_\beta\)). Expression analysis of the sIL-18R\(_\beta\) and its full-length membrane bound IL-18R\(_\beta\) in different murine tissue was achieved through immunofluorescence. To investigate the in vivo mode of action, sIL-18R\(_\beta\) was systemically overexpressed in collagen type II-immunized male DBA/1 mice. Systemic overexpression was achieved through intravenous injection of 3 x 10\(^5\) pfu Ad.Sl-18R\(_\beta\) or the control vector (AdLuc) before clinical manifestation of collagen-induced arthritis (CIA). At 1 and 4 days post adenoviral injection, spleenocytes were harvested and the cytokine profile in plasma and splenocyte culture supernatants was determined.

Results Short IL-18R\(_\beta\) mRNA was highly expressed in tissue of lymphoid origin, and no expression could be observed in immune privileged organs like the testis, the eye and the brain, suggesting a prominent role in immune regulation. Expression of sIL-18R\(_\beta\) was disease regulated in mice suffering from CIA, whereas the full-length IL-18R\(_\beta\) was not regulated. Splenocytes of sIL-18R\(_\beta\)-treated immu-
nized mice produced significantly less interferon gamma and IL-10 compared with control treated animals. Adenoviral overexpression of the sIL-18R\(_\beta\) before clinical manifestation of CIA significantly aggravated arthritis, which was accom-
pained by a reduction of circulating IL-10, interferon gamma and a significant increased anti-bovine collagen II IgG\(_\beta\). Conclusion Our results describe the existence of a novel short soluble form of the membrane IL-18R\(_\beta\), which is mainly expressed in lymphoid tissues. This sIL-
18R\(_\beta\) expression appears regulated during CIA. Furthermore, we show that this novel soluble IL-18R\(_\beta\) functions as a putative modulator of IL-18 signaling, aggra-
vating CIA, by modulating T-cell immunity.

Expression in chronically activated Tc cells

U Niesen\(^1\), I Albrecht\(^2\), R Baumgrass\(^1\), M Janitz\(^2\), L Hesshach\(^2\), T Hauepl\(^2\), J Grun\(^2\), GR Burmester\(^2\), A Gruzdka\(^2\), A Radbruch\(^1\)

\(^1\)German Arthritis Research Centre, Berlin, Germany; \(^2\)Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany; \(^3\)Department of Rheumatology and Clinical Immunology, Charité University Medical Centre, Berlin, Germany; \(^4\)Oligene Inc., Berlin, Germany


Lympocytes are considered to be key players in chronic inflammation. Upon repeated re-stimulation and differential instruction, they can develop a stable mononuclear cell infiltrates and perivascularly. Activation of JNK was recognized in cells of the lining layer, in some sublining cells infiltrates and the endothelium. The com-
posite histological severity score was significantly lower after etanercept treatment (median score 1 versus 1; P < 0.02). Etanercept therapy resulted in a significant decrease in ERK (median normalized fluorescent area 0.096 versus 0.04; P < 0.03) and JNK (median normalized fluorescent area 0.91 versus 0.34; P < 0.03) but not in p38 activation (median normalized fluorescent area 0.04 versus 0.07; P > 0.07).

Conclusion Different MAPKs are activated in psoriatic arthritis synovium. The activation pattern suggests distinct roles for specific MAPKs in synovitis. The activation pattern of p38 and pERK strongly mimics the pattern described in rheumatoid arthritis \[2\]. Activation of JNK in the lining layer of rheumatoid arthritis synovium has not been reported. Etanercept therapy had a significant effect on JNK and ERK but not on p38 activation. These data suggest that other, probably TNF-independent, signals activate p38 in psoriasis arthritic synovium.

References


Hierarchical clustering of differentially expressed genes among doublets of the nine investigated cell populations (w, weeks in culture; res, 3 hours re-stimulated) using Affymetrix Mouse Genome 430A 2.0 Arrays and DNA-Chip Analyzer (dChip).

memory for the expression of distinct genes coding for cytokines, chemokines, adhesion molecules, and so on. This functional memory contributes considerably to the chronicity of inflammation and to the resistance to therapy.

Here, we describe the global gene expression profiles of in vitro repeatedly reactivated murine Th1 and Th2 cells, and compare them with those of naive and once activated Th1 and Th2 cells, both before and after re-stimulation (Fig. 1). Among differentially expressed genes is a novel transcription factor, which downmodulates IL-1 receptor antagonist (IL-1Ra) expression and is secreted in repeated re-stimulation of Th1 cells. High expression of this gene can be detected in Th cells isolated from the site of inflammation of patients suffering from distinct forms of rheumatic diseases or ulcerative colitis, but not in Th cells isolated from healthy tissue or from blood. Expression of this gene is thus a marker for chronic T-cell activation in chronic inflammation and may represent an endogenous mechanism to limit inflammation. Apart from its diagnostic value, this molecular pathway also points to a new therapeutic target.

**P91**  
**Intracellular IL-1 receptor antagonist (icIL-1Ra1) does not antagonize growth inhibitory effects of pre-IL-1α in SaOS-2 cells**

G Palmer, S Trolliet, D Talabot-Ayer, F Mézin, D Magne, C Gabay  
Division of Rheumatology, University Hospital of Geneva and Department of Pathology and Immunology, University of Geneva School of Medicine, Geneva, Switzerland

Results icIL-1Ra1 alone did not affect cell growth. Moreover, co-expression of icIL-1Ra1 did not reverse the growth inhibitory effect of pre-IL-1α. However the induction of IL-6 secretion, a classical, receptor-mediated effect of pre-IL-1α, was inhibited in icIL-1Ra1 co-transfected cells.

Conclusions Expression of pre-IL-1α decreased the growth of SaOS-2 cells. Co-transfection of icIL-1Ra1 did not antagonize this effect. These observations suggest that intracellular effects of pre-IL-1α are not necessarily susceptible to inhibition by icIL-1Ra1.

**P92**  
**Expression of microsomal prostaglandin E synthase-1 in muscle tissue of patients with idiopathic inflammatory myopathies**

M Korotkova, S Barbasso, P-I Jakobsson, I Lundberg  
Rheumatology Unit, Department of Medicine, Karolinska Institutet/Karolinska University Hospital, Stockholm, Sweden


Background Microsomal prostaglandin E synthase (mPGES-1) catalyzes the formation of prostaglandin (PG) E₂ from cyclooxygenase (COX)-derived PGH₂. mPGES-1 is induced by proinflammatory cytokines, such as IL-1β and tumor necrosis factor alpha, and is linked to conditions with high PGE₂ biosynthesis and inflammation. A recent study has demonstrated enhanced COX-1 and COX-2 expressions in affected muscle tissues of patients with polymyositis (PM) and dermatomyositis (DM), suggesting their important role in the pathophysiology of these diseases. However, expression of mPGES-1 in muscle tissue has not been investigated.

Objective To study the expression of mPGES-1 in muscle tissue of patients with idiopathic inflammatory myopathies.

Methods Muscle biopsies were obtained from 13 patients with idiopathic inflammatory myopathies (six PM, four DM, one juvenile DM, two inclusion body myositis) and from six healthy subjects. Immunohistochemical analysis was performed using antibodies against mPGES-1.

Results mPGES-1 staining was detected in all patients with PM, DM and inclusion body myositis. Specifically strong intracellular staining was observed in inflammatory cells in infiltrates, in endothelial cells of capillaries, in scattered mononuclear cells and in fibroblast-like cells. In some patients mPGES-1 staining was localized in smooth muscle cells and endothelial cells of large vessels. In healthy subjects, weak mPGES-1 staining was detected only in scattered fibroblast-like cells, in a few mononuclear cells surrounding large vessels and in some capillaries.

Conclusion These results demonstrate the upregulation of mPGES-1 in muscle tissue of refractory patients with idiopathic inflammatory myopathies compared with healthy controls, suggesting a role of mPGES-1 in the pathophysiology of these diseases.

**P93**  
**Quantifying the contribution of the second HLA-DRB1 susceptibility allele to the risk of rheumatoid arthritis: a meta-analysis**

IA van Rossum¹, AH Zwinderman², PP Tak¹, N de Vries¹  
¹Department of Clinical Immunology & Rheumatology, AMC/University of Amsterdam, The Netherlands; ²Division of Medical Statistics, AMC/University of Amsterdam, The Netherlands


Background HLA-DRB1 alleles encoding the shared epitope (SE) susceptibility sequence predispose to rheumatoid arthritis (RA). Having two copies results in even higher risk. This study analyzes whether the contribution of the second SE allele to RA risk is identical to that of the first SE allele.

Methods In a meta-analysis of 44 datasets of case–control studies meeting predefined criteria, the odds ratios OR₁ and OR₂ are calculated, as an estimate of the relative risk for RA for individuals having one compared with zero, or two compared with one SE allele; from these, the ratio OR₂/₁OR₁/₀ is calculated.

Results Overall the weighted mean ratio OR₂/₁OR₁/₀ (95% confidence interval) was 0.90 (0.80–1.01). In the 39 studies in which all patients met the ACR criteria for RA, the overall ratio OR₂/₁OR₁/₀ was 0.89 (0.78–1.01); see Fig. 1). In a multiple regression analysis on a group level the ratio OR₂/₁OR₁/₀ was not influenced by racial origin, the frequency of compound heterozygosity (0401/0404 or 0401/0408), the percentage of female or rheumatoid factor-positive patients, disease duration or age at disease onset.

Conclusions The contribution of the second SE allele to RA risk does not differ significantly from that of the first SE allele. This result will help to pool immunogenetic data across populations, resulting in a detailed description of the contribution of immunogenetic factors to RA risk.

In addition this finding implies that pathogenetic models for RA that incorporate the role of HLA should explain the fact that the first and the second SE alleles increase RA risk equally. Such effects might, for example, be described for models incorporating presentation of pathogenic antigenic peptides.
Here we report for the first time evidence of high and sustained efficiency of IL-18 and IL-18BPc adenoviral gene transfer to salivary glands of mice treated with high doses of SmD1(83-119) into submandibular glands. This experiment was performed using a trackable compound to demonstrate the efficiency of local SG delivery through retrograde submandibular duct cannulation as well as a murine SG-DEC line transfected with IL-18 and IL-18BPc gene transfer. In addition, we successfully adapted a cannulation technique previously used in bigger animals for in vivo local delivery of modulatory molecules to salivary glands. Local delivery of IL-18/IL-18BPc adenoviral vectors in vivo in salivary glands of NOD mice and other murine models of SS through retrograde submandibular excretory duct cannulation will provide evidence of a possible pathogenic role of IL-18 in participating in autoimmune sialoadenitis and will establish a rationale for using IL-18 blocking agents as therapeutic tools in SS.

**References**


**P95**

**Type 1 regulatory T cells in treatment of murine lupus**

R Undeutsch1, JM Humrich3, BH Hahn3, FHA Liew3, A Radbruch1, G Jormakka2

1Charité University Hospital, Berlin, Germany, 2University of California, Los Angeles, California, USA, 3German Arthritis Research Centre, Berlin, Germany


Systemic lupus erythematosus is a severe systemic autoimmune disease characterized by loss of tolerance towards a restricted panel of autoantigens. As a result, pathogenic autoantibodies against dsDNA or the Sm proteins occur. We identified the SmD1(83-119) peptide, the C-terminus of the spliceosomal protein SmD1, as a major B-cell and T-cell autoantigen in human and murine lupus [1-3]. In previous work we could show that intravenous high-dose application of SmD1(83-119) prolongs survival in NZB/W F1 mice and delays occurrence of anti-dsDNA autoantibodies [4]. Higher percentages of CD4+ T cells that produce IL-10 and interferon gamma were detected on restimulation with phospholipid 12-myristate 13-acetate/sonomyecin later on in the spleen, indicating involvement of type 1 regulatory T cell (Tr1 cell)-mediated tolerance [4]. Transfer of splenic CD90+ T cells from mice treated with high doses of SmD1(83-119) into untreated mice delayed the occurrence of anti-dsDNA autoantibodies in these recipients as well [4].

We now performed a SmD1(83-119) specific analysis of the CD4+ T cells after high-dose application of SmD1(83-119) and detected SmD1(83-119)-reactive CD4+IL-10+ Tr1 cells in the spleen and in draining lymph nodes after additional

**P94**

**Efficient IL-18 and IL-18BPc adenoviral gene transfer to cultured murine submandibular gland epithelial cells and successful murine retrograde submandibular duct cannulation to modulate IL-18 function in the salivary gland of animal models of Sjogren’s syndrome**

M Bombardieri1,2, F Barone1,2, G Proctor3, FA van de Loo4, WB van den Berg5, G Valesini5, IB McInnes1,2, C Pitzalis1

1Rheumatology Department, GKT School of Medicine, KCL, London, UK; 2Rheumatology Unit, University of Rome ‘La Sapienza’, Italy; 3Salivary Research Group, KGT School of Dentistry, KCL, London, UK; 4Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, University Medical Center Nijmegen, The Netherlands; 5Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow University, UK


**Introduction**

We recently demonstrated that the proinflammatory and immune-regulatory cytokine IL-18 is strongly upregulated in salivary glands (SG) of Sjo- gren’s syndrome (SS) patients. IL-18 gain or loss of function experiments in animal models of human diseases have provided evidence of the pathogenic role of this cytokine in chronic inflammation. However, in SS the pathogenic relevance of IL-18 in the development of murine autoimmune sialoadenitis has not as yet been evaluated. Here we describe in vitro experiments in which murine SG epithelial cells were tested for transfection efficiency with IL-18 and IL-18BPc gene transfer. In addition, in preparation for in vivo SG modulation of IL-18 function by AdV-mediated gene transfer, we optimised retrograde SG cannulation in mice.

**Methods**

Primary SG ductal epithelial cells (SG-DEC), established from submandibular glands of C57BL/6 mice using the explant outgrowth technique, as well as a murine SG-DEC line were used for AdV transfection. A mIL-18AdV from same mIL-18BPcAdV construct as previously reported [2]. AdVs encoding for plasmid IL-18 TG3652 [1] was developed in our laboratory while we used the same mIL-18BPcAdV construct as previously reported [2]. AdVs encoding for LacZ or luciferase were used as controls. All AdVs were incubated at 50 MOI. Efficiency of gene transfer was evaluated through detection of IL-18 and IL-18BPc protein expression assessed by both immunostaining and western blot. Beta-galactosidase staining confirmed effective transfection of SG-DEC by LacZAdV.

**Results**

High efficiency of transfection of cultured murine SG-DEC was obtained with both IL-18AdV (Fig. 1) and IL-18BPcAdV (Fig. 2). Western blot confirmed the presence of protein production detectable as single bands from target-geneAdV but not control-geneAdV transfected SG-DEC. A time-course study demonstrated in vitro gene expression up to 3 weeks after transfection. Feasibility of local SG delivery through retrograde submandibular duct cannulation was demonstrated by injection of trackable compounds.

**Conclusion**

Here we report for the first time evidence of high and sustained efficiency of IL-18 and IL-18BPc AdV gene transfer in murine SG-DEC. In addition, we successfully adapted a cannulation technique previously used in bigger animals for in vivo local delivery of modulatory molecules to salivary glands. Local delivery of IL-18/IL-18BPc adenoviral vectors in vivo in salivary glands of NOD mice and other murine models of SS through retrograde submandibular excretory duct cannulation will provide evidence of a possible pathogenic role of IL-18 in participating in autoimmune sialoadenitis and will establish a rationale for using IL-18 blocking agents as therapeutic tools in SS.
immunization with SmD1(83-119). In vitro experiments showed that Tr1-cell-mediated suppression of anti-DNA autoantibody production is dependent on the activity of IL-10 as the addition of neutralizing anti-IL-10 antibodies abrogated this effect. Further in vivo experiments by Callabut et al. showed transfer of SmD1(83-119) reactive Tr1 cells into recipient mice delayed the occurrence of anti-DNA autoantibodies in the recipient mice as well. We conclude that high-dose application of SmD1(83-119) induces SmD1(83-119) specific tolerance in NZB/W F1 mice, which is mediated by SmD1(83-119)-reactive Tr1 cells. These results may open new ways for future autologous specific cell-based therapies in systemic lupus erythematosus.

References

Acknowledgements RU and JH contributed equally to this work.

P96
Hearing improvement in a variant Muckle–Wells syndrome case in response to IL-1 receptor antagonist

M Royne, C Maclean, MF McDermott, P Emery
Academic Unit of Musculoskeletal Disease, Department of Rheumatology, Leeds General Infirmary, Leeds, UK


Background The proinflammatory cytokine IL-1β has been implicated in the pathogenesis of a number of the hereditary periodic fever syndromes. One such syndrome, Muckle–Wells syndrome (MWS), is characterised by the triad of urticaria, progressive sensorineural deafness and systemic amyloid A amyloidosis. Other features include rigors, leucocytosis, raised acute phase reactants and serum amyloid A levels. A number of case reports have recently emerged involving treatment with the recombinant human IL-1 receptor antagonist, Anakinra (Kinerka; Angen, Cambridge, UK) [1–3].

Case report A 59-year-old caucasian female presented with increasingly severe and intractable disease over a 15-year period. In addition to the above features, she also exhibited papilloedema and chronic aseptic meningitis. No other family members were affected. Upon commencing treatment with Anakinra, there was complete resolution of her inflammatory symptoms within 24–48 hours, and rapid normalisation of her C-reactive protein and serum amyloid A levels (from 415.0 mg/l to 12.6 mg/l after 4 weeks of therapy). Her intracranial pressure and CSF white cell counts also returned to normal. Audiometry confirmed a 15–30 decibel improvement in the 250–4000 Hz frequency range in each ear. No mutations of the responsible gene – NALP3/CIAS1 on chromosome 1q44 – were demonstrated on her DNA sequencing.

Discussion Our patient is the oldest reported case of MWS. Heterozygous missense mutations have thus far been reported in only 60% of MWS patients analysed [4]. The confirmed improvements in hearing, intracranial pressure, and CSF white cell counts seen here with Anakinra lend further support to the treatment of the autoimmune inflammatory conditions by targeting IL-1. The pathogenesis of the sensorineural deafness in MWS is unclear although it is postulated that expression of mutated NALP3/CIAS1 in cartilage may have a causative role [5].

References

Acknowledgements The authors gratefully acknowledge the invaluable assistance of Alison Bybee (Royal Free and University College Medical School, London) and Ebun Aganna (Queen Mary’s School of Medicine and Dentistry, London) for their sequencing of our patient’s DNA.

P97
The cytokine memory of SmD1(83-119) autoantigen-specific Th cells of systemic lupus erythematosus patients

S Langereis, D Langnickel, P Enghard, G Burmester, F Hiepe, G Riemekasten
1Department of Rheumatology and Clinical Immunology, Charité University Hospital, Humboldt University of Berlin, Germany; 2German Rheumatism Research Center, Berlin, Germany


Objective The aim of the study was to analyze the cytokine memory of Th cells derived from systemic lupus erythematosus (SLE) patients and healthy donors enriched for autoantigen-specific T cells by in vitro stimulation with SmD1(83-119), a common autoantigen in SLE.

Method Autoantigen-specific CD3+ T cells derived from 37 SLE patients and 14 healthy donors were enriched by repetitive ex vivo stimulation of peripheral blood mononuclear cells with SmD1(83-119). For control, peripheral blood mononuclear cells were stimulated only with IL-2. After two rounds of antigen stimulations, cultures were stimulated with phorbol 12-myristate 13-acetate/ionomycin for intracellular cytokine staining. Frequencies of cytokine expressing T cells were analyzed and, in SLE patients, compared with disease activities and autoantibody levels.

Results Comparing cultures from SLE patients with those from healthy donors, SLE patients displayed higher frequencies of tumor necrosis factor alpha-positive T cells and the frequencies correlated with disease activity. SmD1(83-119)-induced tumor necrosis factor alpha expression was found to be associated with serum anti-DNA antibodies.

The frequencies of IL-10-expressing T cells were lower in cultures from SLE patients. Cultures from patients with high frequencies of IL-10+ T cells revealed low disease activities. SmD1(83-119)-induced increases in IL-10-expressing T cells were associated with low anti-dsDNA and anti-SmD1(83-119) antibody levels in culture supernatants.

Conclusion The enrichment of SmD1(83-119)-reactive T cells by in vitro cultures showed that cytokine changes specifically occur in lupus patients. The results give insight into the cytokine memory of autoreactive Th cells and their role in lupus pathogenesis.

P98
PTPN22 as a rheumatoid arthritis susceptibility but not severity gene

J Wesoły, VEH Cartlon, A Chokkalingam, AHM van der Helm-Van Mil, REM Toes, AB Begovic, TWJ Huizinga
1Department of Rheumatology, Leiden University Medical Center, The Netherlands; 2Celera Diagnostics, Alameda, California, USA


Background Due to the complex multigenic nature of rheumatoid arthritis (RA) identification of RA susceptibility and severity genes appears to be more challenging than originally anticipated. Among many recently reported RA susceptibility genes, a missense single nucleotide polymorphism in the protein tyrosine phosphatase, non-receptor type 22 (PTPN22) appears to be involved in susceptibility to multiple autoimmune diseases including diabetes, systemic lupus erythematosus and Graves disease. Whether this polymorphism is also associated with severity of the phenotype in diseased individuals is not known. PTPN22 encodes a hematopoietic phosphatase also known as Lyp that functions as a negative regulator of T-cell activation via interaction with the c-Src tyrosine kinase Csk and phosphorylation of regulatory tyrosines or other Src family kinases, such as Lck and Zap70. The R620W polymorphism results in substitution of conserved arginine with tryptophan in the proximal SHH-3 binding domain of PTPN22, which is necessary for interaction with Csk. In vitro experiments show that the W620 variant of PTPN22 is less efficiently to Csk, suggesting T cells expressing this allele may be hyper-responsive and more prone to autoimmunity.

Objective To investigate the association of R620W polymorphism with RA in a Dutch Caucasian population and to determine whether this polymorphism associates with a qualitative phenotype of RA (remission versus progression) or a quantitative phenotype (rate of joint damage).

Methods PTPN22 genotyping was performed on DNA from 425 RA and 343 undifferentiated arthritis patients participating in the Leiden Early Arthritis Clinic and over 200 control individuals, both of Dutch Caucasian origin. Samples were genotyped using allele-specific kinetic PCR. Disease features were measured as previously published, X-rays were scored every year.

Results We confirmed association of the R620W allele of PTPN22 polymorphism with RA in our Dutch Caucasian population. Minor allele frequencies of 0.07 and 0.12 were found in controls and cases, respectively, with P = 0.008 and an allelic odds ratio of 1.91, 95% confidence interval = 1.18–3.11. Surprisingly, PTPN22 appeared to be a susceptibility gene for undifferentiated arthritis that either progresses or does not progress to RA. PTPN22 status did not influence the disease persistency, as analyzed in the remission versus non-remission group, or the disease severity as determined by analysis of joint damage.
Progression of joint damage (Sharp–van der Heijde units).

Conclusion: Our results suggest that the R620W allele of PTPN22 increases susceptibility to RA but does not confer risk to a more severe disease course either with respect to joint destruction or with respect to disease severity.

P99
Tryptase as a PAR-2 activator in joint inflammation
EB Kelso1, L Dunning2, JC Lockhart2, WR Ferrell1, R Plewin1, CP Sommerhoff1
1Centre for Rheumatic Diseases, University of Glasgow, UK; 2Biological Sciences, University of Paisley, UK; 3Department of Physiology & Pharmacology, University of Strathclyde, Glasgow, UK; 4Department Clinical Biochemistry, University of Munich, Germany


Background Protease-activated receptor-2 (PAR-2) is one of a family of G-protein coupled transmembrane receptors activated by proteolytic release of a ‘tethered’ ligand. We previously reported this receptor has a pivotal role in chronic joint inflammation using a PAR-2 ‘knockout’ mouse [1], but the serine protease responsible for its activation remains uncertain.

Objective We investigated whether β-tryptase has proinflammatory actions in the mouse knee and specifically whether a tryptase inhibitor can modulate experimentally induced chronic joint inflammation.

Methods Five micrograms of human β-tryptase was injected into the knee joint cavity of two groups of anaesthetized (Halothane/O2/N2O) mice (30 g): wild-type (PAR-2+/+), C57BL/6j mice and PAR-2 gene disrupted (PAR-2-/-) mice. Joint swelling was assessed by comparing caliper measurements of knee joint diameter pre-injection and post-injection. Chronic monoarthritis was induced using the protease-activated receptor-2 (PAR-2) activator 4-amidino phenyl pyruvic acid (APPA) with FCA (100 µg) and 5% methylcellulose. In a parallel group of mice, 50 µg of the tryptase inhibitor 4-amidino phenyl pyruvic acid (APPA) was co-administered with the FCA/methylcellulose emulsion. Joint diameter was measured over 10 days.

Results Intra-articular injection of β-tryptase resulted in rapid joint swelling in wild-type mice that was completely abrogated in PAR-2-/- mice (Fig. 1a). Joint swelling was assessed by comparing caliper measurements of knee joint diameter pre-injection and post-injection. Chronic monoarthritis was induced using the protease-activated receptor-2 (PAR-2) activator 4-amidino phenyl pyruvic acid (APPA) with FCA (100 µg) and 5% methylcellulose. In a parallel group of mice, 50 µg of the tryptase inhibitor 4-amidino phenyl pyruvic acid (APPA) was co-administered with the FCA/methylcellulose emulsion. Joint diameter was measured over 10 days.

Conclusion The present study extends our previous finding [1] that PAR-2 plays a key role in mediating chronic joint inflammation, by demonstrating that tryptase may be a crucial activating protease required for such PAR-2-mediated actions.

Reference

P100
HLA DR-DQ haplotypes and genotypes in patients with systemic lupus erythematosus with co-existing Sjögren’s syndrome, systemic lupus erythematosus without Sjögren’s syndrome and primary Sjögren’s syndrome: clinical and laboratory associations
Georgoupolou3, E Zintzaras1, M Papadimitropoulos1, M Spyropoulos3, A Stavroupolos1, M Moussoupoulos1, MN Manoussakis1
1Department of Pathophysiology, Athens University Medical School, Athens, Greece; 2Biomathematics Unit, Thessaly University Medical School, Larissa, Greece; 3National Tissue Typing Center, George Gennimatas General Hospital, Athens, Greece


Background Comparative immunogenetic studies of systemic lupus erythematosus with co-existing Sjögren’s syndrome (SLE-SS), systemic lupus erythematosus without Sjögren’s syndrome and primary Sjögren’s syndrome (pSS) are lacking.

Objective In the present study, we conducted a thorough evaluation of the geno-type and haplotype profiles in well-defined subgroups of patients with SLE-SS, SLE-noSS and pSS, including their association with disease parameters.

Methods HLA-DRB1, HLA-DQA1 and HLA-DQB1 alleles were determined by PCR and hybridization with sequence-specific oligonucleotide probes in DNA specimens derived from 23 patients with SLE-SS, 41 patients with SLE-noSS and 55 patients with pSS (all Caucasians). Patients' records were retrospectively evaluated for various clinical and laboratory parameters.

Results Compared with healthy controls (odds ratios analyses), SLE-SS and pSS patients displayed a statistically increased frequency of the DRB1*0301-*0101 haplotype, whereas SLE-noSS patients had an increased frequency of the genotypes DAO1*0401-*0501, DRB1*0301-*1501 and DRB1*0301-*0602. Such statistical associations were stronger for genotypes than single alleles. The analysis of haplotype estimated frequencies (by EM algorithm) had revealed an increased frequency of the DRB1*0301-DAO1*0501-DBB1*0201 haplotype, as well as of the extended haplotype DRB1*0301-DAO1*0501-DBB1*0201/DRB1*1104-DAO1*0501-DBB1*1001 in SLE-SS and pSS patients. In contrast, SLE-noSS patients had an increased estimated frequency of the DRB1*1501-DAO1*0102-DBB1*0602 haplotype. In SLE-SS patients, positive associations of the DBB1*0201 allele with anti-dsDNA (strong) and of DAO1*0501 with anti-La/SSB (marginal) were observed. In SLE-noSS, DAO1*0301-*0602 was strongly positively associated with interstitial lung disease, DBB1*0201-*0602 with central nervous system involvement, DAO1*0501 with serositis and DRB1*1501 with anti-dsDNA, whereas DBB1*0301 homozygosity demonstrated a significant protective effect for glomerulonephritis. In pSS patients, the DRB1*0301-*1104 and DAO1*0201-*0301 genotypes were strongly positively associated with purpura, DRB1*1104-*1501 with arthritis, DBB1*0201-*0502 with renal tubular acidosis, DBB1*0301 homozygosity with lymphadenopathy, DAO1*0501 homozygosity with low C4 and DRB1*0301 allele with anti-La/SSB, low C4 and cryoglobulinemia. In these patients, the extended haplotype DRB1*0301-DAO1*0501-DBB1*0201/ DRB1*1104-DAO1*0501-DBB1*0301 associated strongly with the occurrence of low C4, anti-La/SSB and purpura.

Conclusions The present study indicates that SLE-SS and the SLE-noSS patients are immunogenetically dissimilar, whereas there is an apparent close immunogenetic relationship between SLE-SS and pSS patients. Furthermore, our data corroborate that the synergistic interactions between distinct pairs of alleles in the DR or the DQ locus confer higher relative risk for these diseases and for distinct clinical manifestations than each of these alleles individually. In pSS, the presence of the extended haplotype DBB1*0301-DAO1*0501-DBB1*0201/ DRB1*1104-DAO1*0501-DBB1*0301 appears to associate with adverse predictors for lymphoma development.

P101
Specific inhibition of FoxO transcription factors in rheumatoid arthritis synovial tissue
J Ludikhuize, TJM Smeets, M Vinkenoog, ME Sanders, PP Tak, KA Reeedquist
Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands


Background Phosphorylation-dependent inactivation of FoxO transcription factors by the proto-oncogene product protein kinase B (PKB) plays a central role in promoting cellular survival, proliferation, and activation mediated by PI3-kinase. PI3-kinase-dependent activation of PKB has been observed in rheumatoid
To determine whether FoxO transcription factors (FoxO1, FoxO3a, FoxO4) are specifically inactivated in RA synovial tissue, to identify cell types in RA synovial tissue in which FoxO proteins are inactivated, and to identify inflammatory stimuli relevant to RA that inactivate FoxO transcription factors in cultured RA fibroblast-like synoviocytes (FLS) in vitro.

**Methods**

Expression and PKB-dependent phosphorylation of FoxO1, FoxO3a, and FoxO4 were determined using specific antibodies in immunohistochemical and computer-assisted quantitative digital analysis of synovial tissue sections obtained from 12 RA and nine osteoarthritis (OA) patients. Double labelling with cell-specific antibodies was performed to identify FoxO expression and inactivation in specific cell populations. In vitro, cultured RA (n = 3) and OA (n = 2) FLS were stimulated with tumour necrosis factor (TNF) α, transforming growth factor (TGF) beta, or soluble CD154 prior to lysis and detection of FoxO phosphorylation by immunoblotting. FLS proliferative responses to these stimuli were determined in the presence and absence of the PI3-kinase inhibitor LY294002 by crystal violet staining.

**Results**

Phosphorylated inactive FoxO1, FoxO3a, and FoxO4 were observed in both RA and OA synovial tissue. Inactivation of FoxO1, FoxO3a, and FoxO4 was restricted to FLS, T lymphocytes, and synovial macrophages, respectively. Inactivation of FoxO1 and FoxO4 was significantly enhanced (P < 0.05) in RA synovial tissue compared with OA synovial tissue. No significant differences in the inactivation of T lymphocyte FoxO3a were observed between RA and OA synovial tissue. In vitro, PI3-kinase-dependent inactivation of FoxO1 was observed in RA FLS following stimulation with TNF, TGF, and soluble CD154. Inactivation of FoxO1 was not sufficient to promote FLS proliferation, as only TNF and TGF but not CD154 could induce FoxO1 inactivation. PI3-kinase-dependent FLS proliferation. Our studies demonstrate that inactivation of FoxO1 and FoxO4 is enhanced in RA compared with OA, provide the first (patho)physiological evidence of FoxO4 inactivation in vivo, and suggest important roles for FoxO1 and FoxO4 in maintaining, respectively, FLS and macrophage activation and survival in RA synovial tissue.

**P102**

Quantitative and qualitative analysis of CD4+CD25+ regulatory T cells in systemic lupus erythematosus patients

M Bonelli, JS Smolen, C Scheinecker

Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria


CD4+CD25+ regulatory T cells (Treg) that specialize in the suppression of immune responses play a critical role in the regulation of peripheral immune tolerance and thus might be critically involved in the pathogenesis of autoimmune diseases. As for systemic lupus erythematosus (SLE), however, data concerning Treg are so far limited. We therefore initiated detailed quantitative and qualitative analysis of naturally occurring CD4+CD25+ Treg from SLE patients as compared with healthy controls. FACS analysis revealed increased proportions of CD4+CD25+ Treg, as well as activated CD4+CD69+ T cells, among peripheral blood mononuclear cells in SLE patients as compared with healthy controls. Ongoing experiments aim to analyze the capacity of purified CD4+CD25+ Treg to suppress the proliferation of autologous or allogeneic T cells. Preliminary results indicate a tendency towards a reduced suppressive capacity of CD4+CD25+ Treg in SLE patients as compared with healthy controls. Additional experiments will determine the statistical significance of this observation and will correlate quantitative and/or qualitative defects of Tregs in SLE patients with clinical data. Finally, this study will also allow one to experimentally abrogate potential defects of Treg in SLE patients. This might provide the basis for new therapeutic concepts in the treatment of SLE and other autoimmune diseases.

**P103**

HSP70/J-protein chaperone machines: expression analysis in granulocytes

A Zgaga-Griesz, A Adolf, S Haak, R Rzepek, I Melchers

Clinical Research Unit for Rheumatology, University Medical Center, Freiburg, Germany


Background

Polymorphonuclear leucocytes (PMNLs) represent the first line of defense of the innate immune system. PMNLs are the predominant leucocyte accumulating in the synovial fluid of rheumatoid arthritis (RA) patients and play a crucial role in the development of tissue damage. Unstimulated PMNLs are postmitotic terminally differentiated cells whose default setting is death by apoptosis. Pathogens or inflammation induce a profound transcriptional and translational activity, Abruptly expressing the proliferation of autologous or allologeneic T cells. Preliminary results indicate a tendency towards a reduced suppressive capacity of CD4+CD25+ Treg in SLE patients as compared with healthy controls. Additional experiments will determine the statistical significance of this observation and will correlate quantitative and/or qualitative defects of Tregs in SLE patients with clinical data. Finally, this study will also allow one to experimentally abrogate potential defects of Treg in SLE patients. This might provide the basis for new therapeutic concepts in the treatment of SLE and other autoimmune diseases.

**P104**

Genotype-dependent NOS-3 expression and rheumatoid arthritis

M Cattaruzza1, I Melchers2, M Hecker1

1Department of Cardiovascular Physiology, University of Göttingen, Germany; 2Clinical Research Unit for Rheumatology, University Medical Center, Freiburg, Germany


The -786C/C-variant of the endothelial nitric oxide synthase nos-3 gene has been shown to be associated with coronary artery disease because of a blunted inducibility of gene expression [1]. IL-10, a cytokine involved in Th1-Th2-cell differentiation, is a new stimulus for NOS-3 expression [2].

We here address the question whether IL-10-induced NOS-3 expression is decreased in individuals with the -786C/C genotype and, if so, whether a Th1-mediated disease like rheumatoid arthritis is associated with this genotype.

Endothelial cells were isolated from an umbilical cord vein of known genotype and cultured as described [1]. The expression of NOS-3 was analysed by real-time semi-quantitative RT-PCR [1]. Genotyping was performed as described elsewhere [1]. Patients met the revised criteria of the ACR for the classification of rheumatoid arthritis, and donated blood samples after informed consent. Primary human umbilical vein endothelial cells with the -786C/C genotype did not respond with an increase in NOS-3 expression to IL-10 incubation (5 ng/ml). This defect could be repaired after pre-incubation of the cells with a decoy oligonucleotide (10 µmol/l) directed against the C-variant of the promoter. Among 587 patients with rheumatoid arthritis tested, incidences for the -786C/C genotype were significantly higher than in the general population (179 women, 179 men, p< 0.001). NOS-3 is one mediator of anti-inflammatory IL-10 actions. Individuals with the -786C/C nos-3-genotype have an increased risk for the development of rheumatoid arthritis. This might be due to the IL-10 insensitivity of the C-variant of the promoter.
Anti-high-density lipoprotein antibodies and lipoprotein characteristics in systemic lupus erythematosus-related cardiovascular disease

J Su, A Cederholm, E Hurt-Camejo, E Svenungsson, J Frostegärd
Department of Medicine, Karolinska University Hospital, Stockholm, Sweden


Background The risk of cardiovascular disease (CVD) in systemic lupus erythematosus (SLE) is exceedingly high. Previously, a lupus pattern of dyslipidemia has been described (raised triglycerides, and low high-density lipoprotein [HDL]) and we recently reported that these lipid abnormalities were associated with tumor necrosis factor (TNF) activity.

Methods Twenty-three women (52 ± 8.2 years) with SLE and a history of CVD were compared with 26 age-matched women with SLE and no clinical manifestation of CVD (SLE controls) and 26 age-matched healthy women (controls). Lipoprotein-related measurements included lipoprotein particle size determination by use of NMR spectroscopy and affinity of low-density lipoprotein (LDL) to proteoglycans. Antibodies against apolipoprotein A1 (apoA1) in HDL and THF was measured by ELISA. Common carotid intima-media thickness was measured by B-mode ultrasound as a surrogate measure of atherosclerosis.

Results Anti-apoA1 were raised in SLE cases as compared with SLE controls (P = 0.03) and controls (P = 0.001), and in SLE controls as compared with controls (P = 0.01). Among SLE cases, anti-apoA1 was associated with TNF (P = 0.001). Small dense LDL were more common among SLE controls and controls than in SLE cases (P = 0.038 and 0.086, respectively). Small HDL was more common among controls than in SLE cases and SLE controls (P = 0.001). LDL association with proteoglycans did not differ between groups Activity in the TNF system was significantly associated with triglycerides and negatively with HDL (R < 0.01).

Conclusion SLE-related dyslipidemia showed a surprising pattern with large LDL and HDL rather than small; that is, not an expected 'atherogenic' lipid profile. Anti-apoA1 antibodies where strongly associated with CVD in SLE. Whether they may play a pathogenic role (e.g. by inhibiting anti-inflammatory properties of HDL) is presently under investigation.

Acknowledgements Supported by the Swedish Heart Lung Foundation, the King Gustav V 80th Birthday Fund, the Torsten and Ragnar Söderberg Foundation, and the Swedish Science Fund.
chronic autoimmune response are rarely found in RA. It has been previously documented that RA T cells are severely impaired in their ability to differentiate into Th2 effectors while exerting enhanced Th1 differentiation. The mechanisms underlying this function abnormality, however, have not been delineated. As IL-4 is a most critical determinant in regulating immune responses by promoting Th2 cell development and inhibiting Th1 cell differentiation, we analyzed the role of single nucleotide polymorphisms (SNPs) in the IL-4 receptor (IL-4R) α-chain, which is critical for binding of IL-4 and for IL-4 signal transduction, in the differentiation of human T cells. Three hundred and sixty-one healthy individuals were genotyped by allele-specific PCR for the two IL-4R α-chain SNPs that are located in functionally important regions of the IL-4R α-chain – the 50SV SNPs50 and the 551R SNPs51 in the IL-4-binding and STAT6-binding domains, respectively. Naive and memory CD4-positive T cells were isolated from the peripheral blood of individuals who were homozygous for either allele at SNPs50 and SNPs51, and were primed for 5 days with mAbs to CD28 and/or CD3 in the presence or absence of exogenous IL-4. The phenotype of the resulting differentiated effector cells was then analyzed by flow cytometric analysis of cytoplasmic cytokines. The SNPs51 alleles did not affect T-cell differentiation. In contrast, the inhibitory effect of IL-4 on Th1 cell differentiation was significantly diminished in CD4 T cells that were homozygous for the mutated allele at SNPs50 (50V) as compared with those with the wild type allele (50I). Likewise, the augmenting effect of IL-4 on Th2 cell differentiation was enhanced on T cells that were homozygous for the wild-type allele as compared with T cells expressing the mutant allele. These data indicate that the mutant allele of the IL-4R α-chain at SNPs50 is associated with a decreased T-cell response to IL-4. To delineate a potential mechanism of different responses to IL-4 in the cells expressing different alleles of the IL-4R, T cells form individuals who were homozygous for either the wild-type or the mutant allele at SNPs50 were primed with different culturing conditions. IL-4 and analyzed by flow cytometry for STAT6 phosphorylation and phosphorylated STAT6. Whereas STAT6 concentrations were not different between T-cell expressing 50I or 50V, STAT6 phosphorylation in response to IL-4 stimulation was significantly reduced in T cells expressing the 50V allele compared with T cells expressing 50I. Thus, the 50SV SNPs50 allele of the IL-4R α-chain might regulate T-cell differentiation by diminishing T-cell responses to IL-4, resulting in a reduced STAT6 phosphorylation and subsequently in diminished Th2 cell differentiation. The 50SV SNPs50 allele might thereby contribute to the development of unbalanced Th subset activation, as characteristic for autoimmune diseases, such as RA.

P109
Role of IL-10 as a susceptibility factor for rheumatoid arthritis and cardiovascular disease

FAS Kurreeman,1 J De Vries,1 R Westendorp,1 AH Van Den Biggelaar2,3,4, JR Kalden2, J Schulze-Koops2,3,4

Reference

P110
Regulation of myeloid cell function and MHC class II expression by tumor necrosis factor

RB Mueller1,2, A Skapenko1,2, M Grunke1,2, J Wendler2, B Stuhlmüller4, JR Kalden2, J Schulze-Koops1,2
1Nicholas Fiebiger Center for Molecular Medicine, Clinical Research Group III, University of Erlangen–Nuremberg, Erlangen, Germany; 2Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen–Nuremberg, Erlangen, Germany; 3Rheumatologische Gemeinschaftspraxis, Erlangen, Germany; 4Department of Rheumatology and Clinical Immunology, Charitä University Hospital, Berlin, Germany

Reference
Methods Activation of H-Ras, K-Ras, and N-Ras homologs in RA SF T lymphocytes were determined by activation-specific GTPase precipitation and immunoblot analysis. T-lymphocyte intracellular ROS production was measured by FACS-based analysis of DCF oxidation. Control, active Ras, and RapGAP constructs were introduced into human Jurkat T cells and healthy donor peripheral blood T lymphocytes by electroporation and nucleofection techniques, respectively. For ROS analysis, cells were cotransfected with RFP to detect transfected cells. For static adhesion assays, a luciferase reporter plasmid was used to detect transfected cells: cells were allowed to adhere to immobilized fibronectin or recombinant human intracellular adhesion molecule, non-adherent cells washed off, and adherent cells quantitated by luciferase assay. In some experiments, cells were preincubated with the pharmacological inhibitors BAPTA-AM, LY294002, and DPI, indicating a calcium-sensitive hydrogen peroxide source of ROS that does not require a functional NADPH oxidase. These results are consistent with our previous observations in purified RA SF T lymphocytes. In contrast, N-Ras, but not H-Ras or K-Ras, induced integrin-dependent adhesion in Jurkat T cells and peripheral blood T lymphocytes. N-Ras-induced adhesion was sensitive to LY294002, indicative of PI3-kinase signaling. Additionally, inactivation of Rap1 with RapGAP had no effect on N-Ras-induced adhesion. This represents the first (patho)physiological signaling pathway by which integrins can be activated independently of Rap1. Our results suggest that selective targeting of H-Ras and N-Ras may allow specific modulation of T-cell ROS production and integrin activation in RA T lymphocytes.

Results All three homologs of Ras were found to be constitutively activated in RA SF T lymphocytes. Active H-Ras, but not K-Ras or N-Ras, stimulated ROS production in both Jurkat and peripheral blood T lymphocytes. H-Ras-induced ROS production was sensitive to BAPTA-AM and calcin, but not LY294002 or DPI, indicating a calcium-sensitive hydrogen peroxide source of ROS that does not require a functional NADPH oxidase. These results are consistent with our previous observations in purified RA SF T lymphocytes. In contrast, N-Ras, but not H-Ras or K-Ras, induced integrin-dependent adhesion in Jurkat T cells and peripheral blood T lymphocytes. N-Ras-induced adhesion was sensitive to LY294002, indicative of PI3-kinase signaling. Additionally, inactivation of Rap1 with RapGAP had no effect on N-Ras-induced adhesion. This represents the first (patho)physiological signaling pathway by which integrins can be activated independently of Rap1. Our results suggest that selective targeting of H-Ras and N-Ras may allow specific modulation of T-cell ROS production and integrin activation in RA T lymphocytes.


P112 Requirement of IL-17 receptor signaling in resident synoviocytes for development of full blazed destructive arthritis E Lubberts1,2, P Schwarzenberger2, W Huang3, JR Schum1, JJ Peschon3, WB van den Berg1, JK Kolls2
1University Medical Center St Radboud, Department of Rheumatology, Nijmegen, The Netherlands; 2LSU Health Sciences Center, Department of Medicine, Gene Therapy Program, New Orleans, Louisiana, USA; 3Ametry, Seattle, Washington, USA


Chronic arthritis is characterized by persistent joint inflammation and concomitant joint destruction. IL-17 is a novel proinflammatory T-cell cytokine suspected to be involved in inflammatory and autoimmune diseases such as rheumatoid arthritis. Here, we report that IL-17 receptor (IL-17R) signaling is required in resident synovial cells for full progression of chronic synovitis and bone erosion. Repeated injections of Gram-positive bacterial cell wall fragments (SCW) directly into the knee joint of naïve IL-17R-deficient (IL-17R−/−) mice had no effect on the acute phase of arthritis but prevented progression to chronic destructive synovitis as was noted in wild-type (wt) mice. Micro-array analysis revealed significant down-regulation of leukocyte-specific chemokines, selectins, collagenase-3, and IL-1 in the synovium of IL-17R−/− mice. Bone marrow (BM) chimeric mice revealed the need for IL-17/IL-17R signaling in resident synovial cells for development of full blown synovitis. Chimeric mice of host wt and donor IL-17R−/− BM cells developed destructive synovitis in this chronic relapsing SCW arthritis model similar to wt → wt chimeras. In contrast, chimeric mice of host IL-17R−/− and donor wt BM cells were protected from full blown destructive arthritis similar to IL-17R−/− → IL-17R−/− chimeras. These data strongly suggest T-cell IL-17−/IL-17R signaling in resident synovial cells to be a pivotal mechanism through which an acute macrophage-driven joint inflammation progresses into a chronic destructive synovitis. Prevention of local synovial IL-17−/IL-17R signaling warrants consideration as a therapeutic target in chronic destructive arthritis.

P113 Different molecules at the surface of stimulated T cells induce IL-1β, tumour necrosis factor and IL-1RA in human monocytes D Burger, N Molnar, I Gruz, JM Dayer Division of Immunology and Allergy, Clinical Immunology Unit, Faculty of Medicine, University Hospital, Geneva, Switzerland


Impairment in cytokine homeostasis is thought to play an important part in the pathogenesis of chronic inflammatory diseases such as rheumatoid arthritis. We demonstrated that T cells might exert a pathological effect through direct cellular contact with monocyte-macrophages, inducing a massive upregulation of IL-1β and tumour necrosis factor (TNF) [1]. We showed that this mechanism that might be responsible for chronic inflammation is specifically inhibited by high-density lipoproteins (HDL) [2]. Like many other stimuli, besides proinflammatory cytokines, the contact-mediated activation of monocytes induces the production of cytokine inhibitors such as IL-1Ra. HDL inhibited the production of IL-1β and TNF but not that of IL-1Ra in monocytes activated by membranes isolated from stimulated T cells to mimic cellular contact. This was also the case in peripheral blood mononuclear cells stimulated by either phytohaemagglutinin or tetanus toxoid. Similarly, IL-1Ra mRNA expression was not inhibited contrary to IL-1β and TNF mRNA. This demonstrates that different molecules at the surface of stimulated HUT-78 cells are involved in the induction of IL-1β, TNF and IL-1Ra in monocytes, IL-1β and TNF being activated by HDL-specific ligand(s). Separation of CHAPS-solubilized membrane molecules by liquid isoelectric focusing showed that two activity peaks were present: one activating IL-1β, TNF and IL-1Ra production, the other inducing the production of IL-1Ra in the absence of IL-1β and TNF. Further isolation of these two types of factor by gel filtration demonstrated that factor(s) inducing IL-1β, TNF and IL-1Ra displayed a M 70,000 kDa and 30,000 kDa. Thus different factors are expressed at the surface of stimulated T cells that differentially trigger the production of proinflammatory and anti-inflammatory factors, and are differently affected by HDL.


P114 Infliximab treatment does not induce apoptosis in peripheral blood mononuclear cells up to 24 hours after initiation of treatment in rheumatoid arthritis patients CA Wijbrandts, P Reinders-Blankert, P Klarenbeek, TJM Smeets, MJ Vervoordeldonk, PP Tak

Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, The Netherlands


Background Apoptosis of peripheral blood T lymphocytes from patients with Crohn’s disease has been described after in vitro activation followed by incubation with infliximab. These ex vivo data raised the question of whether in vivo treatment of rheumatoid arthritis (RA) with the chimeric tumor necrosis factor alpha antibody, infliximab, causes apoptosis in peripheral blood mononuclear cells. This study was designed to detect the early effects of infliximab treatment on apoptosis in the peripheral blood of patients with RA.

Methods Ten patients with active RA (Disease Activity Score [DAS 28] > 3.2) received 3 mg/kg infliximab intravenously in combination with methotrexate (mean dose of 25 mg weekly). All 10 patients underwent blood sampling before, 1 hour after and 24 hours after the administration of infliximab. Apoptosis was determined using double staining with annexin-V, as an early marker of apoptosis, and 7-amino-actinomycin D (AAD) to exclude necrotic cells from this population. Peripheral blood erythrocytes were lysed and the mononuclear cells were incubated with the different antibodies. The percentages of annexin-V-positive and 7-AAD-negative monocytes and lymphocytes were analyzed by flow cytometry. For statistical analysis, a paired t test was used to compare the percentages of apoptotic cells 1 hour and 24 hours after treatment with those at baseline.

Results All samples were analyzed for the presence of and change in apoptosis. At baseline, the median percentage of apoptotic monocytes was 0.90% (range 6.23–0.19); 1 hour after treatment, the median percentage was 0.56% (range 2.90–0.32) and 24 hours after treatment the median percentage was 0.21% (range 2.90–0.00). In the lymphocyte population, the median percentage of apoptotic cells was 0.98% (range 2.15–0.00) at baseline as compared with 0.52% (range 6.30–0.00) 1 hour after treatment and 0.39% (range 2.85–0.00) 24 hours after infliximab administration.

Conclusion In this in vivo study we found no statistically significant increase from baseline in the percentage of apoptotic monocytes or lymphocytes in the peripheral blood of RA patients at 1 hour or 24 hours after infliximab treatment.

Acknowledgement Supported by Centocor.
P115 Resistance of rheumatoid arthritis synovial fibroblasts to p38 MAP-kinase inhibition of pro-destructive functions mediated by tumor necrosis factor alpha/tumor necrosis factor receptor-1
E Kunisch1, B Ukena1, R Fuhrmann2, A Roth3, R Winter2, RW Kinne1
1Experimental Rheumatology Unit, Friedrich Schiller University Jena, Germany; 2Clinic of Orthopedics, Friedrich Schiller University Jena, Germany

Objectives In rheumatoid arthritis (RA), tumor necrosis factor (TNF) alpha is a major inducer of the proinflammatory/pro-destructive functions of synovial fibroblasts (SFB). These effects are predominantly mediated via the TNF receptor-1 (TNFR1). In addition to the NF-κB pathway, the p38 MAP kinase seems to play a central role for the underlying signal transduction. In the present study, RA-SFB were compared with osteoarthritis (OA)-SFB concerning the TNF-α/TNFFR1/2-induced secretion of IL-6, IL-8, prostaglandin (PGE2) and matrix metalloproteinase-1 (tissue inhibitor of matrix metalloproteinase-1 (MMP-1)/TIMP-1), as well as the sensitivity to p38 MAP-kinase inhibition.

Methods Early-passage (second) RA-SFB and OA-SFB were analyzed for TNF receptor expression and in vitro sensitivity to p38 MAP kinase inhibition. Association studies of genetic factors were performed.

Results RA-SFB and OA-SFB both expressed TNFR1 and TNFR2 on their surface. Without significant differences between the two groups, secretion of IL-6, IL-8, PGE2 and MMP-1, but not TIMP-1 was significantly augmented by stimulation of RA-SFB and OA-SFB with TNF-α. Except for PGE2 (induced via both TNFRs), these effects were exclusively mediated via the TNFR1. Inhibition of p38 kinase reduced the secretion of IL-6 and PGE2 significantly and equally well in RA-SFB and OA-SFB. However, the secretion of MMP-1 was significantly suppressed only in OA-SFB, whereas RA-SFB were insensitive to the inhibition of MMP-1 secretion by p38 inhibition.

Conclusion In early-passage RA-SFB and OA-SFB, TNF-α-induced proinflammatory/pro-destructive functions are predominantly mediated by TNFR1. Strikingly, RA-SFB are partially resistant to the suppression of pro-destructive MMP-1 by p38 MAP-kinase inhibition. The underlying structural or functional alterations of the p38 MAP kinase in RA-SFB may contribute to the pathogenesis and/or therapeutical sensitivity of RA.

Acknowledgements This study was supported by the German Federal Ministry of Education and Research (MBMF; grant FKZ 01ZZ0105 to RWK, Interdisciplinary Center for Clinical Research Jena) and the German Research Foundation (DFG; grant KI 439/7-1 to RWK), as well as a grant for the advancement of female scientists to EK (LUBOM Thuringia).

P116 Patterns of gene expression in rheumatoid arthritis synovial tissue: inter-patient variability greater then intra-patient variability in a small study
J Lindberg1, E af Klint2, A Stark3, T Andersson2, P Nilsson2, L Klareskog2, A Ulfgren1, J Lundeberg1
1Royal Institute of Technology, Stockholm, Sweden; 2Department of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 3Department of Orthopaedics, Karolinska University Hospital, Stockholm, Sweden

Background The synovial membrane is not entirely homogeneous, leading to a local variability within a joint. Synovial tissue can be retrieved from patients in a number of ways (e.g., open surgery, blind needle-biopsy, and arthroscopy). Aim To study inter-patient versus intra-patient variability in gene expression in rheumatoid arthritis (RA) synovial tissue.

Patients and methods Orthopaedic samples Three synovial biopsies were taken from three RA patients (patients 1–3) at joint replacement surgery. All nine biopsies were divided into three, creating nine samples from each joint, and a total of 27 samples.

Arthroscopic samples Two to four synovial biopsies were sampled at arthroscopy from four RA patients (patients 4–7) with an inflamed knee joint. Multiple samples were taken from different sites in all patients.

Handling of synovial tissue and microarray analysis All samples were snap frozen and stored at −80°C. Following RNA extraction (at 4°C), reverse transcription, cDNA amplification and labelling, each sample was hybridised in duplicate against a reference, on a cDNA array locally produced, representing 18,139 unique genes. After data filtering, genes were defined as differentially expressed (DE) if they had a B score > 0 and a fold change > 2. Several hierarchical clusterings were performed to obtain an overview of the data. DE genes in the samples were used to compare the variation between samples from one biopsy, the variation between biopsies from one joint and the variation between biopsies from different patients. Clustering also allowed comparisons between the sampling techniques.

Results In the orthopaedic subset, variation between samples within one biopsy (patients 1–3) was between 1.2% and 6.7% of analysed genes. The amount of DE genes between biopsies was between 1.2% and 5.9%. Hierarchical clustering of biopsies showed more similarities within a patient than between patients, except for one biopsy. One biopsy from patient 1 clustered with biopsies from patient 2 because the other two biopsies from patient 1 had higher fat cell content (confirmed microscopically) than any of the other biopsies. This was confirmed by gene expression profiles with activity in the fatty acid and lipid metabolism. When these genes were removed from the analysis, the samples clustered perfectly according to patient. The analysis of the arthroscopic subset (patients 4–7) showed a variation of DE genes between biopsies of 0.3–1.6%, and a perfect matching in cluster analysis with all biopsies from the same patient clustering together, without any further labouiring with data.

Table 1

<table>
<thead>
<tr>
<th></th>
<th>Average sample weight (mg)</th>
<th>Total RNA yield (mg)</th>
<th>RNA yield per milligram of tissue (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients 1–3</td>
<td>32.9</td>
<td>14,808</td>
<td>502</td>
</tr>
<tr>
<td>Patients 4–7</td>
<td>19.0</td>
<td>9834</td>
<td>407</td>
</tr>
</tbody>
</table>

Conclusions This study shows that inter-patient variability is greater than intra-patient variability in gene expression, in RA synovial tissue. We found that one biopsy is enough to represent one patient as they clustered nicely together, with one exception, which was related to high content of fat cells in the biopsy. Variability is in the same order of magnitude in samples close to each other as compared with those further apart within the same patient.

P117 Association of FCGR2A and FC gamma receptor haplotypes with Spanish polymyalgia rheumatica and giant cell arteritis
AW Morgan1, MA Gonzalez-Gay2, JI Robinson3, SJ Babbage4, L Haroon-Rashid2, AH Hajeer1, WER Ollier1, JD Isaacs1,2
1Academic Unit of Musculoskeletal Disease and Molecular Medicine Unit, University of Leeds, UK; 2Rheumatology Division, Hospital Xeral-Calde, Lugo, Spain; 3The Centre for Integrated Genomic Medical Research, The University of Manchester, UK; 4School of Clinical Medical Sciences (Rheumatology), University of Newcastle-Upon-Tyne, UK

Background Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are two inflammatory diseases that are thought to arise from a complex interaction between multiple genetic factors and environmental triggers. We have previously demonstrated an association between the FC gamma receptor (FcγR) genetic locus on chromosome 1q22-23 and rheumatoid arthritis, and have now extended our study to include other inflammatory/autoimmune diseases.

Methods The FCGR2A-131R/H, FCGR3A-158F/V and FCGR3B-N/A/N2 functional polymorphisms and a novel FCGR2B 3′-UTR polymorphism were examined for association with PMR (n = 89) and GCA (n = 83) in two well-characterised clinical cohorts from Northern Spain. In view of the close molecular proximity between FCGR2A, FCGR3A, FCGR3B and FCGR2B we have examined FcγR haplotypes for association with rheumatoid arthritis. Pairwise disequilibrium coefficients (D′) were initially calculated in 115 matched controls. The EHPlus program was used to estimate haplotype frequencies for patients and controls and to determine whether significant linkage disequilibrium was present. A likelihood ratio test was performed to test for differences between the haplotype frequencies in cases and controls. A permutation procedure implemented in this program enabled 1000 permutations to be performed on all haplotype associations to assess significance.

Results There was borderline linkage disequilibrium between FCGR2A and FCGR3A (D′ = −0.313, P = 0.03) with more significant disequilibrium between FCGR2A and FCGR3B (D′ = −0.646, P = 0.0001). There was a significant difference in the FCGR2A allele (P = 0.03) and genotype frequencies (P = 0.03) with GCA compared with controls. Specifically, there was an increase in the FCGR2A-131R/H genotype in both the PMR (odds ratio [OR] = 2.15; 95% confidence interval [CI] = 1.0–4.7, P = 0.05) and GCA (OR = 2.53, 95% CI = 1.3–5.1, P = 0.01) populations compared with controls. Increased homozgyosity for the FCGR2A/FCGR3A 131R/158F haplotype was associated with 25% of PMR (OR = 4.20, 95% CI = 1.3–13.1, P = 0.01) and 24% GCA (OR = 4.46, 95% CI = 1.5–3.3, P = 0.004) individuals. Logistic regression analyses suggested that both FCGR2A and FCGR3A contributed to GCA susceptibility. In addition, homozgyosity for the
FCGR3A-FCGR5B 158F-NA2 haplotype was found in 25% controls compared with 44% GCA subjects (OR = 2.35, 95% CI = 1.0–5.7, \(P = 0.06\)). Logistic regression analyses suggested that FCGR3A was the most important site contributing to GCA susceptibility. A subgroup of GCA patients who had experienced visual symptoms was examined as a marker of disease severity. The most significant findings were increased homozygosity of a FCGR2A-FCGR3A 131R-158F haplotype (8% controls, 16% GCA without visual manifestations and 50% GCA with visual manifestations [OR = 12.86, 95% CI = 1.3–128.2, \(P = 0.03\)]). Additionally, the FCGR3A-FCGR5B haplotype was found in 11/13 individuals who sustained visual manifestations. Homozygosity was seen in 25% controls, 27% GCA without eye involvement and 63% GCA with visual manifestations (OR = 5.83, 95% CI = 0.9–38.9, \(P = 0.08\)). For each haplotype logistic regression analyses suggested FCGR3A was the most important site.

Conclusions We have demonstrated that FCGR2A may contribute to the ‘susceptibility’ of PMR and GCA in this Spanish population. The increased association observed with a FCGR2A-FCGR3A haplotype suggests the presence of additional genetic polymorphisms in linkage disequilibrium with this haplotype that may contribute to GCA susceptibility. FCGR3A-FCGR5B haplotypes may define a subpopulation of individuals at greater risk of vascular occlusion. These findings may ultimately provide new insights into disease pathogenesis.

Acknowledgement This work was funded by The Health Foundation.

P118 Noggin haploinsufficiency influences severity of arthritis in different mouse models

M Daans, RJU Lories, I Derese, P Tydzanowski, FP Luyten
Laboratory for Skeletal Development and Joint Disorders, Department of Rheumatology, University Hospitals Leuven, Katholieke Universiteit Leuven, Belgium


Introduction The severity and outcome of chronic arthritis is determined by the balance between destructive and homeostatic or anabolic molecular signaling pathways. Increasing evidence suggests a role for embryonic signaling pathways: essential for development and growth, in the maintenance of tissue homeostasis and in the induction of repair. Untimely or inappropriate activation of such pathways may also have a role in the progression of some diseases. Bone morphogenetic proteins (BMPs), originally identified as protein factors that induce a cascade of endochondral bone formation, have critical functions in cell proliferation, differentiation, adhesion and death. We have previously identified different BMPs in patients with chronic arthritis [1]. In this study, we evaluate the effect of shifting the balance in BMP signaling by reducing endogenous levels of noggin, a BMP-binding protein, in a mouse model of rheumatoid arthritis (COL2A1 promoter-driven expression of noggin (noggin) or noggin under control of a control gene and insertion of a BMP morpholino [mBMPA]-induced monoarthritis and a model of ankylosing enthesitis and spondyloarthritis (spontaneous arthritis in male DBA/1 mice). Materials and methods Heterozygous mice with a targeted inactivation of the noggin gene and insertion of a β-galactosidase reporter (noggin+/LacZ) (a gift from R Benecke, Baltimore, USA) originally in the C57Bl/6 background, were backcrossed into the DBA/1 background for more than eight generations. mBMSA-induced arthritis was induced by intra-articular mBSA injection on day 1, followed by injection of subcutaneous IL-1 on three consecutive days. Mice were sacrificed at day 7. Severity of disease was determined with a histological score based on exudate, inflammatory cell infiltration in the synovium, pannus formation, cartilage and bone destruction. Cartilage destruction and glycosaminoglycan loss was further quantified using safranin O staining and digital image analysis of the articular surfaces from tibia, patella and femur. CIA was induced by ileo-implumation with chicken type II collagen emulsified in complete Freund adjuvant on day 1, followed by intraperitoneal booster injection of type II collagen on day 21. Arthritis characterized by ankylosing enthesitis is spontaneously occurring in aging male DBA/1 mice after grouped caging (> 4 males per cage) from the age of 14 weeks onwards. Incidence and severity of arthritis was assessed clinically and by histology in the latter two models. Presence of noggin was determined by immunohistochemistry in wild-type mice and by LacZ staining in noggin+/LacZ mice.

Results Noggin haploinsufficiency did not affect the incidence or clinical severity of CIA in DBA/1 mice. No differences in histological severity were seen. The histological severity of mBMSA-induced monoarthritis in noggin+/−/− mice was similar to that of wild-type mice. However, cartilage destruction as determined by digital image analysis of proteoglycan content was significantly reduced in noggin+/−/− mice suggesting a protective role for BMP signaling. Disease incidence and severity of spontaneous arthritis was similar in noggin+/−/− and wild-type DBA/1 mice. However, histological analysis of this arthritis showed a slower disease progression in the haploinsufficient mice. Progression of ankylosing enthesitis, in particular chondrocyte hypertrophy and new bone formation, was delayed as compared with wild-type mice. The involvement of noggin in these processes was confirmed by immunohistochemistry in noggin in wild-type mice and LacZ staining in noggin+/−/− mice. Conclusions Noggin haploinsufficiency has a protective effect on proteoglycan loss in a mouse model of cartilage destruction. Noggin haploinsufficiency also slows the progression of ankylosing enthesitis in a mouse model of spondyloarthritis. The role of noggin in ankylosing enthesitis is similar to what is seen during endochondral bone formation in development. These data provide further evidence that embryonic molecular signaling pathways, and BMP signaling in particular, are involved in the balance between tissue destruction, homeostasis and repair.


Acknowledgements MD and RL contributed equally to this work. RJUL is the recipient of a post-doctoral fellowship (RA) from the Swiss National Science Fonds. This work was supported by research grant 0.390.03 from the Fund for Scientific Research Flanders and a Bristol-Myers-Squibb EULAR Young Investigator Award to RJUL.

P119 Toll-like receptor expression in synovial fibroblasts and normal skin fibroblasts and induction of matrix metalloproteinase expression by various Toll-like receptor ligands

D Kyburz1, F Brentano1, O Schor2, BA Michel1, RE Gay1, S Gay1
1Center of Experimental Rheumatology, University Hospital, Zurich, Switzerland

Toll-like receptors (TLRs) are pattern recognition receptors of the innate immune system. TLR2 has been demonstrated to be expressed in synovial tissue of patients with rheumatoid arthritis (RA) as well as in cultured synovial fibroblasts of patients with RA and osteoarthritis. However, it is not known whether other members of the TLR family are expressed in synovial fibroblasts. We have therefore examined the expression of TLR1–TLR8 in these cells and performed stimulution experiments using specific TLR ligands. TLR and matrix metalloproteinase (MMP) mRNA expression was analysed by real-time PCR using 18S-RNA as an internal control. A difference of five or more cycles between cDNA of the samples and non-RT control was considered to be the detection limit. While all fibroblasts expressed TLR1–TLR6, the expression of TLR2 and TLR3 was significantly higher in synovial fibroblasts from patients with RA as compared with normal skin fibroblasts. TLR7, TLR8 and TLR9 mRNA did not reach the detection level. To assess the function of these TLRs, cultured synovial and skin fibroblasts were stimulated with the TLR ligands bacterial lipopolysaccharide, poly (I:C), lipopolysaccharide and flagellin. All ligands stimulated the expression of MMP1, MMP3, MMP9 and MMP13 to a certain extent. Whereas the TLR2 ligand bacterial lipopolysaccharide preferentially induced the expression of MMP1 and MMP3, the TLR3 ligand poly (I:C) was a more efficient inducer of MMP13 and MMP3 and also induced MMP1 to a lesser extent. Normal skin fibroblasts expressed significantly lower levels of MMP3 and MMP13 mRNA as compared with synovial fibroblasts of patients with RA. Our data extend previous reports on the expression of TLRs on synovial fibroblasts to include TLR1–TLR8 and document that these TLRs are functional. Depending on the TLR ligand used, MMP expression is differentially induced. This supports the notion that activation of TLR signalling pathways might contribute to joint inflammation and destruction in RA.

P120 Exploring mechanisms of inflammatory hyperalgesia in murine collagen-induced arthritis

JJ Inglish1, P Anandi, P Facere, G Criado1, M Feldmann2, RO Williams1
1Kennedy Institute of Rheumatology, Imperial College London, UK
2Neuroscience and Psychological Medicine, Imperial College London, UK


Rheumatoid arthritis (RA) is an autoimmune inflammatory disorder, characterised by joint swelling and diffuse chronic pain. RA patients display both hyperalgesia (an exaggerated painful response to a noxious stimulus) and allodynia (a painful response to a non-noxious stimulus). Collagen-induced arthritis (CIA) in the mouse is a well-established model of RA that may be useful in the study of inflammatory hyperalgesia. The aim of this study was to establish CIA as a model for studying inflammatory hyperalgesia in vivo. We measured inflammatory hyperalgesia as an exaggerated painful response to a noxious stimulus and allodynia (a painful response to a non-noxious stimulus). Collagen-induced arthritis (CIA) in the mouse is a well-established model of RA that may be useful in the study of inflammatory hyperalgesia.
The development of mechanical hyperalgesia in mice with collagen-induced arthritis.

Prior to onset of inflammation (post immunisation), little hyperalgesia occurred. Following arthritis onset there was a rapid decrease in both mechanical (Fig. 1) and thermal thresholds, reaching a maximum at 7–10 days after onset. Thermal threshold returned to naive levels 24 days following arthritis onset, while mechanical hyperalgesia remained throughout the study. Increased glial fibrillary acidic protein expression was detected in the spinal cord from the day of arthritis onset, indicating that astrocytic activation occurs in CIA. This is in agreement with a well-established inflammatory model used for the study of pain, complete Freund’s adjuvant-induced monarthritis. Our results indicate that CIA can be used in the study of pain, and that changes occur in the nociceptive system during inflammation. As CIA is a well-established and validated model of RA, it may be of benefit to test analgesics aimed at inflammatory pain in this model and to understand the mechanisms involved in inflammatory hyperalgesia.

Acknowledgement This work is supported by GlaxoSmithKline.

P121

Association of FCGR3A and FCGR3B haplotypes with rheumatoid arthritis and primary SJögren’s syndrome

S Mackie1, JI Robinson2, JH Barnett3, CA Lawson3, S Martin3,4, LH Haroon-Rashid1,2, D Cooper1,2, SI Bowman4, CT Pease5, PG Conaghan6, M Green7, M Quinn7, JD Isaacs1,2, P Emery8, AW Morgan1,2

1Academic Unit of Musculoskeletal Disease, University of Leeds, UK; 2Molecular Medicine Unit, University of Leeds, UK; 3Cancer Research UK Genetic Epidemiology Division, University of Leeds, UK; 4Rheumatology Department, University Hospital Birmingham (Selly Oak), Birmingham, UK; 5School of Clinical Medical Sciences (Rheumatology), University of Newcastle-Upon-Tyne, UK

Background Rheumatoid arthritis (RA) is an autoimmune disease that is thought to arise from a complex interaction between multiple genetic factors and environmental triggers. We have previously demonstrated an association between a Fc gamma receptor (FcγR) haplotype and RA in a cross-sectional cohort of RA patients. We have sought to confirm this association in an inception cohort of RA patients and matched controls. We also extended our study to investigate a second autoantibody associated rheumatic disease, primary SJögren’s syndrome (PSS).

Methods The FCGR3A-158F/V and FCGR3B-NA1/NA2 functional polymorphisms were examined for association in an inception cohort of RA patients (n = 448), and a well-characterised PSS cohort (n = 83) from the United Kingdom. Pairwise disequilibrium coefficients (D’) were calculated in 267 Blood Service healthy controls. The EHLplus program was used to estimate haplotype frequencies for patients and controls and to determine whether significant linkage disequilibrium was present. A likelihood ratio test is performed to test for differences between the haplotype frequencies in cases and controls. A permutation procedure implemented in this program enabled 1000 permutations to be performed on all haplotype associations to assess significance.

Results There was significant linkage disequilibrium between FCGR3A and FCGR3B (D’ = -0.445, P = 0.001). There was no significant difference in the FCGR3A or FCGR3B allele or genotype frequencies in the RA or PSS patients compared with controls. However, there was a significant difference in the FCGR3A FCGR3B haplotype distributions with increased homozygosity for the FCGR3A-FCGR3B 158V/NA2 haplotype in both our inception RA cohort (odds ratio = 2.15, 95% confidence interval = 1.1–4.2, P = 0.027) and PSS (odds ratio = 2.83, 95% confidence interval = 1.0–8.2, P = 0.047) compared with controls.

Conclusions We have confirmed our original findings of association between the FCGR3A-FCGR3B 158V/NA2 haplotype and RA in a new inception cohort of RA patients. This suggests that there may be an RA-susceptibility gene at this locus. The significant increased frequency of an identical haplotype in PSS suggests the FcγR locus may contribute to the pathogenesis of diverse autoantibody-mediated rheumatic diseases.

Acknowledgements SM and JR are joint first authors. This work was funded by the Arthritis Research Campaign.

P122

Non-traditional risk and protective factors for cardiovascular disease in systemic lupus erythematosus

A Cederholm1, E Svennungsson2, D Stengel3, G-Z Fei4, AG Pockley4, E Ninio5, J Frostegård1

1Department of Medicine, CIM and CME, Karolinska University Hospital, Huddinge, Sweden; 2Department of Rheumatology, Karolinska University Hospital, Solna, Sweden; 3INSERM U 525/IFR14 Ceur Muscule Vaissaeux and Université PM Cure/Faculte de Medicine Pitil-Salpêtrière, Paris, France; 4Division of Clinical Sciences (North), University of Sheffield, UK


Background There is an important inflammatory and autoimmune component to atherosclerosis and cardiovascular disease (CVD). It is therefore interesting that the risk of CVD is so exceedingly high in patients with systemic lupus erythematosus (SLE).

Objective To investigate the role of non-traditional risk and protective factors for CVD related to inflammation and immune activation in SLE-associated CVD.

Methods Twenty-six women (52 ± 8.2 years) with SLE and a history of CVD (SLE cases) were compared with 26 age-matched women with SLE and no clinical manifestations of CVD (SLE controls) and 26 age-matched healthy women (population controls). As a surrogate measure of atherosclerosis, common carotid intima-media thickness and plaque occurrence were detected by B-mode ultrasound. Circulating levels of oxidized low-density lipoprotein (LDL) were measured by a mAb-4E6-based competition ELISA. Several novel non-traditional risk factors identified by us and others were determined in serum: heat shock protein (HSP)-related factors (Hsp60, Hsp70 and anti-human Hsp60, anti-human Hsp70 and anti-mycobacterial Hsp65 antibody levels), platelet activating factor-acyetylhydrolase activity (PFA-AH) and secretory phospholipase A2 G1a (sPLA2). Anti-bodies against endothelial cells (aEC) were measured by in-house ELISA.

Results The circulating levels of oxidized LDL and activity levels of PFA-AH, but not HSP-related measurements, aEC antibodies or sPLA2, were significantly raised in SLE cases. Oxidized LDL levels and PFA-AH discriminated between SLE controls and SLE cases (P = 0.0282 or P = 0.008, respectively). PFA-AH was significantly associated with LDL and cholesterol among SLE/CVD (r = 0.50, P = 0.009 and r = 0.54, P = 0.004), but not in the other groups tested.

Conclusion The difference in oxidized LDL levels between SLE cases and SLE controls may indicate that increased LDL modification by oxidation is one of the underlying factors implicated in SLE-related CVD. The association between PAF-AH and LDL adds support to the notion that PAF-AH, which binds to LDL, might contribute to atherogenesis in SLE patients. We cannot exclude that PAF-AH is simply a secondary marker of other as yet unknown processes. The role of HSP-related measurements in CVD in general is complex, since aHSP65 appears to be atherogenic while HSP70 may be protective. In the present cross-sectional study, the HSP-related measurements and those of aEC and sPLA2 were not associated with SLE.

P123

Immunomodulatory effect of unpulsed-immature dendritic cells in collagen-induced arthritis

PL Pilewski1, F Apparailly2, LM Van Duivenvoorde2, LM Charbonnier3, REM Toes4, C Jorgensen1

1INSERM U475, Hospital LaPeyronie, service Immuno Rhumatologie, Montpellier France; 2Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands


Objective Dendritic cells (DC) play an important role for initiation and regulation of immune response. Recent experimental evidence points out the fact that immature dendritic cells (iDC) can mediate tolerance, presumably by the induction of regulatory T cells. Therefore, we explored the effects of iDC injection on the development of collagen-induced arthritis in mice and compared them with tumour necrosis factor-matured DC, which we were previously shown efficient in collagen-induced arthritis.

Methods Murine bone marrow-derived DC where cultured in the presence of GM-CSF and IL-4 for 6 days and were incubated or not for 24 hours with bovine type II collagen (bCII). The immature phenotype of DC was controlled by flow

Available online http://arthritis-research.com/supplements/7/S1
cytometry, IL-12p40 secretion and MLR assays. The iDC were repetitively injected 7, 5 and 3 days before arthritis induction with bCII. Mice were boosted on day 21 and the disease course was monitored until day 50. Paw swellings were measured over time, and radiological and histological analyses of paws were performed at euthanasia. The antigen-specific T-cell proliferative response of spleen cells, the Th1/Th2 cytokine production, and the serum levels of IgG1/ IgG2a, anti-bCII antibodies were measured.

Results The repetitive injection of tumour necrosis factor alpha-modulated DC loaded with bCII protects the mice from severe arthritis. This protective effect is antigen dependent of the DC loading with bCII. The immunosuppressive effect is associated with a decrease of the anti-bCII antibodies from the IgG2a isotype, together with the inhibition of interferon gamma synthesis and the decrease proliferation of anti-bCII-specific cells.

Our data show that repetitive injection of immature unloaded DC protects the animals significantly as 70% of the mice did not develop clinical signs of the disease. We quantitated the various regulatory populations in the vaccinated mice, and observed in the liver and spleen an increase of the T-cell population expressing the CD49b molecule (DX5 cells). The relevance of this population in induced protection is under investigation.

Conclusion The use of iDC to modulate the autoimmune response is a rational approach for cell therapy in diseases such as rheumatoid arthritis.

P124 Cytokine expression was assessed during antigen-induced arthritis in the synovial membrane, inguinal lymph node, and spleen using competitive RT-PCR and sandwich ELISA RW Kinne, D Pohlers, A Siegling, E Buchner, CB Schmidt-Weber, E Palombo-Kinne, F Emmrich, R Bräuer

Experimental Rheumatology Unit, Friedrich Schiller University, Jena, Germany


In the synovial membrane, early mRNA expressions of IL-1β and IL-6 (6 hours; 450- fold and 200-fold, respectively) positively correlated with the joint swelling. A sifold tumour necrosis factor alpha increase was not significant. Not only IL-2 and interferon gamma (IFN-γ) (104-fold and 200-fold, respectively), but also IL-5 and IL-10 increased acutely (6 hours– day 1; threefold and 35-fold, respectively). In general, the protein levels for IL-1β, IL-6, tumour necrosis factor alpha, IFN-γ, IL-4, and IL-10 (increase between fourfold and 15-fold) matched the course of mRNA expression.

In the inguinal lymph node there were early mRNA elevations of IL-6 (6 hours; 2.5-fold; positively correlated with the joint swelling) and IL-2 (6 hours; fourfold), as well as later rises of IL-4 and IL-5 (day 3; 2.5-fold and fourfold, respectively). At the protein level no significant elevations were observed in comparison with day 0, except for IL-1β (day 6) and IL-10 (day 1).

In the spleen, there were significant mRNA elevations at 6 hours of IL-1β (1.5-fold), IL-6 (fourfold; positively correlated with the joint swelling), IFN-γ (threefold), and IL-2 (sevenfold to 10-fold), IL-5 and IL-10 (twofold and threefold, respectively) peaked, GM-CSF, GM-CSF to day 3. Increases at the protein level were significant compared with day 0 only in the case of IL-2 (day 6).

By day 6 (transition to the chronic phase) the mRNA for cytokines declined to or below pre-arthritis levels in all organs, except for IL-1β in the synovial membrane and IL-6 in the spleen. antigen-induced arthritis is thus characterized by: early synovial activation of macrophages, Th1-like, and Th2-like cells; late, well-segregating Th2-like responses in the inguinal lymph node; late, overlapping Th1-like/Th2-like peaks in the spleen; and chronic elevation of synovial IL-1β mRNA and spleen IL-6 mRNA.

P125 Long-term immune reconstitution after autologous stem-cell transplantation for severe autoimmune diseases T Alexander1, G Massenkeil2, E Gromnica-Ihle3, GR Burmester1, A Radbruch1, R Arnold4, F Hiepe4, A Thiel4

1Department of Rheumatology and Clinical Immunology, University Hospital Charité, Berlin, Germany; 2Department of Hematology and Oncology, University Hospital Charité, Berlin, Germany; 3Rheumaklinik Berlin Buch, Germany 4German Rheumatism Research Center Berlin, Germany


Objectives We performed a detailed analysis of the newly developing immune system in patients treated with autologous stem-cell transplantation (ASCT) for severe autoimmune diseases with special respect to the origin and the kinetics of repopulating B-cell and T-cell subsets in correlation to the clinical response.

Methods Peripheral blood lymphocytes were analyzed using multiparameter flow cytometry, including monitoring of the TCR-Vbeta repertoire on CD4+ Th cells. Thymic activity was determined assessing absolute counts of peripheral blood CD3+ CD4+ CD8- naive T cells.

Patients and results Thirteen patients with a median follow-up of 54 months have so far been included in the trial: polyarthritis (n = 1), systemic lupus erythematosus (SLE) (n = 6), systemic sclerosis (SSc) (n = 3), panniculitis (n = 1) and multiple sclerosis (n = 2). Clinical remission has been achieved in all patients with polyarthritis (n = 1), SLE (n = 6) and multiple sclerosis (n = 2) whereas we observed progression of disease in all patients with SSc (n = 3) and panniculitis (n = 1). One SLE patient relapsed after being free of any clinical and serological symptoms for 17 months.

T-lymphocyte compartments reconstituted functionally in all patients, indicated by the reappearance and persistence of CD45RA+CD31+ thymic naive Th cells in high numbers with high levels of T-cell receptor excision circles and restored diversity of the T-cell receptor repertoire. In terms of Th-cell memory no autoreactive Th cells could be detected in responding patients. Reconstituted B cells were primarily of naïve phenotype (IgD+CD27+) in the first 12–18 months after ASCT. As a cellular marker for disease activity, frequencies of CD19+CD27++CD52– plasma blasts, elevated in SLE patients prior to ASCT, normalized after treatment in all patients in case of the non-responding patients (n = 2). The CD20+ B cells were not affected by treatment. However, no major differences in the pattern of lymphocyte reconstitution could be detected as compared with responding patients.

Conclusion The newly developing immune system after immunosuppressive therapy could be characterized as ‘juvenile’ in all patients. However, in some patients the B-cell repopulation did not seem to be sufficient to regain self-tolerance. We conclude that both the resetting of central and peripheral tolerance and the efficient eradication of autoreactive lymphocytes seem to be a prerequisite for stable induction of remission.

P126 The effect of B-cell depletion with an anti-CD20 antibody on the immunoglobulin heavy-chain repertoire in a patient with rheumatoid arthritis A-S Rouzière1, C Kneitz2, T Dömer3, H-P Tony4

1Department of Medicine II, Rheumatology and Clinical Immunology, University of Wuerzburg, Germany; 2Charité University Hospital, Berlin, Germany


Purpose B-cell depleting therapy has been described to have beneficial effects to patients suffering from rheumatoid arthritis (RA). Nevertheless, the role of B cells in pathogenesis is not clear. In particular, it is not known whether B-cell depletion causes changes in the B-cell repertoire after peripheral regeneration. Therefore we analysed the distribution of the immunoglobulin heavy-chain (Ig H) genes usage of a RA patient before, 7 months and 17 months after anti-CD20 therapy with rituximab.

Methods A patient with active RA has been treated with four weekly doses of 375 mg/m² rituximab. During the treatment phase, prednisolone was elevated up to 12.5 mg daily for 4 weeks. After that, the patient remained on a stable dose of 7.5 mg prednisolone per day without any immunosuppressive drugs. Ig H genes amplified from genomic DNA of peripheral B cells by nested PCR using family-specific oligonucleotides. PCR products were subcloned and the sequences of more than 500 clones were analysed.

Results Following antibody treatment, the patient experienced a good clinical response lasting over 1 year. Before therapy, the overall VH gene usage of the RA patient was largely similar to the distributions expected from published data for normal individuals, except for certain genes (4-34, 1-69, 3-07), which have already been reported with a biased distribution in autoimmune disorders. In addition, several clonally related sequences were found in the VH5 family. B-cell regeneration occurred 7 months after anti-CD20-anitbody therapy. Significan changes in the distribution of different genes could be observed: 4-34 and 1-69 decreased to a proportion that would be expected in healthy individuals. Clonally related sequences were not found anymore. A greater overall variety of the VH gene segments used was observed, in particular in the larger families like VH4 and VH9. Interestingly, somatic hypermutation was significantly enhanced at the time point of B-cell regeneration.

Seventeen months after therapy, the general distribution of the VH genes was comparable with that observed before treatment, except for some genes (4-34 remained at the level found after therapy). No clonally related sequences were found. Somatic hypermutation was significantly reduced to the frequency determined before therapy.

Conclusion B-cell depletion by anti-CD20 monoclonal antibody leads to a significant modulation of the expressed immunoglobulin-VH gene repertoire after B-cell regeneration, which is accompanied with a clinical benefit in a single patient.

P127 Direct analysis of bone turnover in experimental arthritides K Poizler, B Tuerk, K Redlich, S Hayer, J Smolen, G Schett

Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria


Introduction Chronic arthritis usually leads to loss of periarticular bone. Inflammatory bone loss results from an imbalance between bone formation and bone resorption. Recent research has focused on the role of osteoclast formation and
To assess bone resorption and bone formation simultaneously, we developed a histological technique that allowed visualization of osteoblast function by in situ hybridization for osteocalcin and osteoclast function by histochemistry for tartrate-resistant acid phosphatase simultaneously on the same section. Paw sections from human femurs necrosis factor transgenic mice, which develop erosive arthritis, were analyzed at three different sites: subchondral bone erosions, adjacent Haversian bone channels and endosteal regions distant from bone erosions.

**Results** In subchondral bone erosions, resorption sites were far more common than formation sites. Thus, both the areas covered by osteoclasts as well as numbers of osteoclasts showed a fivefold increase compared to the area covered by osteoblasts and osteoblast numbers, respectively. In contrast, adjacent Haversian channels showed a completely different bone turnover, with functional osteoblasts significantly more frequent than osteoclasts. Bone turnover in Haversian channels was even higher (50% bone surface covered by osteoclasts or osteoblasts) than in subchondral bone erosions (30%). At endosteal sites distant from bone erosions, bone turnover was far lower (6%) and again bone formation exceeded bone resorption.

**Conclusion** These data indicate that bone resorption dominates at skeletal sites close to synovial inflammatory tissue, whereas more distant sites such as the Haversian channels attempt to counterregulate this process by increased bone formation.

**P128**

**Antibodies to ferritin in rheumatoid arthritis are associated with disease severity**

D Mewar, DJ Moore, PF Watson, AG Wilson

1Division of Genomic Medicine, University of Sheffield, UK; 2Department of Radiology, Royal Hallamshire Hospital, Sheffield, UK; 3Division of Clinical Sciences North, University of Sheffield, UK

**Background and objectives** A number of autoantibodies have been described in individuals with rheumatoid arthritis (RA) leading to interest in their use as diagnostic or prognostic markers in RA as well as their pathogenic relevance. By immunoscreening of a phase-display expression cloning system with RA patient sera we isolated a CDNA clone encoding the ferritin H chain polypeptide. The objectives of this study was to establish the frequency and clinical associations of anti-ferritin antibodies in RA.

**Methods** We employed an ELISA for the measurement of anti-ferritin antibodies in RA sera. Briefly, 96-well plates were coated overnight with purified ferritin from equine spleen. Sera diluted 1 in 100 were reacted with the plates for 16 hours at 4°C. After three washes, a goat anti-human IgG/horseradish peroxidase conjugate was used to detect bound IgG. The signal for each serum sample was non-linearised using a reference serum included on each plate. Anti-ferritin antibodies were measured in 291 subjects with RA, 73 healthy blood donors and 91 subjects with osteoarthritis. Antibody-positive and antibody-negative individuals were compared with respect to severity of disease as measured by modified Larsen’s score, demographic variables, rheumatoid factor status and carriage of HLA DRB1 shared epitope alleles. Correlations were examined between antibody levels and severity of joint damage assessed by the Modified Larsen’s score.

**Results** Using a cut-off index of three standard deviations above the mean of the control group, 49/291 (16.8%) RA patients were positive versus 2/73 (2.7%) healthy donors and 2/91 subjects with osteoarthritis (P < 0.01). In six positive and six negative sera these findings were confirmed by western blotting. Anti-ferritin antibodies were more common in males with RA (25.3% males versus 13.7% females, P < 0.02) and levels were positively associated with severity of joint damage (R = 0.33, P = 0.02).

**Conclusions** Anti-ferritin antibodies are present in a subset of individuals with RA and are associated with more severe joint damage. Ferritin is an abundant protein in serum and synovial fluid, and therefore ferritin/anti-ferritin immune complexes could form in these individuals and contribute to joint damage. An alternative possibility is that anti-ferritin antibodies could modulate the iron-binding properties of ferritin and so lead to the release of toxic-free iron in the joint. We are currently examining the frequency of anti-ferritin reactivity in patients with early RA at two timepoints in order to establish whether or not these antibodies are present in early disease or are simply a result of longstanding disease, as well as their frequency in other autoimmune diseases. These data will be presented.

**P129**

**Polymorphism within the telomeric MHC and expression of rheumatoid arthritis candidate genes**

D Mewar, I Marinou, JM Timms, R Kilding, AG Wilson

Division of Genomic Medicine, University of Sheffield, UK


**Background and objectives** Several recent studies have indicated a second susceptibility locus for rheumatoid arthritis (RA) in the telomeric MHC close to the tumour necrosis factor locus, a region containing a number of genes of unknown function including HLA-B associated transcripts 1 and 2 (BAT1 and BAT2) and lymphotixin alpha (LTA). Single-nucleotide polymorphisms have been described in this region and their functional significance is not known. In this study we sought to examine the association of individual single-nucleotide polymorphisms with expression of each mRNA transcript in response to an inflammatory stimulus.

**Methods** Peripheral blood mononuclear cells were collected from healthy blood donors and adherent cells were allowed to differentiate into macrophages by culture in the presence of 5% serum for 7 days. Cells were then stimulated with 100 ng/ml lipopolysaccharide and harvested at 4-hour and 18-hour timepoints. Total RNA was prepared using standard methods and reverse transcription performed. Resulting cDNA was used as a template for real-time PCR using gene-specific primers for each gene. Each PCR product was detected with the double-stranded DNA-binding dye SYBR Green® I (Applied Biosystems, Foster City, CA, USA) and the ABI 7900HT sequence detection system (Applied Biosystems). Quantification was performed using standard curves generated from plasmid DNA containing each cloned PCR product and 18s was used as a loading control. Levels of mRNA transcripts were expressed in relative units (RU). Genotyping was performed for the BAT1 –991 (1751673), BAT2 (1688185), LTA (1720807) and TNF –308 (1718089) polymorphisms using TaqMan allelic discrimination assays. Expression levels of each mRNA transcript were compared between individuals of genotype 1.1, 1.2 and 2.2 using Kruskal–Wallis tests.

**Results** Expression of BAT1 mRNA transcripts was significantly less in BAT1 –991 2.2 individuals (n = 6) compared with both 1.1 (n = 6) and 1.2 (n = 5) (median levels 0.22 RU compared with 0.76 RU and 1.1 RU, respectively) (P < 0.02). Expression of BAT2 transcripts was lower in 1.1 individuals relative to both 1.2 (n = 8) and 2.2 (n = 4) genotypes (median levels 0.43 RU compared with 0.77 RU and 0.82 RU, respectively) (P = not significant). For LTA expression, individuals of genotype 2.2 (n = 4) produced the highest levels, those of genotype 1.1 (n = 6) the lowest, with those of 1.2 genotype (n = 6) intermediate (median levels 0.91 RU compared with 0.81 RU and 2.1 RU, respectively) (P = 0.02). Expression of all three transcripts had fallen to low levels by the 18-hour timepoint and no differences were apparent between individuals of different genotype.

**Conclusions** Polymorphism in the BAT1 –991, BAT2 and LTA genes are associated with levels of each mRNA transcript produced in response to an inflammatory stimulus. This suggests the possibility that they may be able to influence susceptibility to RA, and that the protein products they encode may play a role in inflammatory signalling. We are currently extending this genotype–phenotype analysis to the other members of this gene cluster particularly 1G7, LST1 and A1F1.
also prevented oxidative stress in PB T cells exposed to SF monocytes, which suggested a central role for CD28. PB T cells were therefore stimulated with TNF-α, interferon gamma, IL-1β, or transforming growth factor beta, in the presence or absence of anti-CD28. Here we found that stimulation with anti-CD28 by itself was sufficient to induce Rap1 inhibition and induce a moderate increase in ROS production. Co-incubation of PB T cells with TNF-α strongly enhanced the intracellular ROS production.

Conclusion In vitro exposure of PB T cells from rheumatoid arthritis patients to synovial monocytes leads to a strong increase in intracellular ROS production. This is mediated by simultaneous Ras activation and inhibition of Rap1. Where Ras can be activated by a variety of stimuli, Rap1 inhibition is induced by SF monocytes through CD28 costimulatory signaling.

P131 Molecular response to cartilage injury

F Dell’Accio, C De Bari, C Pitzalis

Department of Rheumatology, King’s College London, UK


Background Post-traumatic osteoarthritis (OA) represents 13% of all OA of the knee, 9% in the hip, and 73% of all OA of the ankle [1]. The molecular mechanisms that underlie the development of chronic joint surface degeneration following a localised, acute joint injury are not known. The aim of this study is to utilise the cartilage explant model system to identify molecular mechanism of cartilage damage and repair induced by acute mechanical injury.

Methods Explants of articular cartilage from preserved areas of the femoral condyles or the patellar groove of patients undergoing total knee prosthesis were cultured in vitro under different conditions. After 4 days in culture the samples were subjected or not to mechanical injury by performing full thickness cuts at a distance of 1 mm. At different time-points the explants were partly snap-frozen for further histochecmical/immunohistochemical evaluation and partly used for RNA extraction and RT-PCR analysis. The original cartilage was graded using the Mankin score.

Results Gene regulation was detected as early as 4 hours and lasting for at least 6 days after mechanical injury. BAX mRNA, possibly associated with apoptosis of chondrocytes, MMP-3 and TIMP-1 mRNA were upregulated in the injured explants. BMP-2 mRNA was also upregulated by mechanical injury. We could not detect changes upon damage of cell proliferation as measured by PCNA mRNA levels at the analysed time points.

Conclusions The explant model system represents a controlled experimental set-up to study the molecular mechanisms of cartilage degeneration in post-traumatic OA and to identify potential molecular targets for its prevention.

Reference


P132 Binding properties of anti-histone H1 antibodies suggest that nuclei of necrotic cells rather than cells undergoing apoptosis are engulfed in the LE cell phenomenon

E Feierl, JS Smolen, T Karontsch, GH Stummvoll, H Ekhart, CW Steiner, M Aringer

Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria


Background The LE cell phenomenon is a classical test for systemic lupus erythematosus (SLE). Granulocytes engulf bodies, the nature of which has not been unequivocally demonstrated. Hypothoses range from isolated nuclei to intact cells undergoing apoptosis. Using the fact that it is autoantibodies to histone H1 that induce this phenomenon, which thus have to bind the material in question, we investigated histone H1 accessibility to antibodies.

Methods Polymorphonuclear cells (PMNC) were isolated by centrifugation from human peripheral blood using the 1.077 g/ml Ficoll Paque. Cells were either used while vital or after the induction of apoptosis (using glotoxin for PMNC and actinomycin D for peripheral blood mononuclear cells) using a FITC-labelled F(ab’2)2 fragment, as well as by SLE sera testing positive for the LE cell phenomenon and healthy control sera.

Results Apoptosis and necrosis were reliably induced in both PMNC and lymphocytes. The mononuclear anti-histone H1 antibody and a matched control antibody together with a FITC-labelled F(ab’2)2 fragment, as well as by SLE sera testing positive for the LE cell phenomenon and healthy control sera.

Conclusions Since, on cells undergoing apoptosis, histone H1 is not accessible to specific antibodies, necrotic cells or isolated nuclei must be engulfed in the LE cell phenomenon.
end of the experiment. Angiogenesis was quantified by counting both the isolated endothelial cells and vessels stained on each slide. To evaluate the effect of an angiogenesis increase on CIA, vascular endothelial growth factor (VEGF) gene transfer was performed with adenov-associated virus VEGF (AAV-VEGF) injection in the muscles of mice with CIA (1010 AAV-VEGF particles intramuscularly 3 weeks before CIA induction). The AAV vectors used in this study contained either mVEGF164 (AAV-VEGF) or lacZ (AAV-lacZ) cDNA, whose expression were driven by the cytomegalovirus promoter. Results As expected, clinical and histological scores of arthritis, evaluated each week from day 0 to day 55 after induction of CIA, were correlated (P < 0.0001, r = 0.74, Spearman correlation test). More importantly, angiogenesis increased as a function of the disease course. A correlation was observed between joint vascularization and clinical scores of arthritis (P < 0.0001, r = 0.61). A correlation was also shown between vascularization and histological scores (P = 0.0003, r = 0.61). The overexpression of VEGF induced by gene transfer was followed by an aggravation of arthritis as compared with the AAV-lacZ control group (P < 0.0001, analysis of variance test); Histological and quantification of angiogenesis are in progress in this experiment. Conclusion Angiogenesis and inflammation evolved in the same way during the course of CIA. Stimulation of angiogenesis in mice with CIA led to a worse clinical inflammation. These results suggest an early involvement of angiogenesis in joint inflammation development, and emphasize the critical role of angiogenesis in chronic inflammatory arthritis. Acknowledgement GC was supported by Societe Francaise de Rhumatologie.
P138

Autoreactive T cells to histone H1 and core histones in patients with systemic lupus erythematosus

GH Stummvoll, R Fritsch, B Meyer, M Aringer, JS Smolen, G Steiner
Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria


Background Autoantibodies directed against nucleosomal antigens such as dsDNA and histones are a hallmark of systemic lupus erythematosus (SLE). Histone H1 constitutes the major antigen in LE cell formation and antibodies to H1 have been shown to be more specific for SLE than other anti-histone antibodies [1,2]. In order to address the role of histone H1-specific T cells in SLE we investigated the ex vivo cellular reactivity to histone antigen in SLE patients and controls, and characterized H1-specific T-cell clones.

Methods Peripheral blood mononuclear cells of 39 SLE patients and 20 healthy controls (HC) were exposed to purified histones (H1, H2A, H2B, H3, H4), and proliferation as well as cytokine production was measured. In addition, H1-specific T-cell clones were drawn by limiting-dilution cloning of T-cell lines. T-cell phenotyping was done by FACS analysis and the cytokines IL-4, IL-10 and tumour necrosis factor alpha (TNF-α) were detected in the supernatants by ELISA.

Results After stimulation with histone H1, SLE patients showed a significantly elevated proliferative response as measured by stimulation indices (SI) when compared with HC (SI mean ± SD: 2.2 ± 1.4 versus 1.5 ± 0.4, P < 0.03) and a positive response (i.e. SI > 2) in 16 patients compared with only two responders among HC (Fig. 1). The proliferative response to H2A was also elevated in SLE patients (SI, 2.9 ± 2.5 versus 1.7 ± 0.8 in HC, P < 0.03), whereas the response to H2B, H3 and H4 did not differ between patients and HC. Cellular responses to H1 correlated with the presence of anti-histone antibodies but not with clinical features or SLE disease activity. H1-specific T-cell clones obtained from one SLE patient and two HC showed a Th1-like phenotype producing large amounts of IFN-γ and TNF-α but no IL-4.

Conclusion The increased Th1 autoreactivity to histones H1 and H2A in SLE patients suggests that these T cells play an important role in the pathogenesis of SLE not only by driving autoimmune responses but also by virtue of production of the proinflammatory cytokines IFN-γ and TNF-α.

References

Figure 1

Elevated proliferative responses to histone H1 in patients with systemic lupus erythematosus (SLE). Proliferation of peripheral blood mononuclear cells from 39 SLE patients and 20 healthy controls (HC) was analysed by measuring [3H]Thdr incorporation, and a stimulation index (SI) > 2 was considered a positive response.

P140

Microparticles from inflammatory cells are strong inducers of matrix metalloproteinases and inflammatory cytokines in synovial fibroblasts

JHW Distler1, A Jüngel2, A Huber3, A Seemayer4, RE Gay5, BA Michel6, JR Kalden7, S Gay5, DS Pjetsky8, O Distler1

1Center of Experimental Rheumatology, University Hospital Zurich, Switzerland; 2Medizinische Klinik III, University Erlangen–Nuremberg, Germany; 3Division of Rheumatology, Duke University Medical Center, Durham, North Carolina, USA


Background Microparticles (MPs) are membrane-bound vesicles that are released from cells during cellular activation and apoptosis. Synovial fluids from patients with rheumatoid arthritis contain high numbers of MPs. Here we address the effects of monocyte-derived and T-cell-derived MPs on rheumatoid arthritis synovial fibroblasts (RASF).

Methods Apoptosis of Jurkat T cells, U937 macrophages and primary cells was induced by FasL, actinomycin-D, tumour necrosis factor alpha and staurosporine. Cells were also stimulated with IL-2, concanavalin A, anti-CD3 and lipopolysaccharide. Isolation of MPs was performed by differential centrifugation. The presence of MPs was confirmed by FACS analysis for annexin V and CD3 or CD14. Normal synovial fibroblasts, osteoarthrisis synovial fibroblasts and RASF were incubated with MPs for 6–36 hours. Differentially expressed genes were analyzed by real-time PCR and confirmed on the protein level.

Results The release of MPs was induced in apoptotic as well as stimulated cells. Morphological analysis of MPs by electron microscopy showed a population of circular membrane blebs ranging from 200 to 700 μm. MPs from all cell types induced strongly the synthesis of mRNA for MMP-1 (72 ± 13-fold), MMP-3 (80 ± 10-fold), MMP-9 (18 ± 4-fold) and MMP-13 (37 ± 2-fold) in RASF in a dose-dependent manner. Similar effects were seen on osteoarthrisis synovial fibroblasts and normal synovial fibroblasts. The induction of matrix metalloproteinases (MMPs) was time dependent, with effects primarily seen after 36 hours. The dose-dependent upregulation of biologically active MMPs was also observed on the protein level. The induction was specific for the aforementioned MMPs with no induction seen for MMP-2, MMP-14 or TIMP-1, TIMP-2 and TIMP-3. MPs also increased the synthesis of mRNA for IL-8 (65 ± 3-fold), IL-8 (35 ± 3-fold), MCP-1 (5 ± 1-fold) and MCP-2 (27 ± 3-fold) in synovial fibroblasts. No differences in cell viability were observed between fibroblasts stimulated by MPs and controls. In IL-8-transfected RASF, MPs were 50–75% less inducible by MPs compared with wild-type synovial fibroblasts. The stimulation of NF-κB-dependent pathways by MPs was confirmed by EMSA.

Perspective By showing induction of various MMPs and inflammatory cytokines by MPs, these data provide a novel link between activated and apoptotic inflammatory cells and the invasive potential of synovial fibroblasts in rheumatoid arthritis.

P139

CCL21 relationship with lymphoid neogenesis and lymphatic vascular system in chronically inflamed synovium

A Manzo1, S Bugatti2, C Buckley3, D Jackson4, R Caporali2, C Montecucco2, C Pitizal3

1Rheumatology Unit, GKT School of Medicine, London, UK; 2Cattedra di Reumatologia, IRCCS Policlinico S. Matteo, Pavia, Italy; 3Department of Rheumatology, University Hospital, Birmingham, UK; 4Institute for Molecular Medicine, John Radcliffe Hospital, Oxford, UK


Background CCL21 expression in secondary lymphoid organs is instrumental in mediating L-selectin+ CCR7+ naive T-cell and B-cell recruitment from the blood-stream via PNAd+ high endothelial venules (HEV). CCL21 is also constitutively produced by lymphatic vessels functioning as a recruiting factor for CCR7+ mature dendritic cells from peripheral tissues to regional lymphoid organs. The same factor participates to the inflammatory cascade being associated with lymphoid neogenetic events and being upregulated in peripheral lymphatic vessels, increasing the magnitude of T-cell response by favouring dendritic cell recruitment to draining lymph nodes.

Objectives In this study we analysed CCL21 protein and mRNA expression in rheumatoid synovium and its relationship with the organizational features of the inflammatory infiltrate and the vascular system (blood and lymphatic vessels).

Methods Thirty-one rheumatoid synovial samples characterized by a variable degree of inflammation and aggregational tendency were analysed by immunohistochemistry and in situ hybridization for CCL21. Molecular features of synovial vessels were analysed by immunohistochemistry for pan-vascular (CD31), HEV (PNAd) and lymphatic (LYVE-1) markers.

Results Two distinct patterns were recognized: vascular and non-vascular. Non-vascular CCL21-producing cells were specifically localized within lymphoid aggregates, frequently surrounding PNAd+ HEV. This pattern was demonstrated to be similar to human secondary lymphoid organs where, different from the mouse, no CCL21 mRNA was detected directly in HEV. In contrast, CCL21+ vessels did not show a specific association with lymphoid organization, lacking PNAd expression and being recognized inside but also outside perivascular aggregates. Serial section analysis demonstrated the colocalization of CCL21+ vessels with LYVE-1.

Conclusions This study emphasizes a differential regulation of CCL21 in the context of synovial lymphoid organization. The anatomical relationship of CCL21-producing cells with synovial PNAd+ HEV suggests its involvement in cellular homing although, contrary to the mouse, CCL21 is actually produced perivascularly. Furthermore, CCL21 colocalization with LYVE-1+ lymphatic vessels suggests multiple functions of CCL21 in mediating CCR7+ leucocyte synovial homing, intratissue clusterization and promoting exit via lymphatics to draining lymph nodes. These results define CCL21 potential roles in the pathogenetic cascade of rheumatoid synovitis.

References
FcγR-mediated uptake and processing of antigen–immunoglobulin complexes by professional antigen-presenting cells

JMH de Jong1, DH Schuurhuis2, A loan-Facnay3, EIH van de Voort1, TJW Huizinga1, F Ossendorp2, JS Verbeek1, REM Toes1

1Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; 2Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands; 3Department of Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. Arthritis Res Ther 2005, 7(Suppl 1):P141 (DOI 10.1186/ar1662)

Rheumatoid arthritis is characterized by the presence of autoantibodies. Various animal models for arthritis have shown a critical role for antibodies in the induction and progression of the disease, with complement and Fc receptors as the key effector mechanisms activated by antigen–antibody immune complexes (IC) in the effector phase of the disease. Although they are required for the perpetuation of the disease, the possible mechanisms by which Fc receptors could contribute to the chronic inflammation in arthritis are still unclear. It is known, however, that crosslinking FcγR on effector cells induces a variety of cellular responses, ranging from phagocytosis to secretion of inflammatory mediators and antibody-dependent cell cytotoxicity. Furthermore, FcγRs on dendritic cells (DC) are involved in the enhanced MHC class II-restricted presentation of antigen from IC to CD4+ T cells. Considering that also other antigen-presenting cells (APC) (like B cells and macrophages) express FcγR, this could be a possible mechanism of exacerbating/maintaining inflammation in arthritis. Therefore, we sought to explore the role of FcγR and complement in the MHC class II-restricted antigen presentation in vivo and to identify the APC involved in this process.

To gain more insight into the ability of various types of APC to take up and present IC to T cells in vivo, we infused ovalbumin (OVA)-IC into naive mice. Direct ex vivo isolation of the different APC subsets showed that only CD11c+ cells, but not macrophages and B cells, are able to (cross-)present efficiently antigen from IC to T cells, although both macrophages and DC are able to capture IC efficiently. Furthermore, depletion of CD11c+ cells, using transgenic mice, abrogated the enhanced presentation of antigen in IC, confirming that DC are the predominant APC involved in (cross-)presentation of IC.

To study the contribution of different FcγRs (FcγR IIb, FcγR IIa and FcγR III) in IC-facilitated antigen presentation, we injected OVA-IC in wild-type mice and FcγR-knockout mice that have received 3 days earlier CFSE-labeled OVA-specific T cells. Our results indicate that activation of OVA-specific T cells in vivo is 10 times more efficient upon uptake of antibody-complexed OVA than soluble OVA. This effect was absent in mice lacking FcγR IIa or FcγR III, but not in complement factor 3 knockout mice, indicating that the enhanced efficiency was FcγR mediated.

Together, these results indicate that the enhanced presentation of antigen in IC and the subsequent activation of T cells in vivo is mediated primarily by DC, not by macrophages or B cells. Therefore, we consider it more likely that the IC-mediated contribution of macrophages to rheumatoid arthritis is associated with the release of proinflammatory cytokines and molecules upon activation induced by FcγR crosslinking, than to the enhanced activation of autoreactive CD4+ T cells. The ability to orchestrate and steer the T-cell responses is the responsibility of DC, further emphasizing the crucial role of DC in controlling (ongoing) T-cell responses.

P142 Treatment of collagen-induced arthritis with cholera toxin-treated dendritic cells

G Criado1, JJ Inglis, MF Feldmann, RO Williams


Dendritic cells (DC) are professional antigen-presenting cells with the unique ability to stimulate naïve T cells and to trigger strong immune responses. However, DC have also shown tolerogenic ability in several systems under certain conditions, depending on their differentiation/activation status. In particular, treatment of DC with cAMP-elevating agents provides a therapeutic tool for the treatment of antigen-specific autoimmune disorders.

Our objective was to study the effect of cholera toxin (CTx)-treated DC in the development of mouse collagen-induced arthritis (CIA), a well-established animal model of rheumatoid arthritis. CTx was chosen because it maintains sustained high cAMP levels by irreversibly binding to adenylate cyclase.

Arthritis was induced by intradermal injection of 200 µg bovine type II collagen (bCII) in complete Freund’s adjuvant in the base of the tail of male DBA/1 mice. Bone marrow-derived DC, loaded with bCII (50 µg) and treated with CTx (1 µg/ml), were injected at the time of immunization. Arthritis incidence and severity was assessed for 21 days following arthritis onset. For in vitro analysis of the effect of DC in T-cell activation, lymph nodes from bCII-immunized mice were collected before arthritis onset and stimulated with CTx-treated DC. Proliferation and interferon gamma production were determined by thymidine incorporation and capture ELISA, respectively. Injection of CTx-treated DC resulted in a decreased arthritis incidence (Fig. 1) and reduced severity, compared with non-DC treated animals. This effect required the combination of CTx and antigen specificity, as DC treated with CTx in the absence of bCII, as well as non-treated DC in the presence of bCII, did not show a significant reduction in the incidence of arthritis. Furthermore, treatment with DC alone results in an acceleration of disease progression.

In vitro analysis of T-cell responses revealed that CTx-treated DC were able to inhibit both proliferation and interferon gamma production from lymph nodes of immunized mice. Interestingly, this inhibition was not antigen specific, as it was also observed in the absence of bCII, suggesting that additional mechanisms are involved in the reduced arthritis incidence observed in vivo. In summary, our data indicate that manipulation of dendritic cell activity with cAMP-elevating agents provides a therapeutic tool for the treatment of antigen-specific autoimmune disorders.

P143 Decreased binding of annexin V to endothelial cells: a novel mechanism of atherothrombosis in patients with systemic lupus erythematosus

A Cederholm1, E Svenungsson2, K Jensen-Urstad3, C Trollmo2, A-K Ulf gren1, J Swedenborg1, G-Z Fei1, J Frostegård1

1Department of Medicine, CME, Karolinska University Hospital, Huddinge, Sweden; 2Department of Medicine, Rheumatology Unit and Center for Molecular Medicine, Karolinska University Hospital, Solna, Sweden; 3Department of Clinical Physiology, Södersjukhuset, Sweden; 4Department of Surgery, Karolinska University Hospital, Huddinge, Sweden. Arthritis Res Ther 2005, 7(Suppl 1):P143 (DOI 10.1186/ar1664)

Background Patients with systemic lupus erythematosus (SLE) are at high risk of cardiovascular disease, due to atherothrombosis in particular. The mechanistic mechanisms are not clear; however, recently annexin V, an anticoagulant protein, and antiphospholipid antibodies have been implicated.

Methods Twenty-six women (52 ± 8.2 years) with SLE and a history of cardiovascular disease (SLE cases) were compared with two age-matched control groups: 26 women with SLE but no cardiovascular disease (SLE controls) and 26 healthy women (population controls). Common carotid intima-media thickness was determined by B-mode ultrasound as a surrogate measure of atherosclerosis. Annexin V binding to human umbilical vein endothelial cells was assessed by flow cytometry after 24-hour culture with plasma. The presence of annexin V in carotid atherosclerotic plaques was determined by immunohistochemistry. Annexin V levels in circulation and anti-annexin IgG and IgM antibodies were measured by a commercially available high-sensitivity ELISA. Pooled sera with high capacity to inhibit annexin V binding were preabsorbed against different concentrations of antigens such as cardiolipin and against uncoated antigen tetanus toxoid. Annexin V-binding assay with flow cytometry was performed.

Results Binding of annexin V was significantly lower when plasma from SLE cases was used as compared with controls (SLE cases versus population controls P = 0.002, SLE cases versus SLE controls P = 0.02). There was a striking positive correlation between annexin V binding and intima-media thickness (R = 0.73, P < 0.001) among SLE cases. The annexin V levels were increased in SLE cases compared with both SLE controls and PC (P = 0.03 and P = 0.004), but no differences were detected in anti-annexin V IgG or IgM levels. Depletion of
IgG from sera with high capacity to inhibit binding of annexin V induced a 2.7-fold increase in binding and preincubation of sera with cardiolipin and phospholipid-choline resulted in increase of median fluorescence intensity of annexin V binding to human umbilical vein endothelial cells. Immunohistochemical analysis revealed the presence of annexin V in all plaques tested.

Conclusions Decreased annexin V binding to endothelium caused by immunoglobulin may represent a novel mechanism of atherothrombosis. Increasing annexin V binding may thus represent a novel therapeutic possibility.

P144

TLR-9, but not TLR-2, TLR-3 and TLR-4, is upregulated on peripheral blood mononuclear cells of patients with active systemic lupus erythematosus

ED Papadimitriou, E Koutala, G Bertias, C Choulaki, H Kritikos, P Sidiropoulos, DT Boumpas

Department of Rheumatology, University of Crete, Greece


Background Innate immune responses may augment adaptive immune responses via the adjuvant effect of endogenous apoptotic cell death derived nucleic acids that activate Toll-like receptors (TLRs). In animal models of lupus, activation of TLR-9 accelerates renal disease. We studied the expression of TLR-2, TLR-3, TLR-4 and TLR-9 in the peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE).

Materials and methods Peripheral blood mononuclear cells from 18 SLE patients, four patients with other rheumatic disorders and three normal controls were studied for the expression of TLRs by FACS analysis.

Results TLR-2, TLR-3, TLR-4 and TLR-9 expressions were studied in total lymphocytes, CD19+ and CD14+ cells. Disease activity was assessed by the SLEDAI. Patients were divided into those with active/severe disease and those with inactive/mild disease.

Results Eight out of 18 patients had active disease with mean SLEDAI score 12.3 (± 9.9), while 10 had inactive disease with mean SLEDAI score 2.9 (± 0.9). Lymphocyte expression of TLR-9 (mean value and standard deviation) was higher among patients with active/severe disease in comparison with patients with inactive lupus (64 ± 18%, n = 8 versus 19 ± 14%, P < 0.003) (Table 1).

Table 1

<table>
<thead>
<tr>
<th></th>
<th>Active disease</th>
<th>Inactive disease</th>
<th>Other rheumatic diseases</th>
<th>Healthy controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLR-9 in lymphocytes</td>
<td>64 ± 18</td>
<td>19 ± 14</td>
<td>22 ± 21</td>
<td>28 ± 3</td>
</tr>
<tr>
<td>TLR-9 in CD19+ cells</td>
<td>42 ± 20</td>
<td>25 ± 24</td>
<td>17 ± 14</td>
<td>33 ± 5</td>
</tr>
<tr>
<td>TLR-9 in CD14+ cells</td>
<td>31 ± 18</td>
<td>16 ± 13</td>
<td>6 ± 5</td>
<td>24 ± 13</td>
</tr>
</tbody>
</table>

There were no differences between patients and healthy controls regarding the expression of TLR-2, TLR-3 and TLR-4. The expression of TLR-9 on various B-cell subpopulations of patients with SLE is currently under investigation.

Conclusions TLR-9, but not TLR-2, TLR-3 and TLR-4, is upregulated in peripheral lymphocytes from SLE patients with active/severe disease compared with patients with inactive/mild disease. There is also a trend for increased expression of TLR-9 at least on CD19+ and CD14+ cells. Experiments in progress examine the response of these cells to TLR stimulation.

P145

Bystander-activated CD4+ memory lymphocytes: a role in the pathology of rheumatoid arthritis?

JT Beech, SH Owen, P Green, P Amjadi, FM Brennan

Kennedy Institute of Rheumatology Division, Imperial College Faculty of Medicine, London, UK


Background Previous studies in this laboratory have highlighted the importance of the proinflammatory cytokine tumour necrosis factor alpha (TNF-α) in the pathogenesis of rheumatoid arthritis (RA) and suggested a role for bystander-activated lymphocytes in its chronic production in the RA joint. Normal peripheral blood (PB) lymphocytes cultured in the presence of a ‘cocktail’ of inflammatory cytokines (IL-2/IL-6/IL-17)/NF-κα) generated effector cells (Teff) capable of inducing both monomucosalub production by B cells and TNF-α production by monocytes in a contact-dependent manner. This was in contrast to lymphocytes activated antigen dependently, via the T-cell receptor (TCR), which induced production of both TNF-α and the anti-inflammatory cytokine IL-10 [2,3]. Lymphocytes isolated from the RA synovial membrane exhibited contact-dependent cytokine induction properties similar to TCR, but not TLR, cells [4].

Objective We have examined the population dynamics and phenotypic changes induced in PB lymphocytes during culture with IL-2/IL-6/IL-17/n to determine how such cells resemble those found in the RA joint. As the predominant infiltrating lymphocyte population found to accumulate in the RA synovial membrane is the CD4+ T cell we have also explored the possibility of generating monocyte TNF-α-inducing effector cells from purified CD3+CD4+ populations.

Results Lymphocytes cultured with IL-2/IL-6/IL-17 for 8 days demonstrated a threefold expansion of the natural killer cell population, while the proportion of T cells remained static. However, both these natural killer and T-lymphocyte populations were independently able to induce contact-dependent TNF-α production in monocytes. Interestingly, effector cells generated by culture of the purified CD3+CD4+ fraction with IL-2/IL-6/IL-17 for 8 days were able to induce at least threefour fold more TNF-α production compared with such effectors generated from the corresponding unfractonated lymphocyte population. We subsequently characterised the different naive and memory cell populations found within the CD4+ fraction of our bystander-activated lymphocyte cultures (as defined by Lanzavecchia and colleagues [5]). Despite an overall net loss in the percentage and number of total CD4+ T cells, both naïve (CD45RA+CCR7+) and memory populations (effector:CD45RA–CCR7–; central CD45RO+CCR7+) were still present after 8 days of culture. However, a preferential retention of effector memory over central memory lymphocytes has been observed in most donors.

Further phenotypic studies have shown that bystander-activated lymphocytes also express high levels of components of the adhesion molecules VLA-1, VLA-4, VLA-5 and LFA-1 (β1, β2 and β4), but lower levels of L-selectin (CD62L). Such properties are associated with the ability of effector lymphocytes to migrate from lymphoid nodes and into tissues.

Conclusions Our results suggest that exposure of PB lymphocytes to a cocktail of proinflammatory cytokines induces the outgrowth of an activated effector memory lymphocyte population with the capacity to migrate to inflammatory sites. Studies currently underway will examine the effector function of different CD4+ memory lymphocyte subsets in terms of their ability to induce monocyte TNF-α production.

This work will more closely define pivotal cell types responsible for cognate-dependent cytokine production in diseased joints as well as advancing our understanding of the effects and consequences of prolonged cytokine exposure in chronic inflammation.

References


Acknowledgement This work was funded by the Arthritis Research Campaign, UK.

P146

In vivo induction of foxp3 in collagen-induced arthritis treatment with modified dendritic cells

G Falgarone, O Jaen, MC Boissier

Rheumatology APHP, UPRES EA-3408, Paris 13 University, Bobigny, France


We studied the prevention of a mice model of rheumatoid arthritis, the collagen-induced arthritis (CIA) model, with DNA-matured dendritic cell injection and then studied the induction of Treg through this innate immunity stimulation. CIA was induced as described in DBA/1 mice with bovine type II collagen intradermal injections. Intermediate DNA-matured dendritic cells were injected at D14 intraperitoneally. The clinical course of arthritis was followed and B-cell and T-cell responses were assayed. The induction of CD4+CD25+ was tested by flow cytometry and the induction of iNOS and the expression of iNOS was quantified by quantitative RT-PCR. Treatment of CIA with intermediate DNA-matured dendritic cells could prevent arthritis as well as lipopolysaccharide-matured dendritic cells. Neither B-cell and T-cell responses were not modified nor was a TH2 response observed.
Rheumatoid arthritis (RA) is characterized by chronic inflammation of joints, which can cause pain, swelling, and joint damage. The aim of the study was to analyze the occurrence of anti-citrullinated peptide (aCCP)-specific B cells in patients with rheumatoid arthritis (RA). The nature of the arthritogenic peptide is not known, but recent studies have identified post-translationally modified proteins containing citrulline as targets of anti-cyclic-citrullinated peptide (anti-CCP) autobody. It has been shown that in HLA-DRB1*0401 transgenic mice the conversion of arginine to citrulline at the peptide side chain position interacting with the SE significantly increases peptide–MHC affinity and leads to the activation of CD4+ T cells in the transgenic mouse.

Objective The aim of this work was to investigate the relationship between the HLA-DRB1 genotype, the prevalence of anti-CCP autoantibodies, and the frequencies of SE of anti-CCP autoantibodies in sera of patients with RA.

Methods HLA-DRB1 genotyping was performed using PCR sequence-specific primers from the DR low resolution kit and DRB1*01, DRB1*04 subtyping kits as well. IgG anti-CCP antibody levels were measured by the ImmunoscanRA ELISA kit.

Results SE is present in 75 (57.2%) and absent in 56 (42.7%) patients. The prevalence of anti-CCP autoantibodies is significantly higher in the group of SE-positive patients (n = 44, 76%) than in the group of SE-negative patients (n = 28) (P = 0.03; chi-squared test). The average autoantibody level measured in anti-CCP-positive patients carrying SE is 7427.7 U/ml while in the absence of SE alleles it is 437.5 U/ml, which does not differ statistically.

Conclusion Association of the SE and citrullinated antigens may be one of the triggers initiating the production of anti-CCP antibodies.

Acknowledgement This work was supported by the grant OTKA T037876.

P148
Endothelial function and activation in women with systemic lupus erythematosus

E Svenungsson, A Cederholm, K Jensen-Urstad, G-Z Fei, J Frostegard
Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Solna, Sweden


Background Cardiovascular disease (CVD) is common in systemic lupus erythematosus (SLE) patients although it is not clear whether an increased risk of CVD is a general feature of SLE, or whether this applies only to a subgroup of patients.

Objective To measure early signs of atherosclerosis/cardiovascular dysfunction in women with SLE with or without CVD and to control whether these correlate to circulating markers of endothelial activation.

Methods Twenty-six women with SLE and a history of CVD (defined as a history of objectively verified angina pectoris, myocardial infarction, cerebral infarction or intermittent claudication; age 52 ± 8.2 years) were compared with age-matched SLE women without CVD (SLE controls) and population-based age-matched control women (population controls). Flow-mediated dilatation (FMD) of the brachial artery after reactive hyperemia and after sublingual nitroglycerine administration was performed on women who were not already on nitro-related medication.

Results SLE controls and controls did not differ with respect to FMD after reactive hyperemia or after nitroglycerine administration. Only two SLE cases showed endothelial activation/inflammation and were measured in the circulation by use of the ELISA technique.

Conclusion Women with SLE who did not have manifest CVD did not differ from age-matched controls with respect to FMD, a measure of endothelial dysfunction. However, higher levels of circulating markers of endothelial activation/inflammation were present in SLE cases when compared with SLE controls and population controls but these did not correlate to measures of endothelial dysfunction, which may not be a general feature of SLE.
the patients, the synovial tissue contains cellular infiltrates that have formed organized structures resembling structures normally observed in lymph nodes, comprising follicular dendritic cells (FDCs), with distinct T-cell and B-cell areas, and ectopic lymphoid structures. In the remainder of the patients the tissues do not contain FDCs and show either a diffuse lymphocytic infiltrate or an aggregated T-cell and B-cell infiltrate [1].

The aim of our study is to identify the genes that are expressed in tissues with these ectopic lymphoid structures by cDNA microarray analysis to gain more insight into this specific disease process. We previously showed that the gene expression signatures of synovial tissues from RA patients showed considerable variability, resulting in the identification of distinct molecular forms of RA [2,3]. To evaluate whether the genes involved in the formation of ectopic lymphoid structures could be detected by microarray analysis of whole synovial tissues, we performed an analysis focused on a selection of genes that are known to be involved in normal lymph node development from murine knockout studies.

Indeed, four out of 13 tissues showed an elevated expression of lymph-node-associated genes, indicating that microarray analysis of whole synovial tissue allows the detection of these genes. The expression of the FDC-specific marker CD21L and immune histochemical staining of synovial tissue sections confirmed the presence of ectopic lymphoid structures in these tissues. Detailed histochemical analysis further allowed us to subclassify the tissues without lymphoid structures into tissues containing T-cell and B-cell aggregates and tissues with a diffuse type of infiltrate.

Comparison of large-scale gene expression profiles between tissues with the three different types of cellular infiltrates revealed differential expression of genes involved in several processes such as apoptosis, antigen presentation, angiogenesis, chemotaxis and extracellular matrix formation. The results indicate that tissues with ectopic lymphoid structures comprise a distinct type of gene expression profile, that includes a spectrum of genes encoding for adhesion molecules, chemokines, cytokines and their receptors that is required to maintain their highly organized structure.

References

P151
Immunophenotype and functional characteristics of rheumatoid arthritis derived myeloid dendritic cells and plasmacytoid dendritic cells
S Jongbloed, JA Gracie, RD Sturrock, IB Mdmnes
University of Glasgow, UK

Background Dendritic cells (DC) comprise a heterogeneous network of professional antigen-presenting cells, directly linking innate and adaptive immunity. While implicated in the pathogenesis of different chronic inflammatory arthritides, the analysis of DC subsets has been hampered by a lack of specific DC markers and reliable quantitation. Previously, we have described the significant reduction of circulating peripheral blood (PB) plasmacytoid DC (pDC) in both RA and psoriatic arthritis patients. Furthermore, we have shown that both of these DC subsets are present in synovial fluid (SF) from RA and psoriatic arthritis patients, although mDC significantly exceed pDC.

Objectives This present study characterizes the immunophenotype and functional characteristics of RA-derived mDC and pDC in order to assess their potential pathogenic role in arthritis.

Methods pDC and mDC were sequentially purified by magnetic cell sorting (MACS) using anti-neuropilin-conjugated magnetic microbeads (pDC) and biotin-conjugated anti-CD1c followed by positive selection using anti-biotin-conjugated magnetic microbeads (mDC), from RA PB (n = 3) and SF (n = 3) and compared with normal healthy controls (mDC, n = 4; pDC, n = 5). Purified cells were phenotyped using CD1c-FITC (mDC only), BDCA-2-FITC (pDC only), CD123-PE (pDC only), CD83-PE (pDC only), CD11c-PE (mDC only), CD14-PE (mDC only), CD40-APC, CD62L-FITC, CD86-APC, CD83-APC, CD40-APC, CD80-FITC, and CD40-PE pre and post 24-hour stimulation with TLR2 agonist S. aureus peptidoglycan (mDC only) or TLR9 agonist CpG oligonucleotide (ODN) 2216 (pDC). Supernatants were harvested from all cultures and cytokine concentrations analysed using Luminox.

Results Circulating RA PB-derived mDC and pDC display a typical immature DC phenotype compared with mDC and pDC from healthy control subjects; however, relatively lower expression was significantly decrease on RA pDC (P = 0.0369) but not mDC (P = 0.1573). Conversely, while RA SF-derived pDC displayed an immature phenotype directly comparable with their normal PB-derived counterparts, RA SF-derived mDC displayed increased CD80 and CD86, but decreased CD62L, suggesting a less immature phenotype. Moreover, RA SF-derived mDC had a higher CD14 expression, suggesting that these cells may be monocyte-derived mDC. FACSscan analysis revealed that both SF-derived DC subsets expressed upregulated mature markers following treatment with cytokine receptor stimula- tion. Cytokine analysis revealed that while pDC from both normal PB and RA SF produced large levels of interferon gamma and tumour necrosis factor alpha in response to TLR9 stimulation, only RA SF pDC produced low levels of IL-10 and interferon gamma. Similarly, mDC from both normal PB and RA SF produced large levels of tumour necrosis factor alpha; however, RA SF mDC produced more IL-10 than their normal PB counterparts.

Conclusions We report the ex vivo immunophenotype and functional characteristics of circulating RA PB-derived and SF-derived mDC and pDC.

P152
The importance of cell surface RANKL in rheumatoid arthritis
O Krystufkova1, J Sinkora2, K Jarosova1, M Hladikova1, J Niederlova1, Z Rehakova1, D Tegzova1, S Ruzickova1, J Vencovsky2
1Institute of Rheumatology, Prague, Czech Republic; 2DakoCytomation Brno, Czech Republic; 3Institute of Medical Informatics 2nd Medical Faculty, Charles University, Prague, Czech Republic; 4Military Medical Academy JE Purkyne, Hradec Kralove, Czech Republic.

Rationale Local bone destruction and osteoporosis in rheumatoid arthritis (RA) is mediated by the interaction of the receptor activator of nuclear factor kappa B (RANK) with its ligand (RANKL) and osteoprotegerin (OPG). Effector cells – osteoclasts – are generated upon the contact between RANK-positive (RANK+) preosteoclasts with RANKL expressed on the surface of osteoblasts or inflamma- tory cells [1]; a role of the soluble form of RANKL (sRANKL) in synovial fluid (SF) or serum in the osteoclast maturation has also been discussed. We have previ- ously reported higher local production of OPG and sRANKL in RA active joints in comparison with their serum concentration, lower local and systemic concentra- tion of OPG in RA patients in comparison with those suffering from osteoarthritis (OA) and no difference in SF-sRANKL levels between RA and OA groups [2].

Method Surface expression of RANKL in T lymphocytes and monocytes was evaluated by flow cytometry using goat biotinylated polyclonal anti-RANKL and anti-RANK antisera visualized by streptavidin-phycocerythrin and FITC-conjugated anti-CD3, anti-CD4 and anti-CD14 monoclonal antibodies. Six paired RA samples of SF and peripheral blood were analysed. The results were compared with data from peripheral blood of 18 RA donors, 14 OA donors and 14 healthy donors, respectively.

Results In SF of RA patients, higher numbers (17%) of CD3+RANKL+ mononuclear cells (synovial fluid mononuclear cells) were found than in peripheral blood mononuclear cell (PBMC) preparations (5%, P = 0.07). In contrast, relatively more RANKL+CD14+ monocytes (79%) exist in peripheral blood than in SF (20%) in the same individuals. When PBMCs in different groups were analysed, significantly higher numbers of CD3+ (8%) and CD4+ (8.9%) PBMCs bearing RANKL+ surface were found in the RA group compared with OA and controls (4.7%, P = 0.03 and 0.02). In addition, RA patients had significantly higher pro- portions of CD14+RANKL+ PBMC (45.6%) than controls (30.2%, P = 0.013) or OA patients (29.7%, P = 0.046). On the other hand, RANK expression on CD14+ PBMC appeared diminished in RA patients (17.3%) when compared with controls (35.5%, P = 0.013).

Conclusions Our findings suggest that the induction of bone erosions may depend rather on surface-bound RANKL than on its soluble form. This hypothesis is supported by our previous findings (see rationale) as well as by differences in RANKL expression on SF and peripheral blood CD3+ cells and the increased numbers of RANK+ lymphocytes in the peripheral blood CD3+ and CD4+ com- partments in RA patients. The lower ratio of CD14+RANK+ monocytes in peripheral blood of RA patients could reflect selective recruitment of RANK+ cells into the sites with elevated RANKL expression. In such a process, a soluble form of RANKL would probably play an important role [3].

References

Acknowledgement Supported by grants NK 7293-3 MH CR and NR 7898-3 MH CR.
P153
Expression of programmed death (PD)-1 and PD-1 ligands (PD-L1, PD-L2) in peripheral blood mononuclear cells of patients with systemic lupus erythematosus
G Bertias, A Raptopoulou, E Coutala, M Mamoulaki, H Kritikos, P Sidirooulos, DT Boumpas
Department of Rheumatology, Clinical Immunology and Allergy, Medical School, University of Crete, Greece
Background Programmed death (PD)-1 is a newly described member of the immunoglobulin super-family that is expressed on activated T lymphocytes and B lymphocytes. Engagement of PD-1 with its specific ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), inhibits lymphocyte proliferation and cytokine expression, and may play a role in peripheral tolerance and negative regulation of T-cell and B-cell responses in vivo. We sought to investigate the expression profiles of PD-1 and PD-1 ligands in peripheral blood cells of patients with systemic lupus erythematosus (SLE).
Materials and methods Blood was drawn from patients with SLE (n = 16), rheumatoid arthritis (n = 16), other inflammatory disease (n = 4), and healthy controls (n = 9). Peripheral blood mononuclear cells were separated on a ficoll-density gradient, and flow cytometry analysis was performed using monoclonal antibodies against CD3, CD19, CD14, CD25, CD69, PD-1, PD-L1, and PD-L2.
Results See Table 1.
Table 1

<table>
<thead>
<tr>
<th>Disease group</th>
<th>Healthy controls</th>
<th>Systemic lupus erythematosus</th>
<th>Rheumatoid arthritis</th>
<th>Inflammatory disease</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SEM</td>
<td>Mean</td>
<td>SEM</td>
</tr>
<tr>
<td>PD-1+ (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in CD3*</td>
<td>0.6</td>
<td>0.2</td>
<td>0.4</td>
<td>0.1</td>
</tr>
<tr>
<td>in CD19*</td>
<td>1.7</td>
<td>0.9</td>
<td>1.4</td>
<td>0.3</td>
</tr>
<tr>
<td>in CD25*</td>
<td>3.0</td>
<td>1.0</td>
<td>2.4</td>
<td>0.7</td>
</tr>
<tr>
<td>PD-L1+ (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in CD3*</td>
<td>2.8</td>
<td>1.2</td>
<td>4.1</td>
<td>0.9</td>
</tr>
<tr>
<td>in CD19*</td>
<td>3.9</td>
<td>1.3</td>
<td>5.1</td>
<td>0.8</td>
</tr>
<tr>
<td>in CD14*</td>
<td>5.1</td>
<td>2.0</td>
<td>14.0</td>
<td>5.4</td>
</tr>
<tr>
<td>PD-L2+ (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in CD3*</td>
<td>0.6</td>
<td>0.2</td>
<td>0.5</td>
<td>0.1</td>
</tr>
<tr>
<td>in CD14*</td>
<td>2.0</td>
<td>0.5</td>
<td>1.4</td>
<td>0.3</td>
</tr>
</tbody>
</table>

SEM, standard error of the mean. No statistically significant differences were observed.

Conclusions In this preliminary report, SLE patients showed a trend for lower expression of PD-1 and higher expression of PD-L1 in unstimulated peripheral blood mononuclear cells compared with other disease controls. These results corroborate findings linking SLE with polymorphism of the PD-1 gene resulting in putative altered expression of the PD-L2 [1]. Lower expression of PD-1 in SLE lymphocytes could be related to ineffective suppression of autoreactive lymphocytes and thus to disease evolution. Currently, we investigate expression of PD-1 and its ligands on subpopulations of lymphocytes (CD45RO*, CD27*), as well as the kinetics of expression upon stimulation.

Reference

P154
Cultured salivary gland epithelial cells from patients with primary Sjögren’s syndrome and disease controls are sensitive to signaling via Toll-like receptors 2 and 3: upregulation of intercellular adhesion molecule-1 expression
MP Spachidou, EK Kapsogeorgou, EA Bourazopoulou, HM Moutsopoulos, MN Manoussakis
Department of Pathophysiology, Medical School, University of Athens, Greece
Background In previous studies, our laboratory has shown that the salivary gland epithelial cells (SGEC) of patients with primary Sjögren’s syndrome (SS) display an intrinsically activated phenotype, as characterised by high expression of adhesion, costimulatory and antigen-presenting molecules. Stimulation of Toll-like receptors (TLRs) expressed by epithelia by native or synthetic ligands of TLR2, TLR3 and TLR4 may be critically involved in the regulation of immune responses through the induction of various immunomodulators, such as the intercellular adhesion molecule-1 (ICAM-1/CD54).

Materials and methods Cultured, non-neoplastic SGEC lines derived from minor salivary gland biopsies of patients with SS (SS-SGEC, n = 4) and controls (n = 4) were studied. The expression of TLR2, TLR3 and TLR4 mRNA was examined by PCR. SGEC were stimulated with S. aureus peptidoglycan (100 µg/ml, TLR2-ligand), the synthetic analogue of dsRNA poly-inosinic:cytidylic acid (poly(C) (5 µg/ml, TLR3-ligand) and E. coli lipopolysaccharide (100 ng/ml, TLR4-ligand), for 24 and 48 hours. In certain experiments, cells were also primed with interferon alpha (500 IU/ml) for 24 hours, prior to the stimulation with poly(C). The induction of ICAM-1 expression was analysed by flow cytometry on resting and stimulated cells.

Results SGEC lines were found to express TLR2, TLR3, and TLR4 mRNA. In agreement with their intrinsic activation status and previously published reports, SS-SGEC lines displayed high constitutive ICAM-1 expression, compared with control-SGEC lines. Triggering of TLR3 with poly(C) had resulted in significantly increased ICAM-1 expression (SS-SGEC: sixfold, controls: sevenfold) that reached maximum expression after 24-hour stimulation. The response to poly(C) was further enhanced after priming of the cells with interferon alpha. Signalling via TLR2 by peptidoglycan was found to upregulate moderately ICAM-1 expression (SS-SGEC: 10%, controls: twofold) after 24-hour stimulation. Despite expression of TLR4 mRNA (by PCR), as well as of surface CD14 protein (by flow cytometry), lipopolysaccharide stimulation failed to upregulate ICAM-1 expression.

Conclusions Our results indicate the SGEC lines are able to respond to synthetic microbial analogues that stimulate TLR2 and TLR3 by upregulating the expression of the adhesion molecule ICAM-1/CD54.

P155
Prevalence of non-rheumatoid arthritis-associated autoantibodies in sera of anti-cyclic citrulline antibody-positive patients
National Institute of Rheumatology, Budapest, Hungary
Background Serological markers, especially autoantibodies with high disease specificity, have their emphasized role in support of the diagnosis of autoimmune diseases. Detection of anti-cyclic citrulline (anti-CCP) antibodies has gained increasing interest in clinical practice as they have shown to have strikingly high (95%-98%) specificity for rheumatoid arthritis (RA).

Objective The aim of this study is to summarize our experience in testing anti-CCP and other autoantibodies on a large number of sera from patients with suspected and definite connective tissue disease.

Methods A total of 2061 sera derived from 1750 patients were requested for detection of anti-CCP and rheumatoid factor (RF) autoantibodies. Conventional autoantibodies were also tested according to the requests of clinicians in cases of 1560 samples. Anti-CCP antibodies were detected with the ImmunoscanRA Elisa kit, and RF by nephelometry (Behring). Antinuclear antibodies were detected by IF test on Hep-2 cells (Inova). Anti-ENA antibodies, anti- DNA, anti- chromatin, anti-cardiolipin were measured using ELISA kits (Inova). Anti-CCP antibodies exceeding the level of 25 U/ml were considered positive. Samples expressing antinuclear antibodies at dilution of 1:200 or higher were evaluated.

Results Anti-CCP and RF were present in sera of 331 patients, while 59 patients were positive only for anti-CCP antibodies. Autoantibody profile detected in anti-CCP-positive and RF-positive patients (n = 331) – antinuclear antibody positive samples, n = 54 (16.3%): including polymyositis, scleroderma associated antibodies, n = 7 (2%); systemic lupus erythematosus associated antibodies (anti-DNA, anti-chromatin, anti-histone, anti-Sm), n = 12 (3.6%); MCTD associated antibodies, n = 8 (2.5%); Sjögren syndrome associated autoantibodies, n = 10 (3%); anti-centromere antibodies, n = 4 (1.3%); and primary biliary cirrhosis associated antibodies, antimitochondrial antibody, n = 4 (1.3%). In four cases the presence of anti-neutrophil cytoplasmic antibodies was also seen. In the group of patients with only anti-CCP positivity (n = 59) – two (3%) samples were positive for anti-centromer, one of them for Scl70 as well, one was positive for PM/ScIike antibodies, one for anti-DNA, one for anti-Ro/SSa antibody, and one sample showed strong antinuclear antibody positivity.

Conclusion These results show a more complex picture of the occurrence of anti-CCP antibodies as they may associate with different stages of connective tissue diseases. We also aimed to initiate further clinical studies to define the role of this family of autoantibodies in the diagnosis of RA-associated secondary diseases, and also in overlap syndromes.

Acknowledgement This work was supported by Hungarian grant OTKA T037876.
P156
Identification of hnRNP-A2 (RA33) as a major B-cell and T-cell autoantigen in pristane-induced arthritis
MH Hoffmann1,2, J Tuncel3, K Skirner4, M Tohidast-Akrad5, G Schett2, JS Smolen1,2, R Holmdahl6, G Steiner2
1Center of Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; 2Department of Rheumatology, Medical University of Vienna, Austria; 3Section for Medical Inflammation Research, Lund University, Sweden; 4Department of Rheumatology, Charité University Hospital, Berlin, Germany; 5Ludwig Boltzmann Institute for Rheumatology, Vienna, Austria

Background: Pristane-induced arthritis (PIA) in rats is considered an excellent model for rheumatoid arthritis (RA) since it fulfills the criteria for RA including a chronic, relapsing disease course and is not dependent on immunization with exogenous antigen. Although the advent pristane is not immunogenic, the disease is MHC associated and dependent on the activation of (auto)reactive T cells. However, so far it has not been possible to link the immune response to joint antigens or other endogenous components. HnRNP A2, the RA33 autoantigen (A2/RA33), is a multi-functional RNA binding protein involved in splicing and other aspects of post-transcriptional regulation of gene expression. Autoantibodies as well as autoreactive T cells against A2/RA33 have been found in patients with RA but the pathogenetic role of these autoimmune responses is unresolved [1]. It was therefore the aim of this study to elucidate a potential involvement of A2/RA33 in PIA.

Methods: Autoantibodies against A2/RA33 were determined by immunoblotting, and MHC association of the anti-A2/RA33 immune response was specified by the presence of autoantibodies, delayed-type hypersensitivity reactions and T-cell cytolytic reaction in rat sera of different haplotypes. Interferon gamma and tumour necrosis factor secretion by T cells isolated from draining lymph nodes 10 days prior to pristane injection and restimulation with A2/RA33 in vitro was determined. Expression of A2/RA33 in joints and organs was analysed by immunohistochemistry and western blotting. Nasal vaccinations were performed with A2/RA33 7 days prior to pristane injection.

Results: Although anti-A2/RA33 autoantibodies were detected in all four rat strains investigated, the immune response appeared to be particularly linked to the F and U MHC haplotypes. Autoantibodies to A2/RA33 were found in 60% of F rats, and T cells of all F rats tested produced intermediate to high levels of interferon gamma and tumour necrosis factor upon restimulation with A2/RA33. The reaction seemed to be particularly linked to the presence of CD4+ cells showing a Th1 phenotype. Furthermore, nasal vaccination with A2/RA33 significantly delayed the onset and decreased severity of arthritis in F rats. Finally, immunohistochemical and western blot analyses revealed pronounced overexpression of A2/RA33 in joints of rats suffering from acute PIA, but not in healthy joints or in joints from animals with chronic PIA.

Conclusion: The A2/RA33 autoantigen is targeted by autoantibodies and Th1 cells in rats with PIA shortly after pristane injection. The presence of autoreactive Th1 cells in conjunction with synovial overexpression of A2/RA33 strongly suggests involvement of this autoantigen in the pathogenesis of PIA. This is further bolstered by the observed alleviation and delay of onset of PIA following nasal vaccination with A2/RA33. Thus, A2/RA33 seems to be one of the primary autoantigens in PIA that in conjunction with previous observations on the presence of autoreactive T cells in RA patients may argue for a pathogenetic role also in human RA.

References:

Acknowledgements: This work was supported by a grant from the Austrian Academy of Sciences and by Marie Curie Host Fellowship number IR1-CT-2000-00126 of the European Commission Research Directorate.

P157
Influence of methotrexate, leflunomide and tumour necrosis factor alpha inhibitors on immune competence in rheumatoid arthritis patients: a long-run monitoring of Epstein–Barr virus load
N Balandraud1,2, S Guiss1,2, JB Meynard1,2, J Auger1, H Sovran5, J Roudier1,2, C Roulier1,2
1INSERM UMR 639, Faculté de Médecine, Marseille, France; 2Service de Rhumatologie Est, Hôpital de la Conception, Marseille, France; 3Institut de Médecine Traumatique et Service de Santé des Armées, Marseille, France; 4Arthritis Res Ther 2005, 7(Suppl 1):P157 (DOI 10.1186/ar1678)

Background: The risk to develop lymphoma is doubled in patients with rheumatoid arthritis (RA) in the absence of immunosuppressive therapy. This risk is slightly increased by the use of methotrexate or tumour necrosis factor alpha inhibitors (infliximab and etanercept) [1]. Epstein–Barr virus (EBV) is detected in about one-third of lymphoma developing in RA patients. The reason why some patients develop lymphoma is unknown. We have previously shown that RA patients have an almost 10-fold increase of EBV load in their peripheral blood mononuclear cells (PBMCs), compared with normal controls [2]. RA patients’ peripheral blood EBV load is similar to that of healthy transplant recipients (10 copies per 500 ng DNA). In immunosuppressed transplant recipients, elevation of PBMC EBV load above 500 copies/500 ng DNA predicts the emergence of lymphoma.

Objectives: We measured RA patients to evaluate the effects of disease-modifying anti-rheumatic drugs (DMARDs) (methotrexate and leflunomide) and tumour necrosis factor alpha inhibitors (infliximab and etanercept) on PBMC EBV load and to predict lymphoma development.

Methods: One hundred and nineteen patients fulfilling the 1987 ACR criteria for RA were followed for periods of 6 months–4 years. Twenty patients received methotrexate or leflunomide, eight received only infliximab, 61 received methotrexate and infliximab, and 30 received etanercept. A 2.14 bp fragment from the conserved Long Internal Repeat (IR) was amplified by quantitative PCR to evaluate EBV DNA load. Effect of treatment duration on EBV load was analyzed by the method of generalized estimation equations.

Results: EBV load decreased between the beginning and the end of the study in patients receiving DMARDs (mean: 20.24 and 3.27) or etanercept (mean: 4.44 and 0.67). This decrease was significant for DMARDs (P = 0.0038). However, EBV load evolution was not significantly related to treatment duration in patients under infliximab (mean: 6.36 and 7.82) or infliximab plus methotrexate (mean: 13.49 and 11.92). Of interest, in one patient receiving infliximab plus methotrexate, EBV load reached 540 copies/500 ng over a short period of time.

Conclusion: Methotrexate and etanercept decrease EBV load over time. Infliximab alone or with methotrexate does not influence significantly EBV load. Monitoring EBV load might help detecting the few patients who are likely to develop lymphoma.

Acknowledgements: Supported by PHRC 2003, SFR and ARP.

P158
A revised assay for the measurement of T-cell receptor excision circles as a quantitative measure of thymic function in systemic lupus erythematosus
AR Lorenzi, AM Patterson, JD Isaacs
Musculoskeletal Research Group (Clinical Immunotherapy), Clinical Medical Sciences, University of Newcastle Upon Tyne, UK

In 1998 Douek and colleagues described a novel approach to measuring thymic output using T-cell receptor excision circles (TRECs) measured in CD4+ and CD8+ T cells. TRECs are byproducts of T-cell receptor gene rearrangements, whereby sections of excised DNA re-form as stable episomes that do not replicate with T cells. TRECs present in peripheral blood lymphocytes are thus ‘diluted out’ upon T-cell division and can be used as a surrogate marker of thymic output. However, the interpretation of TREC number in lymphocyte subsets is confounded by the influences of T-cell proliferation, intracellular TREC degradation and T-cell death, and it has been criticised as a measurement of thymic function. Here, we describe a method for quantifying TRECs in whole blood. This revised assay provides a representation of ‘total peripheral TRECs’. The effects of T-cell proliferation and cell death on the determined absolute TREC level are minimised, providing us with an improved estimation of thymic function over time. In a series of validation experiments our assay has been shown to have excellent intra-assay and inter-assay reproducibility and to generate results consistent with previously published work in healthy controls. We are now using this assay to determine thymic function in the autoimmune disease systemic lupus erythematosus to test our hypothesis that a defect in thymic function contributes to lupus pathogenesis.

To measure the absolute TREC number per unit volume of blood (as a representation of ‘total peripheral TRECs’), the amount of DNA extracted from a volume of whole blood must be representative of ‘total’ DNA in that volume of blood. We have compared four methods of DNA extraction from whole blood for consistency of yield and purity. Figure 1a shows the mean DNA yield from parallel extractions (n = 10) performed after (a) 1 hour, (b) 6 hours and (c) 24 hours from collection for a single sample. The overall mean yield was 32.23 μg/ml ± 2.3 standard deviations (SDs).

Two further, separate, samples were similarly prepared in parallel to confirm consistency — (d) 26.8 μg/ml ± 1.97 SD and (e) 26.9 μg/ml ± 2.23 SD (n = 10). To measure TREC numbers in samples we have used a quantitative real-time PCR (QTACMAN®) assay to amplify a known proportion of the extracted DNA. The total TREC number per sample is determined absolutely from a standard curve (derived from a plasmid containing TREC sequence) and final values are presented as TRECs per million of whole blood. Figure 1b (top axis) shows that the TREC number is reproducibly calculated from parallel extractions (n = 10). The intra-assay coefficient of variation is 1.4% (range 0.8–2.5%). While the inter-assay coefficient of variation is 2.4% (range 0.6–4.4%). The coefficient of variation is negatively correlated with TREC number.

Arthritis Research & Therapy Vol 7 Suppl 1 Abstracts of the 25th European Workshop for Rheumatology Research
Western blotting demonstrated the presence of PAR-2 in normal murine β = 7) revealed significant differences and peripheral blood monocytes (MO) are activated and release proinflammatory. Genome-wide microarray analyses (HG-U133A/B) were performed to protease-activated receptor-2 (PAR-2) is a G-protein-coupled to test the hypothesis that acute joint inflammation could be inhibited. While measurement of TREC is T cells and their subsets provides a representation of thymic function in the steady state, in the context of autoimmunity, where PAR-2 plays a pivotal role in synovitis, especially at the cartilage–pannus junction. Both PAR-2 and peripheral blood monocytes (MO) are activated and release proinflammatory cytokines (IL-1β, tumour necrosis factor [TNF] alpha). Neutralization of IL-1β and TNF-α leads to clinical improvement in RA. To characterize MO expression profiles of patients with active RA before and after treatment with adalimumab, a fully human, anti-TNF monoclonal antibody, using microarray analysis. To identify differences in expression of signature genes between patients with uncontrolled, active RA and those in remission induced by anti-TNF therapy. Methods Genome-wide microarray analyses (HG-U133A/B) were performed to identify signature genes and RA-MO pathways and to establish a customized cDNA array suitable for monitoring anti-TNF therapy. Untouched MO were negatively selected by magnetic cell sorting from 40 ml peripheral blood samples. Total RNA was extracted for cDNA synthesis, and was hybridized with whole genome oligonucleotide and customized cDNA microarrays. The customized cDNA array consisted of 313 cDNAs derived from gene subtraction analysis and from comparative genome-wide U133A analysis. The array includes RA-relevant signature genes, and genes triggered or repressed during anti-TNF treatment. To identify significant gene expressions, bioinformatical MAS 5.0, self-organizing map clustering and predictive analysis for microarrays (PAM) analyses were performed. Results Genome-wide analysis of MO mRNA expression in patients with active RA before and after receiving anti-TNF-α (n = 7) revealed significant differences in upregulated and downregulated genes. Self-organizing map analysis revealed six different gene expression clusters. MAS 5.0 and PAM analyses identified 103 differentially expressed genes and permitted the separation of RA patients into two subgroups of ‘responders’ and ‘non-responders’, correlating with clinical data (DAS28 and ACR response criteria). Results were confirmed by a customized array using most of the PAM-selected genes. Twenty-four genes were further evaluated by real-time PCR using MO from normal donors and from patients with RA before and during therapy. Signature genes identified were characterized as: disease-relevant genes differentially transcribed in activated RA-MO compared with normal donor MO; genes reversed to ‘normal levels’ by anti-TNF treatment; or pharmacodynamic marker genes probably indicative of anti-TNF action. Selected genes, which may be indicative for the response to therapy, are currently being further evaluated in extended collections of samples. Conclusions Signature are important to define MO activation to characterize disease activity and to support therapeutic stratification. The current gene selection could contribute to the investigation of the role of MO in a wide range of rheumatic diseases and therapeutic intervention, improving rheumatologists’ understanding of regulated MO pathways.

P160 Amelioration of joint inflammation by a PAR-2-specific monoclonal antibody

V King1, EB Kelso1, JC Lockhart2, L Dunning3, WR Ferrell1, JA Gracie1, IB McInnes1
1Centre for Rheumatic Diseases, University of Glasgow, UK; 2Biological Sciences, University of Paisley, UK

Background Protease-activated receptor-2 (PAR-2) is a G-protein-coupled receptor recognized to mediate inflammatory responses. Using a PAR-2 ‘knock-out’ mouse, we previously demonstrated this receptor to play a crucial role in chronic joint inflammation [1]. Inhibition of PAR-2 activation therefore potentially represents a novel therapeutic target in treatment of arthritis, but selective antagonists are not yet available.

Objective To test the hypothesis that acute joint inflammation could be inhibited by targeting the ‘tethered ligand’ sequence of PAR-2 using a specific monoclonal antibody (SAM-11).

Methods The presence of synovial PAR-2 was confirmed in wild-type (PAR-2+/+) C57BL/6 mice by western blotting using SAM-11 (Santa Cruz, USA). The anti-inflammatory potential of this antibody, which inhibits PAR-2 activation by preventing release of its activating ligand, was investigated by intra-articular administration of SAM-11 to mice prior to induction of acute joint inflammation (under halothane/O2/N2O anaesthesia) by injection of 20 μl 0.2% carrageenan and 4% kaolin (C/K) into the knee joint. Joint swelling was assessed by comparing caliper-measured knee joint diameter pre and 24 hours post-injection. The swelling response was compared in untreated, and in two parallel groups of inflamed mice that had received intra-articular injection of SAM-11 at 5 ng or 10 ng, 5 min prior to C/K administration. Selectivity of SAM-11 for PAR-2 was confirmed by immuno-histochemical analysis (in combination with the Animal Research Kit Dako, USA) of the wild-type mouse brain, which expresses PAR-1, PAR-2, PAR-3 and PAR-4 compared with that of PAR-2 gene-disrupted (PAR-2–/–) mice.

Results Western blotting demonstrated the presence of PAR-2 in normal murine synovium and substantial upregulation in acutely inflamed joints. Immunohistochemical analysis of the murine brain with SAM-11 revealed staining in PAR-2+/+ mice but not in PAR-2–/– mice, confirming PAR-2 specificity of this monoclonal antibody. C/K resulted in substantial knee joint swelling, which was significantly and dose-dependently (P < 0.00001; one-way analysis of variance; n = 4 per group) inhibited by SAM-11 pretreatment (Fig. 1). These findings are consistent with a proinflammatory role for PAR-2 in arthritis, and demonstrate that antibody inhibition of PAR-2 activation ameliorates acute joint inflammation.


Figure 1

Twenty-four hours after intra-articular injection of kaolin, knee joint swelling is dose-dependently reduced by SAM-11 pre-treatment. *P < 0.00001, **P < 0.01 (n = 4 per group), NS, no significantly.
P161 Real-time quantitative PCR used as a biomarker for synovial gene expression after oral prednisolone therapy in patients with rheumatoid arthritis

DM Gerfl1, DL Boyle2, P Laub4, T Nash2, PP Tak1, GS Fiepire1
1Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, The Netherlands; 2Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, UCSF School of Medicine, La Jolla, California, USA; 3Astra Zeneca, Macclesfield, UK

The objective of this study was to evaluate the usefulness of real-time quantitative PCR (Q-PCR) using a cellular standard to detect changes in gene expression in synovial tissue samples that could potentially serve as such biomarkers correlating with clinical disease activity. Therefore, the effects of treatment with corticosteroids, a known effective therapy, were analyzed in patients with active rheu- matoid arthritis. Patients were randomized to receive either oral prednisolone (n = 10, 60 mg daily for the first and 40 mg daily for the second week) or placebo (n = 11). All patients underwent an arthroscopic synovial biopsy procedure directly before and 15 days after 14 days prednisolone therapy. Peripheral blood CD8+ cells from healthy volunteer or RA peripheral blood were isolated by immunomagnetic positive selection and activated by phytohaemagglutinin, IL-15 or a cytokine cocktail (IL-6, IL-15 and TNF-α) for 3/6 days, respec- tively. SF T cells were purified by immunomagnetic bead separation. T cells were paraformaldehyde-fixed prior to co-culture with autologous immunomagnetically purified CD14-positive cells. CD8+/CD4+ cells isolated from RA SF were fixed without prior stimulation. Secreted cytokine production by monocytes was measured by ELISA/Luminex after 48 hours. The purity of isolated CD8+/CD4+ popu- lations was assessed by FACS analysis and was routinely > 95%.

Results Mitogen-activated peripheral blood CD8+ cells induced TNF-α production by monocytes in a cell-contact-dependent manner. Peripheral blood CD8+ cells previously activated by IL-15 alone or a cocktail of cytokines similarly stimulated monocyte TNF-α production. Moreover, CD8+ cells isolated directly from RA SF induced autologous monocyte TNF-α production in the absence of exoge- nous TNF stimuli. Levels of monocyte cytokine production stimulated by CD8+ cells were comparable with levels induced by CD4+ cells in all circumstances investigated. Conclusion The ability of CD8+ cells to stimulate monocyte inflammatory cytokine production via a contact-dependent mechanism provides a novel means by which T cell subsets activated within the local cytokine milieu in RA may con- tribute to the ongoing disease process. Further understanding of the contribution made by this population to monocyte/macrophage activation is therefore crucial.

P162 Expression profiling in synovitis: ranking of candidates, diagnostic performance and individualized interpretation

T Häuptl1, A Grützkua1, J Grün1, V Krem1, M Rudwaleit1, B Stuhlmüller1, C Kap1, J Zacher1, A Grützkau1, A Ruddy1
1Department of Rheumatology, Charité, Berlin, Germany; 2German Arthritis Research Centre, Berlin, Germany; 3Institute of Pathology, Charité, Berlin, Germany; 4Oligene GmbH, Berlin, Germany; 5Department of Orthopedics, Helios Clinics Berlin, Berlin, Germany

Objective To provide a systematic overview on expression profiles, to determine a ranking score and to give insight into the heterogeneity of individual patients within the group of arthritis patients.

Methods Synovial tissue samples of 10 rheumatoid arthritis (RA), 10 osteoarthritis and 10 normal donors were subjected to GeneChip HG-U133A expression profiling according to the standard protocol, starting with 5 μg total RNA and using 15 μg cRNA for hybridization. Signals were generated with the GeneChip Operating System and scaled to equal intensities of the whole array. Further analysis included t test and analysis of variance (ANOVA) statistics as well as functional profile compo- nent analysis. Classification was performed according to the Prediction Analysis for Microarrays algorithm. Systematic multiple testing with statistics and classification tools was programmed in perl using subgroups of patients and subgroups of genes.

Results To characterize the homogeneity of each group, ANOVA and f test statis- tics were applied using ‘leave one out’ and ‘leave two out’ for candidate selection. Subsequently, these one or two donors were tested for the predictive value of the selected candidates. This revealed that one RA donor, if not participating in the selection process, grouped to osteoarthritis. Analysis for functional profile compo- nents showed less infiltration and less inflammation in this donor. However, if this RA donor contributed to the candidate selection, all RA patients were correctly classified. Furthermore, donors of other groups were also classified error-free. This demonstrates that RA with reduced molecular markers of inflammation can still be separated from osteoarthritis and that incorporation of such RA patients in the selection process of candidate genes is mandatory for correct classification.

Conclusion Systematic multiple testing of gene expression profiles provides a promising overview of the molecular signature of RA. However, individualized interpretation of gene expression data is necessary to identify candidates for specific contribution to classification and thus an individualized interpretation of gene expression data.

P163 A role for CD8+ cells in cell-contact-mediated inflammation

SE Robertson3, A Crilly1, JA Gracie1, P Life2, IB McInnes1
1Centre for Rheumatic Diseases, Division of Immunology, Infection & Inflammation, GlaxoSmithKline Medical Discovery Centre, UCL; 2GlaxoSmithKline Medical Discovery Centre, UCL; 3Arthritis Research & Therapy Centre, Macclesfield, UK

Background While the aetiology of rheumatoid arthritis (RA) is unknown, emerg- ing evidence suggest that T cell/macrophage cell-cell interactions are critical in disease perpetuation. Cytokine/mitogen-activated CD4+ T cells or CD4+ T cells directly from RA synovial fluid (SF) are known to induce tumour necrosis factor alpha (TNF-α) production by monocytes via a cell-contact-mediated mecha- nism. However, little is known about the ability of CD8+ cells to drive such effects. Objective To investigate the potential role of CD8+ cells in cell-contact-mediated regulation of monocytes, via induction of cytokines. To examine whether CD8+ cells isolated from RA SF, like their CD4+ counterparts, have an inherent ability to drive monocyte activation.

Methods CD8+ or CD4+ cells from healthy volunteer or RA peripheral blood were isolated by immunomagnetic positive selection and activated by pho- tolymphocytotoxin, IL-15 or a cytokine cocktail (IL-6, IL-15 and TNF-α) for 3/6 days, respec- tively. SF T cells were purified by immunomagnetic bead separation. T cells were paraformaldehyde-fixed prior to co-culture with autologous immunomagnetically purified CD14-positive cells. CD8+/CD4+ cells isolated from RA SF were fixed without prior stimulation. Secreted cytokine production by monocytes was mea- sured by ELISA/Luminex after 48 hours. The purity of isolated CD8+/CD4+ popu- lations was assessed by FACS analysis and was routinely > 95%.

Results Mitogen-activated peripheral blood CD8+ cells induced TNF-α production by monocytes in a cell-contact-dependent manner. Peripheral blood CD8+ cells previously activated by IL-15 alone or a cocktail of cytokines similarly stimulated monocyte TNF-α production. Moreover, CD8+ cells isolated directly from RA SF induced autologous monocyte TNF-α production in the absence of exoge- nous TNF stimuli. Levels of monocyte cytokine production stimulated by CD8+ cells were comparable with levels induced by CD4+ cells in all circumstances investigated. Conclusion The ability of CD8+ cells to stimulate monocyte inflammatory cytokine production via a contact-dependent mechanism provides a novel means by which T cell subsets activated within the local cytokine milieu in RA may con- tribute to the ongoing disease process. Further understanding of the contribution made by this population to monocyte/macrophage activation is therefore crucial.

P164 Complement and Fcy receptor cross-talk in the Arthus reaction: the inflammatory cascade confirmed and refined

SR Ali1, J Skokova1, N Shushakova1, S Konrad1, RE Schmidt1, JE Gessner2
1Department of Clinical Immunology, Medical School Hannover, Germany; 2Arthritis Research & Therapy Centre, Macclesfield, UK

Objectives Complement and Fcy receptor (FcR) effector pathways are central triggers of immune inflammation; however, the exact mechanisms for their cooperation with effec- tor cells and their nature remain elusive. Here we describe a novel regulatory cross- talk between complement and FcR on macrophages as the dominant event in the Arthus reaction, the classical animal model of immune complex disease. Specifically, initial contact between immune complexes and macrophages results in cellular regula- tion: plasma complement-independent CsA production; selective G-dependent CsAR alterations towards the FcyRII, the previously shown main inducer of tumour necrosis factor alpha and CXCR2 ligand production. Distinct inhibitors of this refined inflammatory cascade are each effective in disease prevention, thus indicating cellular components of the CsAR–FcR axis as potential new therapeutic targets in the treatment of inflammation and autoimmune diseases.

Acknowledgement Supported by the Deutsche Forschungsgemeinschaft DFG 899/8-1 to JEG.

P165 Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with vasculitis of rheumatic disease

KA Rouster-Stevens1, JA Daru2, LM Pachman1, B Javonovic1, K-L Ngai3
1Northwestern University Feinberg School of Medicine & Children’s Memorial Research Center, Chicago, Illinois, USA; 2Arthritis Research & Therapy Centre, Macclesfield, UK

Introduction Corticosteroids are the drugs of choice for many rheumatic dis- eases, including vasculitis. There is controversy concerning the route of administra- tion. It is known that the target and the blood vessels of the gastrointestinal tract are affected, they may be impaired absorption of oral corticosteroids.

Purpose To determine whether patients with active vasculitis, as evidenced by elevated neutropin, von Willebrand factor antigen (vWFAg), and abnormal nallfold capillaroscopy (NFC), have equivalent bioavailability of oral prednisolone (OP) compared with intravenous methylprednisolone (IVMP).

Methods Six patients with rheumatic disease involving vasculitis (juvenile der- matomyositis, scleroderma, or overlap syndrome), four females, two males (mean age 14 years [range 11–27]; one Hispanic, one Asian, one African American, three Caucasian) were admitted to an IRB-approved Clinical Research Center protocol. After fasting overnight, they received 50 mg/m2 OP on day 1, and
50 mg/m² IVMP on day 2. Baseline blood samples were drawn 1 min prior to each corticosteroid dose (neopterin and vWFAg on day 1; prednisolone level on day 2), at 5, 15, 30, 45, 60, and 90 min and then hourly from the second through the eighth hour. After extraction, samples were analyzed by reverse-phase HPLC for the levels of prednisolone (day 1 samples) and methylprednisolone (day 2 samples). The area under the serum OP or IVMP concentration versus time curve (AUC) was determined using the trapezoid method. NFC images were evaluated by freeze-frame video microscopy as previously described.

Results See Table 1. There was a positive correlation coefficient for $\Delta$AUC (IVMP–OP) with vWFAg, neopterin, and NFC avascularity score of 0.74, 0.68, and 0.66, respectively; there was a negative correlation coefficient for $\Delta$AUC (IVMP–OP) with NFC capillary/mm of 0.64. Linear regression analysis of $\Delta$AUC (IVMP–OP) and vWFAg approached statistical significance ($P = 0.08$) and given that only six patients were evaluated this may be clinically significant.

Table 1

<table>
<thead>
<tr>
<th>Neopterin (mmol/l)</th>
<th>vWFAg capillary/ mm</th>
<th>NFC end row</th>
<th>NFC avascularity</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC (IVMP–OP) normal</td>
<td>blood normal</td>
<td>score, type</td>
<td>= 8–10</td>
</tr>
<tr>
<td>Patient Diagnosis</td>
<td>(min·ng/µl)</td>
<td>normal</td>
<td>10</td>
</tr>
<tr>
<td>1</td>
<td>JDM</td>
<td>+651897</td>
<td>19.5</td>
</tr>
<tr>
<td>2</td>
<td>JDM</td>
<td>−21012</td>
<td>5.3</td>
</tr>
<tr>
<td>3</td>
<td>JDM</td>
<td>+329290</td>
<td>10.7</td>
</tr>
<tr>
<td>4</td>
<td>Overlap</td>
<td>−268419</td>
<td>6.9</td>
</tr>
<tr>
<td>5</td>
<td>Overlap</td>
<td>+924390</td>
<td>14.6</td>
</tr>
<tr>
<td>6</td>
<td>Scleroderma</td>
<td>−70879</td>
<td>14.3</td>
</tr>
</tbody>
</table>

AUC, area under the serum oral prednisolone (OP) or intravenous methylprednisolone (IVMP) concentration versus time curve; vWFAg, von Willebrand factor antigen; NFC, nailfold capillaroscopy; JDM, juvenile dermatomyositis. | Normal values per blood type: A = 48–234; B = 57–241; O = 36–157.

Conclusion Patients with elevated vWFAg, neopterin, and/or evidence of abnormal nailfold by capillaroscopy may have decreased absorption of OP. We speculate that this observation can provide the rationale for the greater efficacy of IVMP in the therapy of patients with active vasculitis of rheumatic disease. More patients will be evaluated to further establish the use of IVMP over OP in active vasculitis.

Acknowledgements Supported in part by grant M01 RR-000498 from the National Center for Research Resources, NIH, Northwestern GCR and, the Marlene Apfelbaum Memorial Foundation.

P166 Characteristics and outcomes in sero-positive late-onset rheumatoid arthritis patients who start a new disease modifying anti-rheumatic drug

VK Ranganath UCLA, Los Angeles, California, USA


Background Controversy exists in delineating the characteristics and therapeutics involved in late-onset rheumatoid arthritis (LORA) and younger-onset rheumatoid arthritis (YORA). Many studies have suggested that the disease process of the LORA patient is distinctly different, and thus requires different treatment. Our preliminary work using a rigidly defined, rheumatoid factor (RF)-positive rheumatoid arthritis prospective cohort of 263 patients suggests that LORA and YORA patients are similar after correcting for age-related factors, for example erythrocyte sedimentation rate and C-reactive protein. In the same cohort of patients, Wu and colleagues recently demonstrated that the presence of both shared epitope-containing DRB1*04 alleles and novel RANKL polymorphisms was associated with an 18–20 year earlier onset of rheumatoid arthritis in YORA patients and did not predict increased severity of disease.

Objective Aim 1 To demonstrate that RF-positive YORA and LORA patients with the same disease duration have similar baseline disease-related characteristics, after adjusting for age-related processes. Aim 2 To compare outcomes of RF-positive LORA and YORA patients with the same disease duration, after accounting for age-related processes.

Hypothesis 2A Responses to disease-modifying anti-rheumatic drug treatments will be similar between LORA and YORA patients with equivalent disease duration. Hypothesis 2B LORA and YORA patients with equivalent disease duration will have comparable side effects to disease-modifying anti-rheumatic drugs.

Methods This study will use the Consortium of Rheumatology Researchers of North America and the Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study 1&2 databases, consisting of 15,000 rheumatoid arthritis patients. Patients with known RF positivity will be included in the cohort, with LORA ≥ 60 and YORA < 60 years of age. We will control for duration by stratification. We will use two methods to demonstrate similarity between YORA and LORA subjects: equivalence testing and confidence intervals. Alternate statistical analyses include generalized matching by the propensity score method and regression analyses.

Significance LORA patients have been treated inconsistently and with much apprehension, due to uncertainty about the diagnosis of LORA and concern about prescribing toxic medications to the elderly. With strictly defined cohorts showing similar characteristics/outcomes, treatment of the LORA and YORA patients by physicians should be similar.

P167 Toll-like receptor 4 polymorphisms and ankylosing spondylitis

R Adam, JA Gracie, RD Sturrock Centre for Rheumatic Diseases, Division of Immunology, Inflammation and Infection, Glasgow Royal Infirmary University Trust, Glasgow, UK


Introduction Ankylosing spondylitis (AS) is a chronic systemic rheumatic disorder, which is characterised by sacroiliitis, enthesopathy, and a variety of extra-articular manifestations. Despite having the strongest association ever described with the HLA antigen, HLA B27, the pathogenesis of AS remains poorly understood. Immunoregulatory genes and Gram-negative gut bacteria are thought to be important in disease expression. It is now known that mammalian immune response to Gram-negative bacteria is mediated by Toll-like receptor 4 (TLR4), a pattern recognition receptor. Two co-segregating missense mutations have recently been described in TLR4 that lead to a diminished host response to Gram-negative bacteria. We hypothesise that TLR4 mutations occur with an increased frequency in HLA B27-positive individuals who develop AS than in healthy HLA B27-positive controls, and allow increased survival and the systemic dissemination of Gram-negative gut bacteria to the joints. This study aims to compare the frequency of two common TLR4 mutations (Asp299Gly, and Thr399Ile) between AS patients and HLA B27 healthy controls.

Methods The TLR4 genotypes of over 100 patients and 100 HLA B27 healthy controls were determined using allele-specific PCR and restriction fragment length polymorphism analysis. The allele frequencies were compared using a chi-squared test of association.

Results There was no significant difference between the frequency of the Asp299Gly allele or the Thr399Ile allele in AS and healthy HLA B27 controls.

Conclusion Two common TLR4 polymorphisms, which cause a functional deficiency in host immune response to Gram-negative bacteria, are not significant in AS.

S9 Follow up study of B-lymphocyte depletion in the treatment of patients with systemic lupus erythematosus

MJ Leandro, ICW Edwards, MR Ehrenstein, G Cambridge, DA Isenberg Centre for Rheumatology, University College London, London, UK


Background Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease in which B-lymphocytes play a pivotal role. We have induced B cell depletion utilising a combination of rituximab, cyclophosphamide, and steroids given intravenously. This regime depletes B-lymphocytes in the peripheral blood. We now report a long-term follow up study of 24 patients who had failed conventional immunosuppression.

Methods 24 patients (22 female, 2 male, mean age 30 years, range 17–49) were treated. The mean disease duration was 7.9 years (range 1–18 years). Twelve of the patients were Caucasian, 8 Afro-Caribbean and 4 of Asian origin. The majority of these patients were treated with two infusions of 1 g rituximab, two infusions of 750 mg cyclophosphamide and two infusions of methylprednisolone 100 mg. Patients were allowed to continue on prednisolone and hydrochloroquine only if they had no symptoms.

Results The global BILAG score reduced from a median of 13.9 at baseline (SEM = 1.18) to 5 (SD = 1) at three months and 5.0 (SEM = 0.6) at six months. 23/24 patients achieved depletion in the peripheral blood (CD19+ <0.005/l) and there was improvement in BILAG score in each of the eight systems or organs. The period of B lymphocyte depletion ranged from three to eleven months except in 1 patient who remained depleted for > 4 years. Whereas the mean total serum immunoglobulin levels remained within the normal range, analysis of the serum C3 levels (in 21 patients) showed a statistically significant improvement ($P<0.0005$) at six months as did anti-dsDNA binding ($P < 0.02$). 1 patient, scored the most active (BILAG global score 45) died of sepsis five months after the infusion having shown a considerable improvement at three months. 1 patient had a severe infusion reaction. No serious adverse events were observed. 7 patients have now been retreated, 1 on two further occasions. 1 patient failed to deplete on retreatment due to a documented specific HACA reaction.

Conclusion B-lymphocyte depletion therapy utilising rituximab has been shown to be an effective treatment for active refractory lupus. Our data further indicate that both clinical and serological improvement is seen in the majority of these patients. The efficacy and apparent safety of this treatment in established cases of lupus indicate the possible use of this treatment in patients earlier in the course of their disease.